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Background. There is substantial evidence of the increasing burden of 
diabetes mellitus (DM) posing a threat to tuberculosis (TB) control globally. 
The global estimate of DM is expected to reach 592 million by 2030. In 
Europe, the estimated prevalence of DM is 8.5% and the rate of TB is 40 
cases per 100,000 persons, with 74, 000 new cases per year (Badawi et al., 
2014).  It is estimated that DM triples the risk of developing TB when exposed 
an actively infected TB case, as well as modify the presenting features of TB, 
with more atypical radiological presentation, adverse TB treatment outcome, 
increased rates of relapse rates and death. The UK has the highest number of 
cases of TB in Western Europe. The London Borough of Newham has the 
highest number of cases in the UK, and this poses a public health risk.  Thus, 
this research is aimed at analysing the prevalence of DM in TB patients in 
Newham and to describe the clinical presentation of Tuberculosis-Diabetes 
Mellitus (TB-DM) patients. Aim and objectives. The major objectives: 1. To 
determine the prevalence of DM in TB patients in Newham, with close 
attention paid to differences between UK-born and non-UK born patients; 2.  
To analyse the demographic, clinical characteristics and microbiological 
features associated with TB-DM compared with TB only patients. 
Methodology. The study was a retrospective cross-sectional survey on the 
prevalence of DM among diagnosed adult TB patients in Newham between 
the period of 2012-2015 with a follow-up period of 24 months from the London 
Borough of Newham, participants recruited from Barts Health NHS Trust. 
Results. Among the 489 TB patients used for this study, the prevalence of 
DM was 25.8 (range 24.3 – 33.0), greater than the UK average of 6.0%, and 
from the general population of Newham (3.9%) at the time of the study.  The 
average patient age ranged from 27.5-49.9 years, with 85.3% of TB cases 
reported in the non-UK born population (P-value 0.087).  Non-UK born 
individuals are more likely to be infected with TB, likely as a result of recent 
travel to high TB incidence areas or reactivation of latent TB, DM is not 
exclusively associated with the non-UK born population. DM was found to be 
significantly associated  with age (P-value <0.005), comorbidities (P-value 
iv 
 
0.007), worsening symptoms (night sweats (P-value 0.01), fever (P-value 
0.02) and weight loss (P-value <0.001), social factors (heavy drinking (P-value 
0.054) and person who injects drugs (P-value 0.04)). Microbiologically, the 
TB-DM cohort was likely to remain infectious for a longer period due to a 
higher bacterial load (P-value <0.001). Conclusion. In conclusion, DM poses 
a major challenge to controlling TB in Newham. A bi-directional screening of 
DM and TB cases, including screening of latent TB with DM, and tackling 
social determinants, i.e. the rise in the homeless population, use of illicit drugs 
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Globally, Tuberculosis (TB) remains a major public health concern and in 
2016, it was estimated that 10.4 million people have developed active TB 
(new cases and relapses), and a further 1.3 million HIV- negative and 374,000 
who were HIV-positive have died from the disease (Noubiap et al., 2019). TB 
disease historically has been associated with risk factors including HIV, 
substance misuse, chronic renal disease, malnutrition, and treatment with 
immunosuppressants or immunosuppressive conditions (Narasimhan et al., 
2013). It is only now that there is a focus on diabetes mellitus (DM) as a risk 
factor for TB. Diabetes triples the risk of developing TB, and poor glycaemic 
control affects treatment outcomes, including treatment failure, relapse and 
death. It is estimated that diabetes accounted for 10.6% of the global TB 
deaths among HIV-negative individuals in 2015 (Harris et al., (2016). In 2017, 
globally, 425 million individuals are estimated to have been affected by 
diabetes and a 48% increase to 629 million individuals who will have diabetes 
by 2045 has been predicted (www.idf.org). The current trend would suggest 
this increase in the prevalence of diabetes will contribute to an increase in TB 
cases. In England, the rates of TB have declined since 2014, with a total 
reduction of 28% in incidence from 2014 to 2018 (PHE, 2019, Tuberculosis in 
England). However, London had the highest rate of TB cases reported and 
the Borough of Newham had the highest in England. Regions which 
experience a high incidence of TB are also likely to experience a large 
increase in the diabetes prevalence (Noubiap et al., 2019). In England, and 
especially in the highest risk cities, further work is required to improve the 
outcome of those most at risk of TB. Current TB work is focused on a 5-year 
TB Action Plan (2020 to 2025) to move England towards TB elimination. 
Therefore, it is crucial that the diabetes epidemic is curbed as part of this 
strategy, to tackle the burden of TB in England and, more predominantly, in 





However, there is limited recent study in England to present a clear estimate 
of a regional burden of diabetes among patients with TB. This is the first study 
on the prevalence of TB and DM studying the London Borough of Newham, 
which has the highest incidence of TB compared to any western city. The 
findings from this study will hopefully help curb the burden of diabetes among 




The increasing burden due to the co-occurrence of TB and DM is an emerging 
global health concern. The relationship between TB and DM was first 
discussed by Richard Morton in 1698 in his Phthislogia: Or a Treatise of 
Consumptions, in which he described DM symptoms as a consuming disease 
associated with TB (Olayika, Anthonia & Yetunde 2013). Prior to the 
development of effective treatment for either disease, TB was the leading 
cause of death among DM patients. In recent times, with the global increase 
of DM and the struggle to eradicate or reduce TB, the incidence has resulted 
in an increased number of individuals experiencing concurrent TB and DM 
conditions. This co-occurrence of TB-DM pandemic exemplifies a new 
epidemiological transition where chronic conditions commonly occur with an 
infectious disease, not only in the same population but the same individual.  
 
1.3 Mycobacterium tuberculosis overview 
 
Tuberculosis disease in humans is caused by the bacterium Mycobacterium 
tuberculosis (Mtb), that is a non-motile, slow-growing, rod-shaped bacillus 
(Figure 1.1) (Grosset & Chaisson, 2017; Brennan, 2003). Mtb spreads via 
respiratory droplets that contain the tubercle bacillus. Bacilli are expelled from 
an infective person and is inhaled by close contacts and infected with Mtb. 
The outcome of the disease is determined by the protective ability of the host 
immune system and the pathogenicity of these bacteria. In the vast majority of 
cases, the host can control the infection and contain it inside a granuloma, 




does not eradicate them, such that they are contained and do not spread the 
disease (Grosset & Chaisson, 2017; Brennan, 2003). 
 
1.4 Host-pathogen interactions 
 
Mycobacteria are a set of micro-organisms which can cause disease in 
humans and they consist of Mycobacterium tuberculosis, Mycobacterium 
africanum, Mycobacterium bovis, Mycobacterium microti and Mycobacterium 
canetti. Mtb is an intracellular pathogen that can infects human and animals. It 
is an acid-fast, non-motile, non-encapsulated, non-spore-forming bacillus. It 
multiplies successfully in tissue with high oxygen content, i.e. the lungs. The 
cell wall of a mycobacterium is rich and can be impermeable to dyes unless 
blended with phenol. Mtb is neither a gram positive or negative bacterium and 
it resists decolourisation with acidified organic compounds (Grosset & 
Chaisson, 2017; Brennan, 2003). Mtb tuberculosis multiples every 15-20 
hours, which makes it a slow-replicating pathogen compared to other 
organisms, such as Escherichia coli which divides every 20 minutes. 
However, the slow replication of the bacterium allows the Mtb to persist in a 
latent state, resulting in the need for a longer treatment duration and 
preventive therapy.  Infection with Mtb results from the exposure of the lungs 
mucous membranes to the infected aerosol droplets from an infected 
individual. These aerosol droplets are 2-4 µm in diameter in individuals with 
active pulmonary TB (Patterson et al., (2018); a single cough can generate 
3,000 infective droplets, with as few as 10 bacilli required to initiate an 
infection. Once the bacilli are inhaled into a host, the tubercle bacilli are 
deposited within the terminal air-space of the lung (Grosset & Chaisson, 2017; 
Brennan, 2003). The organism usually multiplies in 2-12 weeks until it reaches 
between 1000–10,000 in number, which is sufficient to stimulate a cellular 
immune response that can be detected by a response to the tuberculin skin 
test. The proportion of Mtb infected individuals going on to developing active 
clinical tuberculosis infection is low, with a lifetime risk of about 10% due to 
activation of latent TB. Latent TB is a clinical disorder in persons infected with 
Mtb whereby the host retains control over replication of the bacterium to 




infection is highest within the first few years after inhalation of Mtb but 
decreases substantially thereafter.  An immunocompetent person will likely 
eliminate the inhaled Mtb or retain it in a latent state. TB also reactivates from 
latent infection and risk is associated with age, with many aging populations 
have the highest TB incidence rates per capita in older age groups (Ku and 
Dodd, 2019).  
 
Mtb promotes a host immune reaction that is nonspecific and expressively 
antigenic. This antigenicity is owed to the cell wall including phospholipids and 
glycoproteins, which triggers Langerhans cells, including lymphocytes and 
polymorphonuclear leukocytes. In most cases the infection is cleared by the 
host immune system or suppressed into an inactive latent form (Grosset & 
Chaisson, 2017). 
 
1.5 Innate immune defence against Mtb 
 
For Mtb bacteria to cause an infection, they must pass through the physical 
defence mechanisms of the upper respiratory tract (URT), which are the nose, 
nasal cavity, turbinates and the pharynx, and hence avoid the infringement 
and expulsion by mucociliary action or through cough and sneeze reflexes. 
The URT also contains antimicrobial substances which aid in bacteria 
elimination, including cathelicidin and defensin proteins, which play a major 
role in the active lysing of Mtb bacilli (Grosset & Chaisson, 2017).  If Mtb 
bacilli can penetrate through the URT defences they then need to overcome 
the lower respiratory tract (LRT) defence mechanisms (Lerner, Borel & 
Gutierrez, 2015). Any organism of a size of 10 µm or less can pass through 
the initial physical barrier into the LRT, which includes the larynx, trachea, 
bronchi and the lungs. Once in the LRT, mucociliary and antimicrobial action 
takes place to encourage the elimination of Mtb. The bronchioles and alveoli 
are covered with a fluid layer which contains antimicrobial substances, 
immunoglobulins and molecules of both forms of the alternative and the 












Tuberculosis in the lung and formation of granuloma (Copyright made 








1.6  Cellular immune response against Mtb 
 
Once Mtb has penetrated the LRT, several different host immune cells, which 
can all mediate different immune responses after the initial contact with Mtb 
bacterium, are then encountered. Mtb can be phagocytosed by these cells, 
such as macrophages, dendritic cells and/or pneumonocytes (Cooper, 2009; 
Grosset & Chaisson, 2017). This process occurs via many routes: the multiple 
components of the bacterial cell wall act as a ligand for host cell receptors to 
facilitate bacterial uptake. Once Mtb is engulfed by the immune cells, the 
phagosomes are fused with lysosomes, resulting in the formation of a 
phagolysosome. Within the phagolysosome, the bacteria encounter a hostile 
environment. This acid-rich environment creates toxic reactive oxygen and 
nitrogen species, lysosomal enzymes and toxic peptides; such exposure is 
detrimental for Mtb. However, some Mtb bacilli can survive in the phagocytic 
cells by blocking the phagolysosomal fusion process. Macrophages, which 
are unable to destroy the Mtb, become a perfect environment for the bacteria 
to “hide” within and replicate. Dendritic cells, which phagocytose Mtb but are 
also unable to kill the bacilli, migrate to the draining lymph nodes, where they 
present bacterial antigens to naive effector T-cells (Kumar et al., 2016). 
Presentation of the bacterial antigen to naive effector T-cells causes T-cell 
activation. The activated T-cells can then migrate into the circulatory system, 
where they remain until they reach a site of TB infection, such as the lung 
(Cooper, 2009).  
 
Once activated at the site of TB infection, the CD8+ T cells and CD4+ T cells 
can control TB infection, although the mechanism through which this occurs is 
not fully understood. The CD4+ T cells can produce cytokines, such as 
tumour necrosis factor alpha and interferon gamma (IFNγ), which activate 
macrophages, enabling the killing of Mtb bacteria. CD8+T cytotoxic cells can 
destroy infected macrophages and Mtb bacilli by releasing cytotoxic mediators 
such as granulysin, perforins and granzymes (Grosset & Chaisson, 2017). 
Furthermore, certain Mtb can persist, subverting the dendritic immune 




Figure 1.2. Mtb Pathogenesis 
A minimal dose of Mtb aerosolised into a host into the lower airways and the 
alveolar tissue can cause an infection. Once inhaled into the lungs the 
bacteria do not propagate until nine days’ post-infection, when they can be 
found in the draining lymph nodes from the lung. This dissemination and the 
initial activation of naive T cells coincide. The response requires 18--20 days 
to achieve an effective amount and consequently prevent bacterial growth 




1.7  Classic clinical presentation of TB 
 
Tuberculosis disease is a multi-system disease with a myriad presentation. 
The classic features of active pulmonary TB are as follows: 
• Cough 
• Weight loss/ anorexia 
• Fever 
• Night sweats 
• Haemoptysis 
• Chest pain (can be a cause of tuberculosis pericarditis) 
• Fatigue 
 
Other sites of infection include TB meningitis, which is associated with 
headaches, which can be intermittent or persistent for a period of 2-3 weeks. 
With TB meningitis, a subtle permanent mental status changes, which may 
progress over a period of days to weeks, and low-grade or absent fever is 
common. 
 
In skeletal TB, symptoms can range from back pain and stiffness to lower-
extremity paralysis and TB arthritis, which usually involves one joint being 
implicated (Heemskerk et al., 2015). 
 
In gastrointestinal TB, non-healing ulcers of the mouth or anus are common. 
Difficulty in swallowing (with oesophageal disease), abdominal pain, which 
can mimic peptic ulcer (with gastric or duodenal infection), malabsorption, 
pain, diarrhoea and haematochezia (with infection of the colon) are also 
common (Crus & Starke, 2007). 
 
1.8  Immunology and TB-DM 
 
DM increases the risk of TB infection including patients presenting with more 
severe symptoms and worse overall clinical outcome (Gil-Santana et al., 
2016). The dual presentation of TB-DM requires further investigation 




(2017) analysed blood transcriptome for immunological events in the lung, 
and the gene expression profile specific to active TB, comparing non-diabetic 
TB patients to TB-DM patients, and found a difference in the blood of gene 
expression suggestive of a changed immune response. The TB-DM cohort 
had a distinct difference in their plasma cytokine and growth factor levels, 
which was associated with increased neutrophilic inflammation (Prada-Medina 
et al., 2017). 
 
The mechanism responsible for TB susceptibility and severity caused by DM 
is not well understood. However, in-vitro testing in diabetic mice has shown a 
delayed response by alveolar macrophages after infection by inhaling Mtb and 
subsequent expression in the lungs, the T cell medicated immunity showing a 
greater burden of inflammatory pathology due to the higher bacterial burden 
along with possible defects in counter-regulation (Raposo-Garcia et al., 2017). 
The elevated level of plasma cytokines and growth factors are distinguishable 
in the TB-DM mice from the non-diabetic TB mice group. When comparing 
neutrophil inflammation with TB severity, DM amplifies this response, which is 
likely to reflect the high bacterial load, or a specific perturbation of the immune 
function.  
 
In published work on the human blood transcriptomic signature of active TB, a 
role for type 1 IFN signalling in neutrophils has been highlighted (Berry et al., 
2012). A high molecular degree of perturbation was positively related to 
radiographic severity of TB, a high neutrophil count and a low BMI. Previous 
data has demonstrated that BMI is a protective mechanism in TB, but this 
association is lost in diabetic obesity. Low high-density lipoprotein (HDL) with 
high molecular degree of perturbation is unique in the TB-DM subgroup. HDL 
cholesterol modulates innate and adaptive immunity via connections with 
lipids on lymphoid and myeloid cells. The very low HDL cholesterol is 
associated with pre-diabetes and T2DM, which may act as an independent 
factor for increasing susceptibility to Mtb. These findings suggest the 
significance of an increase in cytokines, growth factors and other biomarkers 





The possible factors which may impact the host response from patients with 
DM are short-chain fatty acids (SCFAs), which are a key metabolic product of 
fermentation of non-digestible dietary fibres by the gut microbiota (Knudsen et 
al., 2014). It is believed that DM also alters the make-up of the gut microbiota 
affecting metabolic process and immune response. SCFAs, control immune 
and inflammatory responses, including prompting a response to Mtb. Out of 
all the SCFAs, butyrate (C4) is the most prominent of all SCFAs, as it directly 
affects the immune response via at least two mechanisms: activation of G-
protein coupled receptors (GPCRs) and inhibition of histone deacetylase 
(HDAC) (Knudsen et al., 2014). In the presence of DM both these 
mechanisms are altered causing a dysfunctional immune response. Several 
studies have reported that a drop in C4-producing bacteria in T2DM, which all 
exhibit anti-inflammatory properties, and reduced quantities of C4 reduces the 
Mtb-induced pro-inflammatory cytokine feedback on either the transcriptional 
and/or the translational levels, altering the immune response in TB-DM 
patients (Lachmandas et al., 2016). 
 
The anti-inflammatory result is independent of HDAC activity and Toll-like 
receptor (TLR) signalling, both the eicosanoid pathway and cellular 
metabolism. The inhibitory effect of SCFAs on the production of TNFα and IL-
1B and C2, C3, and C4 has a much stronger inhibitory effect on T-cell-derived 
cytokine IL-17 than on T-cell-derived cytokines IFN-y and IL-22. C4 is also 
strongly correlated with decreased Th17 proliferation; the stimulatory impact 
of C3 and C4 on anti-inflammatory IL-10 release with Mtb, and IL-10 
delineated is an important mediator in Mtb disease as it depresses pro-
inflammatory response to Mtb (Knudsen et al., 2018). The suppression of 
cytokine production and the multinucleated giant cell formation, which is a 
significant element for preventing infection in macrophages and inhibits the 
progression of protective immunity.  
 
1.9 TB diagnosis 
 
Early diagnosis is key to effective treatment of TB disease. However, there is 




standardised diagnostic guidelines are available. Diagnosis of TB can be 
made clinically and/or microbiologically. Testing methods for TB include a 
Mantoux tuberculin skin test with a purified protein derivative (PPD) for 
diagnosis of active or latent TB infection or a blood test based on interferon-
gamma release assay (IGRA) utilizing antigens, which are unique to Mtb, to 
diagnose latent infection. For laboratory microbiology testing, acid-fast bacilli 
(AFB) smear and culture, using sputum or other samples are obtained from a 
patient (Takasaki et al., 2018). AFB culture has come to be the gold standard 
test for the diagnosis of TB. Not having a positive AFB smear result does not 
exclude TB disease. Drug susceptibility testing usually follows a smear then a 
culture test. Symptoms and radiographic film findings do not differentiate 
multi-drug-resistant TB (MDR-TB) from fully-susceptible TB; therefore, further 
testing using automated molecular testing and rapid test (i.e. TB-RIF assay) 
are used - a polymerase chain reaction (PCR) technique which identifies 
Rifampicin-resistant TB. 
 
A chest radiograph is taken, mainly in pulmonary TB, this is to investigate for 
possible pulmonary tuberculosis, which may show the following (see figure 
1.3): 
 
• A cavity formation: which indicates advanced infection, associated with 
a high bacterial load. 
• Non-calcified round infiltrates: this may mimic lung carcinoma. 
• A tuberculoma; calcified nodule (usually 2-20mm) representing an old 
infection. 
• Primary TB: infiltrates in a middle or lower lung region: this may 
present as a pneumonia-like feature. 
• Reactivation of TB: pulmonary lesions in the posterior segment of the 
right upper lobe, apicoposterior segment of the left lobe and apical 











A-E: Chest radiographs in active TB. (A) Chest x-ray (CXR) depicts right (RT) 
upper zone consolidation with prominent RT hilum. (B) CXR in another 
individual show multiple coalescent air-space nodules at RT upper zone. (C) 
CXR at another individual show multiple ill-defined reticulo-nodular lesions in 
both lungs with basal predominance, suggestive of miliary TB. (D) CXR in 
another patient shows active post-primary TB. Cavity with encircling 
consolidation is seen in left (LT) upper zone. Scattered air-space nodules can 
be seen in both lungs using hilar adenopathy. (E) There is a RT-sided 
lobulated pleural effusion with numerous air-space nodules in both lungs 





















1.10 Epidemiology of TB 
 
1.11 Global Epidemiology of TB  
 
Tuberculosis is thought to be a leading cause of death by an infectious agent, 
with multiple people dying every minute from a curable disease (Dodd et al., 
2018). Based on notification reports on the incidence of TB infection, 10 
million new TB cases were reported globally by the end of 2017 (WHO, Global 
Tuberculosis Report, 2017; MMWR, 2019), with 1.3 million deaths in non-HIV 
infected individuals, and an additional 300,000 deaths from TB amongst HIV-
positive individuals. Of these cases, 5.8 million of those with active TB 
infection were men, 3.2 million women and 1 million children. Globally, over 
90% of the cases occurred in the age group over the age of 15 years, 9% of 
the cases occurred in those living with HIV (72% of these are in Africa) and 
two-thirds of the cases were reported in the following eight countries: India 
(27%), China (9%), Indonesia (8%), the Philippines (6%), Pakistan (5%), 
Nigeria (4%), Bangladesh (4%) and South Africa (3%) (figure 1.4) (WHO, 
2017). In addition to these, a further 22 countries in the WHO list of 30 high 
incidences for TB rates accounted for 87% of worldwide cases.  
 
In general, developed countries, including the UK, have low TB incidence 
rates among UK-born nationals, but a rising number of TB cases are reported 
amongst non-UK born residents (Glaziou, Floyd & Raviglione, 2018). Death 
registrations have seen an increasing number of TB cases in the former 
Soviet countries since the 1980s, but falling numbers in Central Europe, Latin 
America and in the industrialised world (Alimuddin, Zumla and Schaaf, 2009). 
It is not possible to assess the precise global trend of TB deaths because 
many countries, including most in Africa and Asia, have no system of death 
registration.  
 
1.12 Risk Factors 
 
The common risk factors associated with TB are human immunodeficiency 
virus and acquired immunodeficiency syndrome (HIV/AIDS), social and 




new adult TB patients were co-infected with HIV in 2017 (figure 1.5), although 
a marked variation is seen amongst regions (WHO, 2017). The extent to 
which HIV is fuelling TB transmission remains poorly understood; one 
analysis suggested that 1-2% of all global transmission events were from HIV 
infected, smear-positive TB cases (Kato-Meda et al., 2013). Immigration from 
high-incidence countries is part of the reason why an increase in TB cases 
has been seen in Western Europe, North America and the Gulf States, which 
had either stopped observing a decline in cases or seen a reversal, with an 
increased number of cases (WHO, 2017). The TB incidence stopped falling in 
some east Asian countries, notably Hong Kong, Japan and Singapore; one 
explanation for this is the rise in cases is a result of reactivation from an 
ageing human population (Yang et al., 2017). In low-incidence country, 
migration is a key driver for TB, with cases mostly related to the reactivation of 










Figure 1.4. Global estimated TB incidence rates, 2017 
 
South Africa region, Asia and Oceania regions have TB rates of 300 per 
100,000 population. Eastern Europe, Russia, China, South American region 
have a TB incidence rate of 200-299 per 100,000. The dark green shades 





Figure 1.5. Global estimated HIV prevalence in new and relapse TB 
cases including all age groups, 2017 
 
In 2016, it is estimated 10% of all TB cases were co-infected with HIV. The 
large proportion of TB cases co-infected with HIV was highest in the African 
Region (WHO, 2017). 
 
1.13 TB rates in England 
 
TB has been a notifiable disease in England and Wales since 1913, and data 
for England has been available since 1971. The data is used to monitor TB 
trends in England and to understand the changing epidemiology of TB. In 
2000, Enhanced Surveillance was introduced, which involved collecting data 
on detailed demographics, clinical information and other risk factors for TB at 




Strategy in 2015, with the aim of eliminating global TB by reducing the 
number of TB deaths by 96% and reducing new TB notifications by 90% by 
2035. 
 
The incidence of TB in England is greater than in any other European country 
and four times greater than the US (Andorra, 2 per 100,000, Austria 7 per 
100,000, Denmark 5 per 100,000, France 8 per 100,000, Germany 8 per 
100,000, Sweden 6 per 100,000, UK 9 per 100,000) (PHE, 2017). The TB 
incidence in England is in a small cluster of high-incidence populations, but 
the risk of multi-drug-resistant TB can occur in any location in England 
(Kendall, Fofana & Dowdy, 2017).  
 
In 2018, 4,655 cases of TB were notified to PHE in England; the number of 
cases had fallen from a peak of 8,280 in 2011, a reduction of 44% (PHE, 
2018). The incidence in 2018 was 8.3 per 100,000 population, the lowest ever 
recorded in England, and a reduction of 8.2% compared to 5,070 in 2017. 
However, if we are to reach the World Health Organisations (WHO)’s End TB 
Strategy Target of a 90% reduction on new notifications by 2035, further 
efforts are required. Non-UK born patients accounted for 72% (3,283/4,580) of 
notifications in 2018, with an incidence rate of 39.0 per 100,000 population. 
The rate is 14 times greater than those born in the UK (2.8 per 100,000).  
 
1.14 TB-HIV co-infection 
 
In 2018, in England, 120 of 4,504 people with TB were co-infected with HIV, 
which was the lowest proportion of co-infection since 2011, with the median 
age of individuals with TB-HIV co-infection being 46 years old (PHE, 2018).  
 
1.15 Latent TB infection 
 
In 2018, in England, 15,883 latent TB tests were positive, an increase of 3.5% 
from 2017. Similarly, the Latent TB treatment completion increased from 





TB is largely concentrated in large urban cities with high numbers observed in 
non-UK born nationals, including London, Leicester, Birmingham, Luton, 
Manchester and Coventry, which have more than three times the national 
average number of cases. Up to 75% of all TB cases in the UK occur in those 
born abroad, mainly from high TB-burden countries and regions, with 85% of 
the cases occurring in those settled non-UK born individuals who have been 
in England for more than two years, as opposed to new entrants. Socio-
economic factors are a risk factor, with 70% of cases among individuals who 
live in two of the most deprived populations in England, and a further 9% of 
these cases have at least one social risk factor (a history of alcohol or drug 
abuse, are or have been homeless or been in prison) (PHE, 2016). 
 
1.16 Epidemiology and clinical characteristics of TB in London  
 
In 2017, 1,919 cases of TB were notified to PHE: a rate of 21.7 per 100,000 of 
the population. This represented a 12% decline in cases reported from 2016 
and a 45% decrease from the peak in 2011, but the rate remains twice the 
rate of England’s average (9.2 per 100,000) and accounts for 37% of the 
5,102 cases reported in 2017. The incidence in London is higher than national 
average, this includes Newham (47 per 100,000), Brent (45 per 100,000) and 
Hounslow and Redbridge (PHE, 2017).  
 
Many of the cases in London are in men, with small differences by age group 
(PHE, 2017). A total of 79% of the cases occurred in individuals born outside 
the UK, with India remaining the most common country of birth, with the 
median time between entry into the UK and the time of diagnosis having 
increased to 10 years. Other common countries of birth include Pakistan, 
Somalia and Bangladesh (PHE, 2017). In London, during 2017, 58% (1,105) 
of all the cases were male (25 per 100,000) and 42% were females (18 per 
100,000). The rates were highest for males aged over 80 (42 per 100,000) 
and for females 70-79 years old (28 per 100,000). This was a change from 
2016, where the highest rate in males was observed in those aged 40-49, and 
in women aged 20-29 years old (Figure 1.6) (PHE, 2017). All TB cases in 




of the TB cases reported in London were from individuals born outside of the 
UK, which is higher than the same population living in England, with an 
average of 74%. The TB incidence in non-UK born in 2017 was 44 per 
100,000, a decline of 15.5% from 2016 (52 per 100,000). However, non-UK 
born are 7 times more likely to have TB than the UK born population (PHE, 
2017). The incidence of TB in UK-born is 6.9 per 100,000 (378 cases) 
compared to 2016 (7.4 per 100,000, 397). The incidence of TB in individuals 
born in the UK in London remains double the England rate (3.2 per 100,000).  
In 2017, the country of birth was known for 97% (1,465/1,518) of individuals 
not born in the UK. The most common country of birth outside the UK was 
India (26%, 379/ 1,456), and the median time since entry was nine years (IQR 
9-17 years), which was an increase from a median of eight in 2016.  
In 2017, almost half of the people with TB had pulmonary disease. Sixty-one 
percent of the TB cases were culture confirmed, 77% of those had pulmonary 
TB (PHE, 2017). In 2017, the enhanced surveillance was implemented which 
included collecting data of key co-morbidities (diabetes, hepatitis B, hepatitis 
C, chronic renal disease, chronic liver disease and immunosuppression); 
more than 1 in 5 cases had a key co-morbidity (22%). With 90% of data 
available on co-morbidity (1,728/1,919) in 2017, the most common co-
morbidity was diabetes: 12% (214/ 1,844) (PHE, 2017). When comparing the 
prevalence of PTB between UK-born and non-UK born individuals, UK-born 
cases had reported more PTB (63%, 238/378) than non-UK born cases (47%, 
717/1,518). Pulmonary TB was more common in the white ethnic group (78%, 
232/296) and less common in Bangladeshi patients (36%, 37/104) (PHE, 
2017). In 2017, 5.7% (108/889) of UK PTB cases were also known to have 
had a previous TB diagnosis, with the median time between diagnoses being 
6.5 years (IQR 3-20) (PHE, 2017).  
Although the TB rates have continued to decline since 2011, this decline is 
mostly seen in the non-UK born population, with only a small decrease being 
seen in the UK-born population of London, where the rate has remained more 
than twice the rate as for England. 




morbidities. Diabetes was the most common co-morbid factor affecting more 
than 10% of all people with TB in London in 2017.  
When comparing social risk factors, 10% of all cases had a social risk factor, 
which was more common in the UK-born cases, particularly in the white or in 
the black Caribbean ethnic groups. This remains the same when compared to 
2015, and patients with social risk factors are more likely to pose an infection 
risk and be hospitalized, as well as being less likely to complete TB treatment 
(PHE, 2017).  
 
All TB patients are offered HIV testing on TB diagnosis, with 97% test 
compliant, and 2.7% of all cases in London are known to be co-infected with 
HIV (PHE, 2017).  
 
In relation to UK-born cases, which includes all ethnicities, the rates have 
fallen but remain twice the England average, with the white ethnic group being 
the most common group to be affected, accounting for 37% of patients born in 
the UK with TB (PHE, 2017).  
 
In 2016, there were 2,210 TB cases reported in London at a rate of 25 per 
100,000 of the population; however, since 2011, a 41% reduction in cases 
has been observed, except for four London Boroughs, including Newham, 
















Figure 1.6. TB case reports and rates by age and sex, London, 2017 
 
 
The graph illustrates the number of TB cases, the rate by per 100,000, and 
age groups of TB cases being reported.  The largest number of cases and 




















Figure 1.8 Active TB case reports and rates, London 2000 – 2017 
 
 





Figure 1.9. Active TB rate per 100,000 of population and local authority 






Dark red shades indicate active TB rate per 100,00 population. Newham and 
Brent continue to have the highest incidence of TB, with a rate greater than 
40-49 per 100,000 population (PHE, 2017). 
 
1.17 Social determinants - increasing the risk of developing active TB 
infection  
 
Social factors are important in the prevalence of TB; determinants such as 
poverty and low-socio-economic factors directly increase the risk of 
developing the condition. Globally, the distribution of TB prevalence is 
unequal, and TB has an inverse relationship with wealth. Colombani et al., 
(2015) identified the social determinants as a risk for TB using National TB 
surveillance data from the WHO European Region (Colombi et al., 2015). The 
study implemented a semi-structured questionnaire sent to 53 national TB 
surveillance programmes, of which a total of 47 countries completed the 
survey. This included reporting on occupation, homelessness, diabetes 
mellitus, alcohol and drug abuse, history of imprisonment, nationality, birth 
country and citizenship status, employment abroad and ethnic group, with a 
further 12 risk factors explored: age, sex, housing status, smoking, silicosis, 
use of alcohol, HIV infection, drug use, chemotherapy, pregnancy, other 
immunodeficiency’s and malnutrition. The data on social determinants found 
more than half of the TB incidents occurred in non-UK born nationals, the 
homeless and those with a history of imprisonment. 
 
A study by Colombani et al. (2015) suggested that employment and being 
homeless are important social determinants of TB infection, having a 
tuberculosis and diabetes mellitus combination, and the use of alcohol are 
important risk factors for the development of TB. The strength of the survey 
was the high participation of countries in the WHO European Region and the 
high levels of accuracy retrieved from the network of national TB surveillance 
programs.  A limitation of the study was that the only languages used in the 
survey were English and Russian, which may have caused some 
misunderstanding or mistranslation of the questions. Similarly, the case 




conditions or social determinants to the wrong category. Hargreaves et al. 
(2011) further supported the social determinants theory and that risk factors 
were important considerations. Social stratification increased the unequal 
distribution of the social determinants of health, including living conditions and 
psychosocial circumstances, as well as behavioural and biological risk factors. 
The key determinants of TB included the global socioeconomic inequalities, 
increase in population mobility, rapid urbanisation and population growth. 
Social determinants also include the lack of food or adequate nutritional 
intake, financial insecurity, malnutrition, poor housing and cultural barriers 
affecting access to health. For instance, poor ventilation and overcrowding in 
homes, workplaces and communities increase the risk of TB transmission 
from an infected host to uninfected individuals. Poverty and malnutrition 
increase the susceptibility to infection and clinical outcome. Those with 
delayed access to healthcare have a delayed diagnosis, which increases the 
severity of the disease and the outcome, and increases the population burden 
of TB, making comparisons with the social determinants in HIV/AIDS, where 
the infections had been controlled, mostly through a better emphasis on social 
factors and treatment access.  
 
Research into gender and socioeconomic inequalities in HIVS have helped to 
reduce HIV infection and the development of effective treatments (Hajizadeh 
et al., 2014; ECDC, 2018). TB is predominantly concentrated in Asia and 
regions of Africa, with smaller proportions of cases reported in the Eastern 
Mediterranean region, Europe and America. It is estimated up to 12% of 
global TB cases are co-infected with HIV, with most being reported in Sub-
Saharan Africa and Southeast Asia (ECDC, 2018). HIV is a risk factor known 
to increase the risk of developing TB infection by 3 to 5 times (Leanardo, 
Jurado & Palacios, 2017).  
 
The current efforts to control TB include increased access to health systems 
in communities and treatment support, surveillance to identify active cases 
through contact tracing and outreach to high-risk populations, an increase in 
TB health promotion to inform at-risk populations of the condition and its risk 




contacts require improvement, with more than 3 million people with TB remain 
undiagnosed each year, therefore, case detection must be optimised (Fox, 
Dodd and Marais, 2019). These efforts have the aim of changing behaviour, 
including smoking and alcohol consumption, to help reduce the TB burden 
(Jurado & Palacios, 2017; Hayward et al., 2018).  
 
1.18 TB rates in the London Borough of Newham 
 
In 2016, 366 cases of TB were diagnosed in Newham, at a rate of 117 per 
100,000 population. The completion of anti-TB treatment was below the 
London average, with 1 in 10 cases being lost to follow-up; drug resistance 
was also higher than London’s average (Aston Mansfield, 2017). The London 
Borough of Newham’s TB rate is 8 times the national average and 3 times 
greater than the London average. The London Borough of Newham is one of 
the most affected of any of the Western European Countries, with a rate 
greater than high burden developing countries. 
 
The total population of Newham in 2017 was 308,000, with a population 
density of 85.1 per hectare compared to 31 per hectare in Central London (UK 
Census, 2017). This reflects that the fact that Central London is a populated 
district and Newham has an even higher density of population. The population 
of Newham is one of the most diverse in the country, with 61% of people 
coming from a non-white ethnic group, including an increasing number of 
ethnic minorities due to refugees and asylum seekers setting in London 
(Contini et al., 2017).  
 
The deprivation level in Newham is the third highest in London, with large 
numbers of people living in dwellings such as high tower blocks and 
overcrowded accommodation with poor ventilation, all of which aids the 
spread of TB. Evidence from the literature supports housing and poverty 
being a driver for TB spread (Vassall, 2009; Anderson et al., 2001). The 
distribution of cases of TB in Newham is also concentrated in certain 
locations, with 70% of the cases focused around Manor Park, Green Street 




comparing the incidence of TB in Newham to other neighbouring boroughs, 
the rate is significant, and it is essential for intervention to be identified and 
implemented to help reduce these rates.  
1.19 DM as a risk factor for TB 
 
DM is a chronic life-long condition in which the glucose content in the blood is 
above normal. There are two types of DM, type 1 DM (T1DM) and type 2 DM 
(T2DM).  In T1DM, also referred as insulin dependent DM, this is an 
autoimmune disorder whereby the insulin producing beta cells of the pancreas 
are destroyed by the body’s own immune system, as a result no insulin is 
produced to regulate blood glucose levels.  In T2DM cases, which are related 
to a lack of insulin production or a resistance to insulin, blood glucose is not 
regulated (Diabetes UK, 2019). T2DM is usually diagnosed later in life 
compared to T1DM, which is more common in younger children and adults 
but can manifest at any age. T2DM is associated more with age (over 40 
years), differs with ethnicity as some ethnic groups are at a higher of 
developing DM. However, with increasing obesity globally T2DM is becoming 
more common in younger age groups. DM can also manifest as gestational 
DM, this occurs during pregnancy and usually diagnosed in the 2nd and 3rd 
trimester of pregnancy. In any form of DM, if not treated and glucose levels 
are poorly maintained this leads to serious health problems. DM causes 
microvascular damages to small blood vessels in the kidney (nephropathy), 
the eyes (retinopathy), peripheral nervous system (neuropathy) or cause 
macrovascular damages, in which the large blood vessels are affected and 
cause cardiovascular disease and peripheral vascular disease. DM also 
increases risk to pathogenic infectious (e.g. bacterial infection causing foot 
ulcers) (Diabetes UK, 2019).  
 
In relation to DM as a risk factor, a gap remains in our understanding of the 
extent to which socioeconomic determinants drive the current TB burden in 
London, and in the proposed study population of Newham Borough. The 
association between TB and DM as a socio-determinant is significant from a 
healthy diet and lifestyle aspect. Recognition of this will aid understanding and 




(Duarte et al., 2018). The key to the success of this study will be the sharing 
of findings with multidisciplinary teams managing patients with TB and DM, 
using an approach with a common conceptual framework, with the 
evaluations of the financial impact for the NHS and the development of local 
programmes for TB control. The findings will be shared formally using Barts 
Health NHS Trust Quality Improvement Framework and actions agreed with 
the clinical supervisor. Furthermore, the study findings will be discussed at the 
yearly TB summit is held annually in March and at internal journal study days 
for peers to comment and discuss findings. The recommend actions based on 
the study outcomes will be included and reflected in the TB Policy for 
management of TB patients at for review in April 2021.  
 
1.20 Historical association of Tuberculosis and Diabetes 
 
Tuberculosis (TB) has been around for thousands of years. It was highly 
prevalent during the 19th century, accounting for 25% of all deaths in Europe 
during this period (Glaziou et al., 2015). During the 20th century, the death 
rate caused by TB fell as living standards (housing, nutrition and income) 
improved alongside the advancement in TB treatment (Glaziou et al., 2015).  
 
Although the first drugs for the treatment of TB were discovered over 60 years 
ago, TB has caused approximately 1.7 million deaths annually worldwide 
(Glaziou et al., 2015). The diagnosis of TB has improved with the advances in 
diagnostic testing and treatment, but this progress has been slowed down by 
the HIV epidemic, and the emergence of drug-resistant strains of the condition 
(Glaziou et al., 2015).  
 
The association between TB and DM has been documented throughout time, 
but only recently has the magnitude of the DM incidence been considered a 
major risk factor. The impact of this association and its potential implications 
has been highlighted (Lee et al., 2017; Girardi et al., 2018). The current 
knowledge of the association of TB and DM as a co-morbidity in the UK and 
globally is limited. This association requires further investigation as the rate of 




estimated to be 9.3% (463 million cases), rising to 10.2% (578 million) by 
2030 and 10.9% (700 million) by 2045 (Saeedi et al., 2019). The global TB 
prevalence in 2018 was estimated to be 10.0 million, the burden of TB varies 
by country and region. The death rate associated with TB is estimated 
amongst HIV-negative individuals to be 1.2 million, with estimated 251,000 
people living with HIV are estimated to have dies from TB, the true prevalence 
of TB-DM is unknown. Therefore, WHO’s End TB Strategy targets (a 90% 
reduction in the number of TB deaths and an 80% reduction in TB incidence 
rates by 2030), are unlikely to be met in the UK, based on current estimates 
(WHO, 2019, Global Tuberculosis report 2019). The current literature on TB-
DM association consists of secondary research and lacks any clinical 
recommendations on the management of TB-DM cases as a dual 
presentation, with limited recommendation on the use of bi-directional 
screening in TB and DM cases, and no alternative treatment regimens 
recommended for patients with TB-DM comorbidity, as is the case in TB-HIV 
patients. 
 
A meta-analysis study based on TB-DM conducted by Lee et al. (2017) found 
that DM increases the risk of developing active TB by statistically pooling data 
from three pre-existing cohort studies which assessed the association 
(relative risk (RR) 3.11, 95% confidence interval (CI) 2.27-4,26). However, the 
validity of this study was questionable as two of the three cohort studies used 
within the analysis involved individuals suffering from renal failure, which itself 
is a risk factor for TB, and likely to have skewed the data in favour of DM as a 
risk factor without controlling the confounding effects.   
 
Future studies on TB-DM association should provide a risk estimate of the 
likelihood of developing TB infection in the presence of DM, which can be 
used to inform policies and change practices to improve disease outcomes 
(Pealing et al., 2015). Current ideology indicates that DM increases the risk of 
TB with a more severe clinical outcome; however, there is a lack in our 
knowledge of the bi-directional effect of TB leading to the development of DM. 




in diabetic cases to identify a risk factor should be beneficial for patient clinical 
outcomes (Pealing et al., 2015). 
 
 
1.21 Association between Tuberculosis and Diabetes 
 
In England, which has experienced an increase in the prevalence of DM, in 
2013, an estimated 2.7 million (6%) of the adult population have been 
diagnosed with DM and this is expected to increase to 9.5% by 2030 
(Diabetes UK). In England, in 2018, 4,655 TB cases have been reported at a 
rate of 8.3 per 100,000.  The rate of TB is higher in the most deprived areas 
by 6-fold compared to the least deprived areas (PHE, 2019, Tuberculosis in 
England 2018).  Therefore, the investigation of DM as a potential significant 
risk factor in developing TB is required to particularly inform policies which 
can target areas of high TB incidence. It is critical to evaluate current health 
policy in regards to managing DM patients with TB, as well as assessing the 
role of ethnicity, age and social factors which may increase the risk of TB-DM. 
Gonzalez et al. (2009) estimated, using general practice (GP) data in the UK, 
that between 1996 and 2005, the prevalence of DM increased from 2.8% to 
4.3% for the general population. It has been further predicted that the true rate 
of DM is unknown, with many cases remaining undiagnosed. In 2010, the 
estimated figure of both diagnosed and undiagnosed DM was estimated at 3.1 
million, and this is expected to rise to 4.6 million by 2030. In comparison, TB 
remains a public health concern, with a UK prevalence increasing from 11.4 to 
13.6 per 100,000 population from 2000 – 2016 (Nnadi et al., 2016). As DM is 
a chronic condition and TB can present in a latent form, and presentation of 
each condition is not a sudden on-set, they are likely to have some 
association with each other, which may help either or both conditions to 
manifest further, increasing the rate of mortality and morbidity. Insight into 
both these co-morbidities is necessary to understand any links, disease 
progression and aid knowledge in managing these cases, singly or in tandem, 





Males are more likely to have TB-DM since male adults acquire the disease in 
earlier years and it persists throughout their life, being related to 
environmental exposure. The use of tobacco is a risk factor for TB and is an 
environmental cause for TB; however, findings remain inconclusive (Barron et 
al., 2018). The relative risk for developing TB caused by smoking is increased 
2.5-fold as smoke activates alveolar macrophages to produce local 
inflammatory responses, and nicotine suppresses the antigen presentation 
function of macrophages, leading to a reduced immune response to Mtb.  
 
Empirical evidence suggests environmental factors, such as sharing of 
needles by intravenous (IV) drug users, homelessness and poor nutrition, 
contribute to a high prevalence of TB. However, being diabetic has not been 
clearly associated with increased prevalence of TB (Barron et al., 2018).  
 
Poor glycaemic control and repeated chest infections are a pre-disposing 
factor for the development of TB. Both reflect a state of decreased immunity: 
hyperglycaemia results in protein glycation and formation of advanced 
glycation end-products (AGEs), which affects the host cell function 
(Skowronski et al., 2014). Such impairments are likely to cause functional 
issues in complement activation, bacterial uptake and phagocytic action, and 
change the binding of host surface receptors to Mtb pathogens (Skowronski et 
al., 2014).  
 
Diabetic patients with TB are widely associated with atypical radiological 
appearance and a higher rate of treatment failure and resultant death 
(Martinez and Kornfeld, 2014). Diabetes alters the innate immune cells; the 
macrophages and monocytes are less expressed in TB-DM and results in a 
decreased hydrogen peroxide production, affecting phagocytosis function via 
the complement or Fc-γ pathway. Martinez and Kornfeld (2014) assessed the 
role of BMI and found a high BMI increases the risk of TB infection; in TB-DM 
cases, a prolonged state of hyperglycaemia was observed.  
 
A quarter of the global population is thought to have latent TB, of which, only 




& Dodd, 2016). Individuals with diabetes in an area of low TB incidence have 
a 2-fold risk of developing active TB, compared to 15% of all TB cases which 
are attributed to diabetes (Restrepo, 2016). The global co-incidence of TB and 
DM is increasing, and the negative impact of this co-morbidity is significant to 
individual health, as well as public health. It is estimated that by 2040, the 
prevalence of diabetes globally will have reached 642 million, and the 
prevalence of latent TB will be twice as high in those with DM than those 
without (Restrepo, 2016).  
 
Disease associations or disassociation may occur due to either: 
 
a) A direct causal relationship, when the presence of a certain disease 
causes another disease to be likely to develop; 
b) An indirect causal relationship, when the presence of a certain disease 
affects a third variable (e.g. an environmental factor) which causes 
another disease to be likely to occur or, in other words, is likely to 
increase or decrease the risk of both diseases through two separate 
mechanisms. 
c) Or a third factor may be causally linked to outcome s (a) and (b) 
 
Identifying any associations or disassociations can aid knowledge about 
disease sequences, aetiology and outcome. Such knowledge allows 
prevention of disease and control of the development of the disease 
(Eybpoosh et al., 2017). For instance, co-infection with HIV increases the risk 
of developing active TB. Such knowledge allows the implementation of 
prevention strategies, which includes routinely testing any patient confirmed 
with TB for HIV. This allows earlier diagnosis of the disease, prompt 
appropriate treatment and a reduction in the disease burden and control 
(Eybpoosh et al., 2017).  
 
DM is thought to worsen the clinical presentation and exacerbate the 
symptoms of TB in those with TB-DM co-morbidity (Astane-Poku, 2019). This 
is further aggravated by poor glycaemic control. TB-DM patients more 




those without DM. Leung et al. (2017) and Gil-Santana et al. (2016) reported 
an independent association of DM with chest symptoms at TB presentation.  
 
Radiologically, it is more common for DM to impact upon the radiological 
features of PTB, with greater infiltrates, cavity lesions and hilar or parabrachial 
lymphadenopathy, compared to non-DM patients. Greater extensive lesions 
with increased involvement of the parietal pleura and a multilobular 
involvement are common in TB-DM cases (Huang et al., 2017). Huang et al. 
(2017) evaluated the impact of glycaemic status on radiological findings in 
PTB cases using a study sample of 214 TB-DM patients with culture-positive 
PTB, of which 123 had computed tomography (CT) scans, compared to an 
equal number of non-DM patients. Glycaemic status was assessed using an 
HbA1c of 8% as a cut-off point. A higher involvement of the lower lobe is 
associated with TB-DM cases, and TB patients with uncontrolled DM often 
present with cavity and nodular lesions (Huang et al., 2017).  Banureka et al. 
(2017) showed sputum conversion in 90% of patients with TB-DM; DM is a 
major risk factor for increased time of sputum conversion in TB patients.  
 
Poorer treatment outcome, with increased rates of failure, relapse and death, 
is associated with TB-DM co-morbidity. Mukhtar and Butt (2018) reported an 
increased risk of adverse TB treatment outcome result (adjusted OR 3.38, 
95% CL 2.19-5.22, p= <0.001) and one-year mortality (adjusted OR 2.80, 
95% 1.89-4.16) in people with TB-DM. The risk of treatment failure and death 
was 7 times higher in TB-DM group compared to TB only. This negative 
outcome is likely related to drug resistance that is greater in TB-DM groups, 
because of weakened cellular immune response, higher drug resistance and 
a lower concentration of TB drug in plasma serum and blood levels of anti-TB 
medication, and the delay in sputum conversion. This was a prospective 
cohort study in the high-incidence country of Pakistan which recruited new 
PTB patients from the age of 15 years and above and commenced treatment 
on anti-TB drugs. The PTB patients were screened for DM using random and 
fasting glucose tests and followed up at the second, fifth and sixth month of 




were recruited, of which 113 had DM and 501 non-DM. Their study found poor 
outcome of treatment in DM-PTB patients.  
 
There is a positive correlation between active TB and the level of HbA1c 
(hazard ratio 1.39, CI 1.18-1.63 per unit increase). It is thought an HbA1c >9% 
(75mmol/mol) increases the severity of TB symptoms, including cough, 
haemoptysis, malaise and weight loss. Using a hospital-based prospective 
study with newly diagnosed smear-positive PTB with DM, a total of 630 
patients were recruited for the study, of which 423 had poor glycaemic control 
(HbA1c >7%). These individuals also had the highest odds (OR 3.55) of being 
smear-positive following two months of treatment and had more extensive 
lung disease, cavitation and a positive sputum smear at baseline (Mahishale 
et al., 2017). Furthermore, uncontrolled diabetes is associated with increased 
cavity lesions on chest x-rays and a higher frequency of positive-smear and 
more severe symptoms and being likely to show a positive culture after two 
months (P= 0.009), treatment failure (P- 0.015) and death (P= 0.027) 
(Siddiqui et al., 2018). 
 
The co-morbidity of TB-DM is likely to lead to MDR-TB because of sub-
optimal treatment drug concentration being a key factor for resistance. A 
lowered serum concentration of rifampicin and isoniazid is likely to happen in 
patients with TB-DM compared to TB only. Anti-TB drugs are thought to 
interact with DM medication and cause suboptimal blood glucose control, or 
the DM medication can also interact with anti-TB drugs, especially newer 
agents and lower their efficacy.   Rifampicin is a hepatic enzyme-inducer, 
known to lower the plasma concentration of numerous oral agents, especially 
sulphonylureas and biguanides, by accelerating their metabolism (Niazi & 
Kaira, 2012).  Isoniazid impairs the release and action of insulin, which leads 
to hyperglycaemia (Niazi and Kaira, 2012). Therefore, insulin dosage should 
be adjusted when prescribing for patients with co-morbidity with TB, and their 
dosage of oral anti-diabetic medications should be adjusted according to their 
plasma glucose concentration. In contrast, DM is thought to lower the plasma 
concentration of anti-TB medication, which is likely to reduce the expected 




studied the concentration of rifampicin in TB-DM cases to find the median and 
interquartile range (IQR) concentrations of isoniazid [6.6 (3.9-10.0) vs 7.8 
(4.6-11.3)] and pyrazinamide [31.0 (22.3-38.0) vs 34.1 (24.6-42.7)], in μg/mL, 
finding significantly lower levels in individuals with TB-DM compared to TB 
only (P = <0.001 for both drugs). Kumar et al. (2017) also reported a negative 
correlation between blood glucose and plasma isoniazid (r = -0.09, P = < 
0.001) and pyrazinamide (r = -0.092, P= <0.001) concentrations. DM reduced 
both isoniazid and pyrazinamide concentrations by 0.8 and 3.0 μg/mL 
respectively and, therefore, a strategy to optimise the dose of these drugs is 
necessary for better therapeutic outcomes in patients with TB-DM. 
 
The current issue surrounding TB-DM is the lack of clinical awareness in the 
diagnosis, prevention, screening, management and reduction of the burden 
caused by both TB and DM. There are currently no clinical pathways to 
optimally manage patients with concurrent TB-DM conditions. Those with TB-
DM should also be managed by specialist endocrinologists for guidance on 
the management of DM alongside the TB specialist. Increasing anti-TB 
medication in TB-DM cohorts has not been reported as no randomised 
controlled trials have assessed the efficacy of extending treatment beyond the 
standard six months for susceptible TB (Baghaei et al., 2013; Workneh et al., 
2017).  
 
1.22 Diabetes Mellitus Epidemiology in the UK 
 
Diabetes is a condition where the amount of glucose in the blood is above the 
normal range. Diabetes can be categorized into two types: type 1 and type 2. 
Type 1 diabetes develops when an individual’s body is unable to produce any 
insulin due to autoimmune attack against the islet cells in the pancreas. It is 
usually acquired genetically. Type 2 diabetes occurs when the body is unable 
to produce enough insulin or categorised by insulin resistance (Sanchez-
Jimenez et al., 2018, Magliano, 2019). The prevalence of type 2 diabetes is 
around 90% in the UK (Magliano, 2019). Currently, in the UK, diabetes is 
diagnosed by measuring the glycated haemoglobin (HbA1c) levels of 




Association, 2009). The risk factors for developing type 2 diabetes include 
advancing age, ethnicity, a familial history of diabetes, increased body mass 
index (BMI) and/ or waist circumference, high blood pressure and heart attack 
or stroke. Men from a deprived socio-economic status are at more risk of 
being diagnosed with T2DM. Deprivation is a key independent risk factor for 
diabetes, and the PHE diabetes prevalence model predicts the significance 
after adjustment for age, sex and ethnicity (P= <0.0001) (Wu et al., 2014).  
 
The PHE figure for 2016 estimates 3.8 million individuals in the UK over the 
age of 16 have diagnoses (diagnosed or undiagnosed) for T2DM. Men are 
more likely to be diagnosed than women, 9.6% compared to 7.6%. The 
prevalence of diabetes is more common in individuals from South Asia and 
black ethnic groups compared to white and other ethnic groups: 15.2% 
compared to 8.0% (PHE, 2016).  
The figures published in 2016 by PHE estimates that 3.8 million people in 
England over the age of 16 have diabetes and that this will increase to 4.9 
million by 2035, approximately 9.7% of the adult population, of which 90% of 
the cases are T2DM, which is largely preventable or managed through 
lifestyle changes. This is equivalent to 1 in 4 people having diabetes. An 
estimated 940,000 people are unaware of their condition and are 
undiagnosed (PHE, 2016). Diabetes is known to lead to serious 
complications, including foot amputation, kidney disease, increased risk of 
stroke and heart disease.  
 
1.23 Diabetes in Newham 
 
Newham diabetes prevalence is more than the national average due to the 
high levels of deprivation and the varied ethnic groups who are at risk of the 
condition. Currently, there are over 20,800 people in Newham living with 
diabetes, with 1,800 more diagnosed every year (Diabetes UK, 2019). The 
current population in Newham is 332,583, with 30% of the population being 
under 20 years old, making it the youngest population in any of borough in 
London or England. 90% of the school population are from an ethnic minority 





1.24 Radiological presentation in TB-DM patients 
 
Studies which focus on the radiological appearance of TB in the presence of 
DM have suggested atypical presentation is common among the TB-DM 
cohort, and they are more commonly misdiagnosed for longer periods of time 
than those presenting with TB alone. Pulmonary TB is normally found in the 
lung apices, but in patients with DM, this does not occur. It is suggested that 
multi-lobular cavity TB is more common in individuals with DM, with increased 
levels of lower lobe involvement and effusion. However, other studies have 
contradicted this, demonstrating no difference in radiological findings between 
PTB suffers with and without DM. Sum et al. (2017) undertook one of the 
largest studies to observe radiological appearance, with the highest statistical 
power, to detect differences in radiological presentation between a TB-only 
cohort compared to a TB-DM cohort. The study concluded that there were no 
differences in the localisation of TB lesions between the groups. Many of 
these studies assessing the radiological presentation of TB in DM patients 
were carried out in low- to middle-income countries, where the incidence rates 
of other co-morbidities are likely to affect the presentation of TB (e.g. HIV).  
 
Radiographically, patients with TB-DM are thought to present with a confluent 
cavity, a wedge-shaped lesion spreading from the hilum towards the 
periphery, predominantly seen in the lower zones. The prevalence of the 
involvement of the lower zone in TB-DM has been seen in up to 29% of 
patients with DM compared to 4.5% in non-diabetic patients (Skowronski et 
al., 2013).  Furthermore, CT scans from patients with TB-DM have also 
demonstrated a higher prevalence of non-segmental distribution (30%) and 
multiple small cavities (44%). 
 
Appleton et al. (2017) assessed 154 patients who attended emergency 
departments six months prior to TB diagnosis, of which 24% (37/154) did not 
have a radiological examination in ED. In PTB cases, 86% (55/64) of patients 
who had a chest x-ray showed abnormality, compared with those with extra-




images also had multiple abnormalities. The three most common 
abnormalities were: consolidation in 55% (42/76), effusions in 26% (20/76) 
and a decreased volume or a collapse in 22% (17/76). Of the patients, 35 
presented with abnormal radiological appearance when TB had not been 
suspected.  In relation to gender, 63% (22/35) were men, with an average age 
of 45, with 71% (25/35) of these patients being foreign and born outside of the 
UK. Furthermore, 69% (107/154) of the patients with an abnormal chest 
image had reported symptoms of cough, fever or weight loss. There is no 
validated scoring system in acute TB diagnosis to correlate the radiological 
appearance to the severity of the symptoms.  
 
Appleton et al. (2017) assessed 397 TB cases, and 39% (154/397) had 
presented to the emergency department within the past six months before TB 
diagnosis. Chest radiography was carried out in 76% (117/154) of those 
patients; in newly suspected TB cases, 73% (41/56) had abnormal 
radiographic demonstration in contrast to 36 percent (35/98) of patients who 
had not. Abnormal x-ray was present in 73% (55/75) of PTB cases and at 
40% (21/52) of EPTB cases. The research highlighted how almost half the 
EPTB cases did not present with classical TB symptoms, and the other three-
quarters presented with other symptoms, with gastrointestinal symptoms 
being the most common. The low level of classic symptoms in EPTB makes 
the diagnosis based on symptoms alone unreliable. Using multivariable 
analysis, suggested abnormal chest x-ray was an independent risk factor, 
along with night sweats, in PTB cases. The study by Appleton et al. (2017) 
suggested standard chest imaging is valuable in diagnosis for both PTB and 
EPTB. The strength of this study is that it is one of the first studies in the UK 
to systematically assess radiological images and symptoms as a risk factor. 
The data collected was based on a large study population across two sites in 
moderately high-incidence populations based in two urban ED department in 
England. The limitation of the approach was the design of the study was a 
retrospective study, which relied on the availability of scanned or electronic 
records, and the study could not confirm if all patients had had active TB six 
months before their diagnosis or if a diagnosis had been made on their ED 




diagnosed 39% of TB at admission on first visits, with a large proportion not 




1.25 TB drug management in TB-DM patients 
 
The initial empirical treatment of TB consists of drug regimens using isoniazid, 
rifampicin, pyrazinamide, streptomycin and ethambutol. Special consideration 
is given to pregnant women, including those not using streptomycin as they 
are at increased risk for isoniazid-induced hepatoxicity (Bothamley, 2001). 
Special considerations are also made for HIV patients with TB, where dose 
adjustments are required, and rifampicin is avoided in those receiving 
protease inhibitors. An early start of anti-TB medication reduces the risk of 
AIDS and death. Patients with a high CD4+ T-cell count may be able to defer 
anti-retroviral therapy until the continuation phase of TB treatment. If MDR-TB 
is suspected, commencing empirical treatment before the culture results 
become available is recommended, and the regimen is modified, as 
necessary. Antibiotics are prescribed in combination and over a prolonged 
period to prevent the development of drug resistance (Prasad, Gupta & 
Banka, 2018) 
 
Diabetes impacts TB drug therapy, particularly for individuals who have poor 
glycaemic control, that is probably because of altered TB medication 
pharmacokinetics at DM (Alfarisi et al., 2018). DM influences drug 
pharmacokinetics, in addition to carbohydrate, lipid and protein metabolism. 
DM affects the enzymes/transporters involved with drug biotransformation, in 
addition to the decrease in plasma protein binding and displacement of drugs 
out of their own protein binding sites (because of high amounts of fatty acids 
at DM) which affect drug pharmacokinetics. Drug toxicity is also likely to 
increase from excessive accumulation in the body, leading to diabetic 





Rifampicin is a hepatic enzyme-inducer; it accelerates the metabolism of oral 
hypoglycaemic agents, particularly sulphonyureas and biguanides, this lowers 
their plasma serum levels, inducing hyperglycaemia in diabetic patients on 
these drugs (Niazi & Kaira, 2012). Non-diabetics also likely to experience 
symptoms of hyperglycaemia and stimulate a pre-diabetes state. Isoniazid, 
however, inhibits the metabolism of oral hypoglycaemic agents and influence 
a rise in the plasma levels of these medications. As a result, both these anti-
TB drugs interact with DM medication, in particularly with sulfonylureas, 
subsequently affecting glucose levels in the blood. It further interrupts the 
release and activity of insulin, leading to hyperglycaemia including in non-
diabetic patients. The dose of insulin should be corrected while removing or 
adding these medications when treating TB patients (Niazi & Kaira, 2012). 
 
1.26 Use of Vitamin D in TB Treatment 
 
Human monocytes have receptors including 1,25-dihyrdroxivitamin D, which 
initiates an anti-mycobacterial reaction in human monocytes and 
macrophages from the mechanism of phagocytosis and granuloma formation 
(Yang et al., 2016). The host response to infection is initiated by reactive 
oxygen and nitrogen intermediates; the suppression of matrix 
metalloproteinase enzymes inhibits the pathogenesis of both peptide and 
cathelicidin. Human vitamin D receptors (VDRs) are polymorphic, they are 
carried on the t allele of taq 1 VDR gene, which is associated with increased 
calcitriol-initiated phagocytosis of Mtb in vitro and more frequent conversion of 
sputum positive in patients with pulmonary tuberculosis. A low vitamin D level 
is associated with an increased risk of developing PTB (Kedzierska et al., 
2003).  
 
Chesdachai et al. (2016) explored the role of vitamin D as a supplementary 
treatment when added to the first-line anti-tuberculosis drugs in treating active 
pulmonary tuberculosis. Using a randomised case-controlled study, involving 
patients above the age of 18 with active PTB diagnosed by sputum 
examination, it was found that vitamin D accelerates the resolution of the host 




trials have reported a significant increase in the serum vitamin D levels from 
the start of anti-TB treatment and at the end of the 2nd month after the 
initiation of anti-TB treatment (p < 0.001). This signifies the good response of 
patients with active PTB to vitamin D supplementation, regardless of the 
vitamin D status in serum before the start of vitamin D therapy.  
 
Sita-Lumsden et al. (2007) reported a lower level of serum vitamin D levels in 
those patients with active PTB compared too controls, including those from a 
similar ethnic and social group. Systematic reviews suggest vitamin D 
deficiency is common in those with TB (Huang et al., 2017) but severe 
deficiency is rare. When assessing the sputum conversion, reports from 
studies show there is a significant negative correlation of vitamin D levels with 
the duration until the sputum conversion (Afzal et al., 2018). This suggests a 
low serum vitamin D increases the risk of TB and potentially affects the 
outcome of treatment (Zhao et al., 2017). Essam et al. (2016) studied vitamin 
D deficiency and its association with impaired immune function and the 
increased risk of active PTB. The study evaluated the use of vitamin D as a 
supplement treatment with first-line anti-TB medication for active PTB. Using 
a case-control approach, based in the El Maamora Chest Hospital, Egypt, 60 
adult cases were identified with active PTB.  One group (n=30) received 
vitamin D (200,00 IU) as an intramuscular injection with TB treatment and the 
other group (n=30) received TB treatment only. Vitamin D was detected in 54 
(90%) of the cases and, when the two groups where compared, there was a 
rapid decline in sputum conversion time and severity in TB infection in group 1 
with vitamin D supplement compared to the TB treatment only group (P-value 
<0.001 and P-value 0.02, respectively). Therefore, vitamin D supplement 
helps to improve TB outcome and therapy, but further studies on the effect on 
immunological interactions and cut-off levels are required (Raposo-Garcia et 
al., 2017).  Kota et al. (2011) studied the effect of vitamin D supplementation 
in DM type 2 with PTB and found in those receiving 60,000 IU of 
cholecalciferol per week in combination with anti-TB medication that the 
duration of sputum conversion to 100% negative for AFB was six weeks, 





1.27 Treatment outcomes in TB-DM patients 
 
Nijland et al.  (2006) noted that rifampicin is not absorbed as effectively in 
people with TB-DM and the plasma concentration of rifampicin was 53% lower 
in Indonesian patients with TB-DM compared to TB-only cases. This was due 
to the differences in metabolism, excretion and body weight between the two 
cohorts.  
 
The WHO considers DM to be a global epidemic which mostly affects low and 
middle-income countries. Globally, 1.7 billion adults are classed as overweight 
and 312 million obese, with 18 million death associated with cardiovascular 
disease in which DM is a predisposing factor (Majumder, Chaudri & Sanyal, 
2019). TB continues to increase mortality, with recent work by the WHO and 
the International Union Against TB and Lung Disease acknowledging the 
need for guidelines on the joint management and control of TB and DM. 
Jimenez-Corona et al. (2012) conducted a population-based prospective 
study of pulmonary TB patients in Southern Mexico, where almost one-third of 
the global TB cases with DM have been diagnosed. The study aimed to 
describe the clinical manifestation and treatment outcome of those with 
confirmed TB and DM compared to TB-only cases. The study included health 
facilities in Veracruz State from 1995 to 2010. Participants included those 
over the age of 15 with positive acid-fast bacilli cultures. All cultures were 
performed on smears (both smear-positive and smear-negative). DM was 
either diagnosed by a physician or confirmed by participants being on either 
oral hypoglycaemic medication or insulin treatment; all radiological images 
were assessed by an independent radiologist.  
 
Jimenez-Corona et al. (2013) reported individuals with TB-DM to have more 
severe clinical manifestations, delayed sputum conversions and a higher 
probability of treatment failure, reoccurrence and relapse. The study included 
the use of molecular testing to differentiate the subsequent episodes of 
infections within patients with DM as either bacteria with the same genotype 
or reinfection caused by a different strain. They observed a higher frequency 




are limited studies published to support these findings. The clinical and 
radiological presentations are more severe in the TB-DM cohort, with the 
study demonstrating a delayed sputum conversion at 60 days, which is 
reflected in other similar studies, although the timing of the delay conversion 
has varied amongst these studies. The independent risk of treatment failure 
associated with DM was at 2.93 (95% CI 1.18- 7.23), which is higher than 
reported in previous studies, and the combined outcome of failure and death 
was set at 1.69 (95% CI 1.36 to 2.12). One limitation of the study included the 
inability to analyse failure as a sole outcome due to the small sample size. 
The rate of reoccurrence and relapse among TB patients with DM were higher 
and this was an independent factor.  
 
Jimenez-Corona et al. (2013) used molecular fingerprinting of Mtb, which 
allowed the determination of whether DM cases experienced subsequent 
episodes of TB caused by reinfection with a different strain or a relapse with 
the same strain. The occurrence of reinfection is seen in one-fifth of all TB 
cases. TB reinfection in patients with DM is likely due to hospital-acquired TB 
transmission occurring because of patients attending clinics in which there is 
a large prevalence of both undiagnosed and diagnosed TB, for instance 
attending TB outpatient clinics (Dunachie & Chamnan, 2018).  
 
Khalil and Ramadan (2016) studied the risk factors for PTB among DM 
patients in a study size of 160 patients, grouped into 80 TB-DM patients and 
80 patients with DM and with chest infections other than TB. The mean age of 
the TB-DM cohort was 52.90 +/- 11.12 and the mean for the TB cohort was 
54.57 +/- 9.84, which were not significantly different. The TB-DM cohort 
comprised men (n=56) vs women (n=24), while in the DM group with no TB, 
the split was 55 male vs 25 females, with no statistically significant difference. 
Men were more commonly infected in the TB-DM cohort in agreement with 
other literature reports, including a Malaysian study with 69.3% males 
amongst the TB-DM the patients and in a study in Saudi Arabia using 187 TB-
DM patients, where men represented 75.9% of the population. BMI was 
statistically significantly different between the TB-DM cohort with a mean BMI 




group, with a p value of <0.01. The lower BMI can be most likely attributed to 
anorexia and consumption caused by the TB infection.  
 
Khalil and Ramadan (2016) further examined risk factors for TB and found 
platelets to be statistically increased in TB-DM patients, with a mean platelet 
count of 351.91 x 109/L compared to the control group of 270.88 x 109/L 
(p=<0.001). A lower total protein in blood and lower serum albumin were also 
associated with a statistically higher risk for TB. The mean serum total protein 
in the TB-DM group was 6.62 g/dl compared to 7.03 g/dl in the DM-only group 
(p= <0.01), serum albumin in the TB-DM cohort was 3.35 g/dl (p= 0.02). 
These results reflect the state of malnutrition common amongst TB-DM 
patients. This is further supported by Karyadi et al. (2000), who found that 
individuals with TB are likely to have a lower serum albumin concentration 
than controls by 10% (p= <0.05) (a case-control study on 82 patients), which 
demonstrates that a poor nutritional state is common among adults with PTB. 
Malnutrition is associated with TB as the patient’s metabolic state varies 
causing immune dysfunction. 
 
1.28 Drug Resistance in TB-DM patients 
Multi-drug-resistant TB (MDR-TB) is caused by the Mtb strain which fails to 
respond to a combination of two of the four main antibiotics (first-line anti-TB 
medication), rifampicin and isoniazid, and Extensively drug-resistant TB (XDR 
TB) is caused by an Mtb strain that is resistant to at least four of the main anti-
TB drugs (rifampicin, isoniazid, fluoroquinolones and second-line injectable 
agents) (NHS England, 2019). Furthermore, it is estimated that 3 in every 
1000 people globally are infected with latent MDR-TB, and the prevalence of 
latent MDR-TB is more than double that in those younger than 15 years of 
age. If this is not halted, the trend of MDR-TB in LTBI patients will continue to 
increase (Knight et al., 2019).  
In 2015, 10.4 million people were reported to have TB, of whom, 580,000 had 
MDR-TB. The risk factors of drug resistance are related to genetic factors, 




The strongest predictor for the presence of MDR-TB is a history of TB 
treatment, partly due to initiation of an inadequate regimen using first line anti-
TB drugs, the addition of a single drug to a failing regimen or failure to identify 
pre-existing drug resistance. Poor compliance with treatment is also seen as 
an important factor in the development of acquired drug resistance. More 
recently, the increased incidence of T2DM has been associated with the 
development of MDR-TB, as studies have reported a higher treatment failure 
rate in those patients with TB-DM (Rumende, 2018). In 2016, it was estimated 
that 4.1% of all new cases and 19% of all previously treated cases have 
MDR-TB. Surveillance data indicated that 600,000 people had developed 
MDR-TB in 2016 and 240,000 had died as a result. In 2016, 8,000 people had 
been diagnosed with XDR-TB globally and it is estimated that 6.2% of those 
with MDR-TB also have XDR-TB (WHO, Global TB Report, 2018).  
Directly Observed Therapy (DOT) is an initiative launched to aid with the 
management of drug-susceptible TB. Nonetheless, it is not enough to control 
recognized MDR-TB. A patient with MDR-TB would receive a regimen 
containing five of the second-line medications for the first months of therapy, 
followed by three to four drugs thereafter in the continuing phase of treatment 
(Davies, 2001). The treatment regimen indicated by WHO for TB-DM includes 
ethambutol, ethionamide/prothionamide, ofloxacin/ciprofloxacin.  
 
Pyrazinamide and aminoglycoside for the first 6 months, with the first three or 
four drugs being administrated for at least a further 18 months. In a large-
scale study in Peru, 55 percent of patients were given an identical regimen to 
WHO recommendation utilizing kanamycin, ciprofloxacin, pyrazinamide, 
ethambutol and ethionamide, following treatment failure with susceptible TB 
therapy, entered retreatment using a short-course routine of streptomycin, 
rifampicin, isoniazid, ethambutol and pyrazinamide for a treatment alternative 
(Davies, 2001), which resulted in reduced relapse of cases. However, it 
remains unclear of the best treatment regimen available as currently MDR-TB 
is treated based on individual cases. This is partly owed to lack of randomised 





Ofloxacin results in significant cure rates of about 80% in MDR-TB cases. The 
WHO, recommends a period of at least 18 months’ treatment including HIV-
negative patients the optimum duration of treatment for patients using MDR-
TB is unclear (Seung, Keshavjee, & Rich, 2015). There is some primary 
evidence which demonstrates that at the very least a percentage of 
immunocompetent patients that managed to achieve a sustained sputum 
culture conversion early in their treatment course, may be treated for 12 
months employing fluoroquinolone-containing regimens (Yew, Lange & 
Leung, 2010). However, in patients who are immunocompromised (including 
people who have DM) or have extensive radiographic signs of illness 
(particularly with fascia), extensive drug resistance in-vitro, postponed sputum 
culture conversion (i.e. following over three weeks of chemotherapy) or extra-
pulmonary involvement, should get longer than 12 weeks of therapy (Yew, 
Lange & Leung, 2010). 
 
In 2006, the WHO declared the emergence of XDR-TB, which is thought to be 
a virulent strain of drug-resistant TB. This follows previous research showing 
the extent of XDR-TB, a newly identified TB threat which is difficult to treat. 
This was based on a survey conducted by WHO and CDC from 2000-2004 
which found XDR-TB had been identified globally but most frequent in Asia 
and former Soviet Union. In South Africa, an outbreak of XDR-TB in HIV-
positive population in Kwazulu-Natal was associated with high mortality rate, 
of 544 patient studies, 221 had MDR-TB. of the 221 MDR-TB, 53 had met the 
definition of XDR-TB. XDR-TB has been identified in all regions of the globe, 
with potentially devastating consequences (Seung, Keshavjee & Rich, 2015).  
Epidemiological studies have shown the DM to be a risk factor for TB by 
increasing the risk from 2- to 4- fold depending on population. Within the last 
decade, a increase in MDR-TB and XDR-TB have been reported globally with 
increasing association with DM. The rate of DM in Mexico where both MDR-
TB and XDR-TB have been reported alongside a rise on DM from 5.8% in 
2000 to 9.2% in 2012. Munoz-Torrico et al. (2017) studied the outcome of TB 
treatment and the impact of DM, as well as the prevalence of adverse events 
(AEs), in a cohort of patient with MDR/XDR pulmonary TB from a national 




more common in the DM cohort (54.4%): the treatment outcome in the DM 
cohort compared to non-DM cohort remained the same, and the DM cohort 
had higher and more severe AEs to TB treatments. DM, therefore, has 
negative outcome amongst TB patients and is likely to be associated with 
increased risk of primary treatment failure using first-line TB drugs in 
susceptible TB cases. To improve treatment adherence compliance a fixed 
drug combination is a pragmatic approach which is likely to provide better 
treatment outcome. However, the implementation of a fixed combination of 
drugs would be difficult to implement, due to the different pharmacokinetics of 
anti-TB drugs and their interactions (Lima et al., 2017).  
 
As DM is reported as an independent risk factor for a slow response to 
treatment and low serum anti-TB drug concentrations, Heysell et al., (2013) 
undertook a Virginia state-wide study on the initiative of early therapeutic drug 
monitoring therapeutic dose of isoniazid and rifampicin for the first 2 weeks 
after TB treatment was commenced in patient newly diagnosed with TB with 
DM. Over a one year period, 21 DM patients had C2hr concentrations 
performed, of which 16 DM patients (76%) had a value below the therapeutic 
range for isoniazid, rifampicin, or both. Fifteen patients of these patients had 
dose adjusted, with 12 patients (80%) showed an increase to within the 
expected range. Early therapeutic drug monitoring in patients with DM is likely 
to increase the response to TB treatment by ensuring appropriate dose is met 
as DM itself and DM medications are known to alter TB medication 
absorption.  
 
Munoz-Torrico et al. (2017) reported the severity of AEs varied from gastritis 
to fatal syndrome with nephrotoxicity and hypothyroidism and ototoxicity most 
likely in TB-DM patients. This was correlated with high levels of HbA1c, which 
is a predisposing factor to the development of systemic chronic complications.  
 
1.29 TB Treatment in HIV infected patients 
 
Treatment of active or latent TB patients with HIV infection is managed as 




significant differences involve avoiding prescribing rifampicin to patients who 
are on medication which are protease inhibitors. An alternative is rifabutin for 
these patients. Patients with HIV and TB are likely to develop a paradoxical 
response immune reconstitution inflammatory syndrome (IRIS) when 
commencing antiretroviral therapy. This response has been linked more 
strongly with the immune response to Mtb, with increasing clinical severity of 
symptoms, including fever, greater pulmonary infiltrates and 
lymphadenopathy occurring (Cohen & Meintjes, 2011). 
 
A randomised controlled trial has proven that survival was improved by the 
initiation of antiretroviral treatment during TB treatment. The analysis found 
that the mortality rate together using the initiation of antiretroviral treatment 
and TB treatment has been 5.4 deaths per 100,000 individual years (25 
deaths in 429 patients). In comparison to 12.1 deaths per 100,000 individual 
years (27 deaths in 213 patients) with antiretroviral treatment beginning after 
the conclusion of TB treatment, a comparative decrease of 56 percent (Karim 
et al., 2011). 
 
Ku et al. (2013) compared CD4+ T cell counts in patients with co-infection 
with HIV and TB, which included patients with high CD4+ T cells. They found 
when starting antiretroviral therapy early (within four weeks after the start of 
TB treatment) patients had reduced progression of TB infection and death. 
There is the possibility of deferring initiation of antiretroviral therapy until the 
continuation phase of TB treatment.  
 
When comparing the duration of treatment of those with a coinfection of HIV 
and TB, studies have shown the TB reoccurrence is slower when a 9-month 
treatment is prescribed compared to a 6-month course of treatment 
(Bruchfeld, Correia-Neves & Kallenius, 2015). The association of TB-DM with 
HIV patients is of great interest. TB is known to induce secondary 
hyperglycaemia and insulin resistance without the presence of DM (Kwan & 
Ernst, 2011). Moreira et al. (2017) evaluated the prevalence of 
hyperglycaemia amongst a co-infected HIV and TB cohort who had 




cohort analysis included adults who had been diagnosed with TB and HIV 
between 2010-2015. They excluded the known DM population at baseline but 
included newly-onset DM after TB treatment and TB outcome had been 
evaluated as successful or adverse. The study found 414 individuals were 
euglycemic (87.5%), 49 hyperglycaemic (10.3%) and 10 had been diagnosed 
with new onset of DM (2.1%).  
 
The risk factors for DM included age, as is observed when comparing 
euglycemic and hyperglycaemic levels in patients (47.9 vs 39.7 years, p = < 
0.0001). The DM patients presented with more cavitation on chest radiological 
imaging compared to the hyperglycaemic and euglycemic patients (50% vs 
23.4% vs 15.3%, P value 0.0007). The hyperglycaemic patients were more 
likely to have new onset of DM at follow-up, compared to the euglycemic (22 
vs 1, P value <0.0001). The hyperglycaemic patients were associated with 
greater adverse outcomes (71.4% vs 24.6%, P value <0.0001) compared to 
the euglycemic patients. Using a 1-year crude mortality rate, this was higher 
in individuals with hyperglycaemia compared with those with euglycemia 
(48.9% vs 7.9%). Moreira et al., (2018) found that transient hyperglycaemia is 
common in HIV infected patients who have commenced anti-TB medication 
and have an increased risk of adverse outcome. A limitation of their study 
included not having HbA1c testing available, which may have led to 
misclassification of hyperglycaemia in cases that had undiagnosed DM. The 
findings are consistent with a study conducted by Said (2017) in Tanzania, 
where there was a reported negative impact of hyperglycaemia during TB 
treatment. They had a median follow-up rate of five months after TB treatment 
had commenced, and the proportion of TB/ HIV co-infection was 32%. 
 
1.30 Summary on the clinical presentation of TB-DM 
 
If DM increased the risk of acquiring TB infection, the manifestation of TB in 
individuals with DM may also likely result in a different clinical presentation 
compared to classic TB presentation. Although the severity of TB in DM 
patients has not been truly investigated, a difference in TB disease severity 




implications. For instance, a baseline TB characteristic can predict which 
patients might not respond to anti-TB drugs or have a higher rate of relapse. 
Smear-positive TB patients produce more bacteria in expectorated sputum, 
which is an indication of higher bacterial load and a greater infection risk 
compared to those who are smear-negative. For instance, a recent study in 
Taiwan found 88% of TB patients with DM had AFB smear-positive TB, with 
only 59% of TB patients without DM being AFB smear-positive (P value 
<0.01) (Workneh, Bjune and Yimer, 2017). However, most studies on the 
microbiological aspects of TB show DM is associated with smear-positive TB; 
whereas others do not and thus studies are inconclusive. Therefore, whether 
DM causes more TB bacterial burden, and consequently more positive smear 
results, remains under-investigated. Radiographs of the chest are used to 
diagnose TB and measure the extent and severity of the disease. Studies on 
TB-DM and radiographic findings suggest CXR of those with TB-DM is likely 
to be more atypical in appearance, with lower-lung involvement with greater 
cavities. If this is true, from these early studies, clinically this has implications 
for the diagnosis.  However, these studies have shown no association and are 
inconclusive. The emergence of TB drug resistance poses a threat to global 
TB control due to a greatly increased risk of poor TB treatment outcomes by 
patients failing to complete TB treatment, not adhering to treatment regimens, 
or suffering from an insufficient absorption mechanism. A meta-analysis of 
MDR-TB on treatment outcome estimated an overall success rate of TB 
treatment at less than 62% of patients, while an estimated 8% fail and 11% 
die (Kibret et al., 2017).  
 
XDR-TB is defined as mycobacteria resistant to at least four of the main anti-
TB drugs (rifampicin, isoniazid, fluoroquinolones and second-line injectable 
agents) (NHS England, 2019). Individuals with XDR-TB have a poor treatment 
outcome, and 20% of XDR-TB patients die because of unsuccessful treatment 
(Eshetie et al., 2018). Similarly, regarding AFB smear and CXR results, most 
studies have shown no association between TB-DM and drug resistance to 
TB, with some exceptions. Absorption of anti-TB medication is important, and 
this may be altered by DM, which could lead to increased development of 




the absorption of rifampicin in TB with and without DM; they both reported 
conflicting results. If a TB patient with DM increases the resistance at the time 
of TB diagnosis or develops drug resistance during therapy, the clinical 
success is important. Sputum culture conversion from positive to negative 
after two months of anti-TB treatment is used as a measure of treatment 
efficacy and is associated with TB treatment success. From evaluating the 
literature from the systematic review on the association between DM and TB 
2-month culture conversion found a delayed response to treatment among the 
TB-DM cohort. Furthermore, the SR review of nine studies that determined 
the proportion of TB-DM patients who converted sputum cultures by two-
month TB treatment, when comparing two-month data, only six of the nine 
reported having found an increased risk of no culture-positive in TB.  
 
Alisjahbana et al. (2007) reported that 71% (67/94) of the TB-DM cohort 
compared to 8.3% of the TB-only (466/540) cohort were AFB sputum negative 
after the initial intensive phase of TB treatment. Although many studies have 
been reported on TB-DM patients being examined for 2-month culture 
conversion, few have used adequate measures of DM or had sufficient 
sample sizes. Relapse among TB patients is defined as a patient who 
previously completed TB retreatment successfully and, subsequently, is 
diagnosed with sputum smear or culture-positive TB. Whether DM increases 
the risk of TB relapse has been examined in few publications. A retrospective 
cohort study in China reported 20% of 203 treatments completed in a TB-DM 
cohort returned to TB clinic within two years of their first completion (Mishkin, 
2018). Baker et al. (2011) developed a pooled risk ratio from five studies to 
help estimate TB relapse. Comparing patients with and without DM, the risk of 
relapse in TB-DM was 3.89 (95% CI 2.43 - 6.23) times the risk of TB patient 
without DM. The mortality rate has been examined as it is thought DM is the 
risk of death in TB-DM patients. A 2011 systematic review by Baker et al. 
(2011) showed that 95.5% (21 of 23) of studies found an increased 
unadjusted risk of death among a TB-DM cohort when compared to TB 
patients without DM. However, there were many limitations to this study, 





1.31 Bi-directional screening 
 
A bidirectional screening for DM in all patients with TB should be considered; 
this would help identifying TB patients with a risk of DM. Screening for DM in 
the initiation of TB drugs should improve the management of DM, with better 
TB treatment outcomes. Further to this, active TB infection should also 
include assessing DM symptoms, including polydipsia, polyuria, polyphagia, 
weight loss, blurred vision and poor wound healing. Bidirectional screening 
would depend on the availability of staff and technology, and would include 
those with known risk factors, e.g. old age, male, smoking, previous history of 
TB (Siddique et al., 2018).  
 
Screening for DM in TB patients also requires further caution as Mtb infection 
elevates blood glucose levels of HbA1c over a shorter duration of time 
(Siddique et al., 2018). Therefore, any screening for DM should be done at 
the earliest stage of TB confirmation (Zheng, Hu & Gao, 2017). In relation to 
testing methods for DM, as a routine practice, they pose problems, with either 
fasting 2-hour post-prandial or HbA1c as the choice of test. A random or 
fasting blood glucose test will aid to diagnose DM but this has low sensitivity 
of fasting blood glucose (FBG). HbA1c offers a better method for screening. In 
the UK, there is a lack of a multidisciplinary integrated program and quality 
evidence on the feasibly of good DM management. A quality study is required 
to understand the association between TB and DM, which would be useful in 
targeting and reducing TB incidence and improving the TB treatment 
outcome. 
 
1.32 Identification of gap in knowledge and current clinical practice for 




A systematic review of recent literature was undertaken to evaluate current 





1.34 Inclusion criteria 
 
Studies included in the review were cross-sectional, case-control and cohort 
studies from adult patients diagnosed with both TB and DM. In addition, latest 
National Institute of Clinical Excellence (NICE), Public Health England (PHE), 
and World Health Organisation (WHO) studies were included. The diagnoses 
included pulmonary TB and extra-pulmonary TB, either diagnosed clinically 
(including commencement of anti-TB medication) or through using laboratory 
diagnosis, i.e. culturing of M. tuberculosis. The diagnosis of DM was defined 
by measurement of fasting plasma glucose, oral tolerance test, self-reported, 
glycated haemoglobin or diagnosis by a physician.  
 
1.35 Exclusion of studies 
• All duplicate publications of studies were removed. 
• Studies where data was not fully accessible. 
• All studies prior to 2010 















Table 1.1. Search Strategy  
Search Category Search Strategy 
1 Therapy 
Tuberculosis AND trial OR TB* OR meta-analysis OR 
TB* OR systematic reviews OR TB* OR therapeutic use 
OR TB* OR Literature Review OR Diabetes AND trial 
OR diabet* OR meta-analysis OR diabet* OR 
systematic reviews OR diabet* OR therapeutic use OR 
diabet* OR Literature Review 
2 Diagnosis 
Sensitive*TB OR diagnosis OR diagnose TB OR 
diagnosed TB OR diagnoses TB OR diagnosing TB OR 
diagnosis TB OR diagnostic TB OR diagnosis OR 
diagnosis. Differential 
3  # 1 AND 2 
4 Aetiology risk*TB OR risk*[TB:noexp] 
5 Prognosis 
Incidence [TB:noexp] OR mortality TB OR follow up 
studies [TB:noexp] OR prognos*TB OR predict*TB OR 
course*TB 





Outcomes*TB OR predictive value of tests 
 
8  # 3 AND 6 AND 7 
9  Studies published in English 
 
1.36 Databases used 
 
The search of databases included Science Direct, PubMed, Excerpta Medica 




association of TB and DM from 1st of January 2010 to 31st of December 2019, 
using the above key terms (Table 1.1). 
  
The search strategy used included using medical subject heading (MeSH) 
terms and text word terms to identify all relevant studies, whether catalogued 
under the relevant terms or not. Special characters, search functions and 
Boolean Operators were used to produce a strict search strategy. The use of 
“exp” and the back slash within search strings 1 to 5 indicate that these 
strings used the explode command; an exploded search string selected 
articles indexed with that search term, plus articles indexed with the related 
narrower terms. The search was restricted to English language papers only. 
All duplicate references were removed after citations were downloaded into 
Mendeley using the duplicate function in the programme. All relevant 
abstracts were reviewed, and where relevant the full articles were reviewed.  
 
1.37 Selection of studies for full review  
 
All relevant studies were assessed using an assessment guide/grid to ensure 
that the selection criteria were reliably applied to all the articles. These full 
texts were screened using a standardised form for final inclusion in the 
review.  
 
1.38 Data extraction and management 
 
Data extracted included authors, country, region, year of publication, study 
design, study period, country of study, DM diagnosis, TB diagnosis, data 
collection method, number of DM cases, age, % of resistant TB and total 
population size. 
 
1.39 Search results  
 
All publications which cited analytical estimates of the association between 
DM and TB were included. After abstract review of 103 citations, 42 
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1.40 Evidence of an association between DM and TB from published 
studies 
 
Nine studies (two cohort and seven case-control studies) estimated DM to 
increase the risk of TB infection in individuals by 1.5 to 7.8-fold. Fourteen 
studies found DM was associated with an overall RR of 3.11 for contracting 
TB, although a limitation of this was the studies by Benoit et al. (2017), 
Caraffa et al. (2016), and Rajapakshe et al.  (2015), which were heavily 
weighted, as pooled results consisted largely of patients with renal failure 
(renal failure was identified as a risk factor for TB), which limited the 
applicability of the findings more widely. Furthermore, the impact of age on 
the estimation of the association between DM and TB, found increasing age 
to increase the risk of TB and this was confirmed in reports by Barss et al. 
(2016) and De La Garza et al. (2016) but not in the study by Ekere et al. 
(2017); Boillat-Blanco et al. (2016); and Davis et al. (2016). 
 
Evidence suggests a potential link between DM and TB, from a UK based 
study by Pealing et al. (2015) using a cohort study approach. They used data 
from the Clinical Practice Research Datalink (CPRD), which contains rich data 
primarily from primary care databases. However, the limitation of this study 
includes the variable completeness of the database, misclassification and 
disease definitions. Patients were identified within the CPRD with incident 
diabetes (types 1 and 2 included), ≥5-years old, who had their first recorded 
diagnosis for diabetes using NHS codes. This study reported an overall 1.3-
fold increased risk of TB in those with DM. There was no evidence for higher 
relative increase in TB rates among DM patients of different age groups or 
ethnicities, longer duration of disease, those using insulin or with worse 
glycaemic control. There was strong evidence for differences among DM 
patients with different health care utilization patterns (adjusted RR 1.30, 95 % 
CI 1.01 to 1.67, P = 0.04). No evidence of effects of age, time since diagnosis 
and severity of DM on the association between DM and TB was reported. 
 
Further research into DM and TB association is needed, especially in high TB 




DM did not contribute to worsening of TB condition i.e. DM increased TB 
treatment failure, relapse, or development of MDR-TB. Similarly, whether TB 
impacted upon the risk of developing DM post treatment (Zhao et al., 2016); 
(Delgado-Sanchez et al., (2015). Although a risk estimation was made, no UK 
study has been done on the prevalence of TB-DM in a regional or local setting 
using primary data. Therefore, a gap in knowledge of the true estimation of 
DM prevalence in the TB population is unmet and should be investigated.  
 
1.41 Risk of DM amongst individuals with TB 
 
Most studies have reported on the risk of DM developing amongst individuals 
with TB. The estimation of the risk of TB developing in DM patients ranged 
from a 1 to 7-fold increase (Bridson et al., 2015; Hermosillia et al., 2017). The 
potential of a bi-directional association between DM and TB is not evident as 
yet. Patients with DM are at increased risk of TB infection and risk factors 
need to be identified for clinical pathways to be created to manage the patient 
with TB including an appropriate testing and treatment regimen. Therefore, a 
gap in knowledge of the true prevalence of DM in the TB population is 
currently unknown.  Pearson et al. (2019), reported a UK based study, which 
recognised an increased risk of PTB among those with DM. However, the 
evidence on whether the association was bidirectional remained sparse, and 
Pearson et al. (2019) investigated the DM rates among those with and without 
TB disease as a reverse. Using data from the UK general practice population 
between 2003 to 2009, from the Health Improvement Network database, the 
study reported DM risk was substantially raised amongst individuals with a 
history of TB disease (IRR 5.65 (95% CI 5.19 to 6.16)), PTB) IRR 5.74 (95% 
CI 5.08 to 6.50)) and EPTB (IRR 4.66 (95% CI 3.94 to 5.51)) compared to 
those without. These findings indicated the need for screening of patients with 
TB for DM, who are at a higher risk of DM and related complications.  
 
1.42 Risk of TB amongst individuals with DM in the UK 
 
From the systematic reviews, only two UK based studies were conducted with 




generally a low incidence country, with selected areas of high incidence, 
therefore is lacking and provides a gap in our understanding of the prevalence 
of TB-DM and its characteristics in UK hot-spot areas, such as Newham.  
 
1.43 Measures of association between sub-types of TB and DM 
 
Of the systematic reviews, 10 did not specify if the studies were assessing the 
association between specific sub-types of DM or TB and were to be assumed 
to be assessing the association between all types of DM and TB. 
• One study specified they were assessing the association between PTB 
and DM (Faurhoult-Jepsen et al., 2011).  
• One study assessed the association between post-transplant TB and 
DM (Zhao et al., 2016).  
• Two studies assessed the sub-types of T1DM, T2DM and TB (Dobler 
et al., 2012 and Leegaard et al., 2011).  
• a single study measured the association between DM and both PTB 
and EPTB (Pearson et al., 2019).  
Papers which included a measure of TB risk amongst individuals with T1DM 
identified an increase in risk, although only one estimate showed significance 
RR 2.27 (95% CI 1.19-3.66) and (Odds Ratio (OR) 2.59 (95% CI 0.44-15.20) 
(Cai et al., 2017). Subtype studies reported an increased risk estimate for TB 
amongst those with T1DM compared to those without T1DM, a reason for this 
is T1DM is associated with hyperglycaemia due to poor glycaemic control 
(Workneh et al., 2016). 
 
Only one study measured PTB and EPTB risk amongst individuals with T1DM 
compared to those without and found that the risk of PTB was significantly 
increased in individuals with DM, whereas there was no significant increased 
risk of EPTB, although the study had a small number of participants (n=69) 
(RR 1.42 (95% CI 1.12-1.80) and (OR 1.05 (95% CI 0.49-2.31)) (Bridson et 
al., 2016). The study was underpowered to explore the potential association 
with EPTB, as it accounts for less than 20% of global TB and only 10% of DM 




many low-income and middle-income countries (LMIC), where TB burden is 
the highest. The most significant finding was the association between T2DM 
and PTB as approximately 90% of individuals with DM have T2DM and PTB is 
the most prevalent infectious form of TB. However, further investigation is 
required. Due to the lack of studies on DM subtypes (T1DM and T2DM) and 
TB subtypes (PTB or EPTB) which are managed differently, a UK based study 
is required to understand the characteristics of PTB and EPTB in terms of 
presentation and diagnosis in patients with diabetes, which is likely to affect 
treatment course.  
 
1.44 Co-morbid DM and TB 
 
The systematic review identified two studies which highlighted the estimation 
of the association between DM and TB on TB incidence (Ruslami et al., 2010 
and Walker et al., 2010).  Both studies calculated the population attributable 
fraction (PAF) of TB due to DM considering best estimates of the association 
size, DM prevalence and TB incidence for specific regions. Walker et al. 
(2010) calculated the PAF for the UK showing that the effects of an 
association between DM and TB would not be negligible in this setting, 
especially amongst those already at an increased risk of TB, due to their 
ethnicity. The risk estimated for all ages varied showing that from 6.9% of 
incident TB (amongst white British) to 19.6% of incident TB (amongst those of 
Asian ethnicity) attributed to concomitant DM.  
 
Ruslami et al. (2010) outlined the estimated proportion of TB incidence 
attributable to concomitant DM in the population in the ten countries with the 
highest incidence of TB: India (12.9%), China (7.8%), Indonesia (9.5%), 
Nigeria (7.6%), South Africa (8.7%) Bangladesh (11.2%) Ethiopia (4%), 
Pakistan (14.4%), the Philippines (12.9%) and the Democratic Republic of 
Congo (5.2%), noting that these estimates would be expected to rise as DM 
prevalence increases. The paper identified the context of the association 
between DM and TB, and highlighted the possible impact of the association, 





Only one UK study demonstrated the TB risk in the non-UK born population to 
be higher, this did not consider other co-morbid factors i.e. renal disease and 
DM (which is linked more to Asian and black ethnic individuals) (Walker et al. 
(2010). Therefore, a further investigation into comorbid links is required in a 
UK TB-DM cohort.  
 
1.45 Radiological appearance 
 
There are several studies which have assessed the radiological presentation 
of TB amongst individuals with DM. Radiological evidence is used to aid TB 
diagnosis and at times may be solely used to diagnose active TB disease. If 
radiographic presentation is atypical, as is the case in DM patients with TB, it 
is likely that they will go undiagnosed for a longer period than those with TB 
alone and clinically have worse outcomes (Moreno-Martinez et al., 2015).  
 
PTB is predominantly found in the lung apices, however, in individuals with 
TB-DM this is thought not to be the case. Lower lung field TB may occur, but 
is often misdiagnosed as pneumonia, bronchial carcinoma or lung abscess, 
as these patients are often smear test negative (Perez-Navarro et al., 2017). 
Studies from this systematic review show individuals with TB-DM are more 
likely to present with lower lobe involvement, with increased numbers of multi-
lobular cavities and increased prevalence of pleural effusion. Kayhan et al. 
(2012) found that multi-lobular cavity TB is more common in individuals with 
DM. Perez-Guzman et al. (2014) conducted one of the largest radiological 
study (TB-DM, n=202 vs control, n= 226; p= 0.02)) with high statistical power 
to detect differences in presentation between patient subgroups, found no 
difference in the localisation of TB lesions in those with and without DM. 
  
Most of the identified studies looking at the differences in the radiographic 
presentation of TB amongst individuals with DM were completed within low to 
middle income countries, where incidence rates of other co-morbidities, which 
may affect presentation of TB are high (such as HIV). Walker et al. (2010) 
reported only 8% of individuals with TB had abnormal radiographic 




national database data which does not report in-depth radiographic 
presentation. As a result, current published data on the lung pathology in TB-
DM individuals is contradictory and evidence should be considered with 
caution. Therefore, further studies are required as this remains inconclusive. 
A closer investigation into TB-DM radiographic images is required and to 
assess whether in areas where there is high TB incidence, there is a 
difference in radiographic appearances in individuals, furthermore, those with 
EPTB (or suspected) i.e. abdominal TB should also have radiographic 
assessment to rule out possible PTB with EPTB. This would allow for a 
clinical pathway to be created for testing TB-DM patients appropriately for 
sending for more routine tests, if set criteria are met. For example, a DM 
patient presenting with a persistent cough for more than 2-weeks would be 
referred for a chest x-ray. 
 
The radiographical presentation of TB is likely to depend on many factors, 
including the duration of illness and the host immune system. Perez-Navarro 
et al. (2017) reported that a large proportion of DM patients with TB had 
lower-lung involvement compared to non-DM TB patients, who presented with 
upper-lobe involvement. Their findings suggested PTB in TB-DM patients had 
an atypical radiographic presentation, with lower-lobe involvement. Clinically 
this is significant, as this may be misdiagnosed as community acquired 
pneumonia. Furthermore, those PTB patients that do not present with upper 
lobe involvement are less likely to have positive sputum smears and culture.   
 
Furthermore, lower-lobe lung involvement is observed in older individuals and 
this change is likely to be related to changes in lower-lobe alveolar oxygen 
tension related to age or DM. Perez-Navarro et al. (2017) have reported multi-
lobar disease or the presence of multiple cavities more commonly in TB-DM 
patients, but lower-lung disease was rare in TB-DM patients compared to the 








1.46 Signs and symptoms 
 
As with radiographic presentation, atypical presentation of signs and 
symptoms amongst TB-DM individuals could increase the likelihood of TB 
being undiagnosed for longer periods of time, than those with TB alone, 
leading to poorer clinical outcomes (Tahir et al., 2016). A late TB diagnosis 
also poses a risk to public health and increases the risk of TB transmission to 
others. As TB remains undiagnosed, the index case will have significant 
contact with core groups of people increasing the spread of TB. Study 
participants also presented with weight loss and weakness, a feature in TB-
DM. Therefore, TB should be considered in patients with DM, who have 
unintentional weight loss and night sweats that cannot be explained by poor 
control of diabetes. Furthermore, TB-DM patients presented with further 
complications including lung abscess, pleural effusion and hydro-
pneumothorax (Gadaliah et al. (2015) and Jerene et al. (2017)).  
 
Evidence from this systematic review suggests that the sociodemographic 
and clinical characteristics of those presenting with TB-DM differ from those 
with TB alone. Individuals with TB-DM are thought to present with TB at an 
older age, predominantly male, have a higher BMI before and after treatment 
and are less likely to present with EPTB, and more likely to present with more 
severe symptoms and differences in radiological features. 
 
Wang et al. (2016) undertook a retrospective study and found that patients 
with TB and DM showed higher frequencies of fever and haemoptysis, 
although symptoms were self-reported. Alladin et al. (2011) found no 
difference in symptoms between patients with PTB in those with or without 
DM, except for polyuria in TB-DM cases. There are few studies which assess 
the role of symptoms of the co-affected DM and TB patients, and with sparse 
data and contradictory findings, further research is required for TB-DM 
cohorts and to determine whether symptoms and diagnostic testing should be 






1.47 Management of TB-DM co-morbidity 
 
Studies have shown a decreased effectiveness of TB treatment amongst 
individuals with DM. DM patients are thought to have impaired gastrointestinal 
drug absorption, due to gastroparesis, which may affect the uptake and 
absorption of medication. The uptake of rifampicin was 53% lower in 
Indonesian patients with TB and DM compared to patients with TB only 
(Khandkar et al., 2015). This could be due to poor gastrointestinal uptake, or 
due to differences in metabolism, excretion and body weight amongst those 
with DM.  Furthermore, individuals with TB-DM are less likely to adhere to 
medication schedules (Khandkar et al., 2015). These findings are inconsistent 
with some studies which demonstrate a lower proportion of co-morbid 
individuals defaulting on their TB treatment compared to those with TB alone 
(Haraldsdottir et al., 2015). The findings of these studies are debatable in 
terms of clinical significance, and further assessment of efficacy of treatment 
regimen amongst TB-DM is required.  
 
It is known that TB medication leads to transient hyperglycaemia, and it is 
likely that amongst those being treated for TB, hyperglycaemia is occurring as 
a side effect of treatment with rifampicin and isoniazid, or that the 
hyperglycaemia is observed as a stress hyperglycaemia rather than a real 
indication of metabolic dysfunction (Restrepo et al., 2011). Therefore, it 
remains to be seen whether TB increases the risk of DM or undiagnosed DM 
leads to poor clinical outcome for TB. A bi-directional screening is likely to be 
of benefit in this instance.  
 
The systematic review identified studies assessing TB outcomes amongst 
those with and without DM. No study proposed treatment regime alteration or 
methods for checking for adherence to medication, which is likely to affect 
patient outcome. Therefore, there is an unmet need to assess whether TB 
medication is in the therapeutic range comparing both TB only and TB-DM 
groups to ensure an appropriate plasma concentration is achieved, and where 





As DM and TB have an increased reciprocal risk, there could be a bi-
directional screening opportunity for TB in DM patients and DM in TB patients. 
Screening for active TB in DM clinics would allow earlier detection of TB and 
reduce the risk of TB transmission in DM clinics and within the community 
(Kornfeld et al., 2016). Especially if a patient presents with a cough for more 
than 2 weeks alongside weight loss, night sweats, fever and a history of TB 
contact. TB is also likely to increase the risk of DM, anti-TB medication, 
predominantly rifampicin can cause hyperglycaemia. Therefore, screening for 
DM should be investigated in all patients over the age 18 years with TB. The 
preferred method for screening for DM and time should also be further 
investigated.  Screening for DM in TB patients has been conducted in India 
and the Pacific Islands, which can be mirrored in other countries with a high 
prevalence of TB, although more evidence for this is required (Pealing et al., 
2015).  
 
In the UK, in high TB incidence localities, screening for DM should be 
investigated and understanding of the prevalence of TB-DM would provide 
evidence for this. Furthermore, individuals with DM who have TB are likely to 
respond less well to treatment than those without DM. Baker et al. (2012) 
found that the risk ratio of treatment failure or death in TB cases was 1.69 
(95% CL 1.36-2.12) after adjusting for confounders such as age, the risk of 
death was 4.95 (2.69-9.10) among individuals with DM compared to those 
without. There was an increased risk of relapse (RR 3.89; 2.423-6.23). 
Individuals with DM have lower plasma concentrations of rifampicin than 
expected. In an Indonesian study, rifampicin levels were 50% lower in TB 
patients with DM compared with those without. It is thought a larger dose 
maybe required for overweight individuals (Delgado-Sanchez et al., 2015).  
 
Furthermore, if DM is thought to alter immunity to TB in affected individuals, 
this is likely to lead to higher mycobacterial burden and increase in time to 
culture conversion with treatment, and a higher rate of relapse may result. 
Three retrospective studies (Dave et al., 2013; Chian et al., 2015 and Chen et 
al., 2014) suggested that mycobacterial burden is higher in DM patients than 




findings. In studies which assessed sputum-culture conversion at 2-months of 
treatment (intensive phase), the conversion proportions were similar in DM 
patients and controls. For instance, in the Indonesian study by Alisiahbana et 
al. (2014) found DM was not a risk factor for sputum smear or sputum culture 
positivity at 2-months of treatment. In a Turkish study Kayhan et al. (2012), 
patients with DM who received TB treatment had longer sputum-culture 
conversion times, TB-DM patients took longer to achieve culture negativity 
than non-DM patients (67 vs 55 days, p=0.02). The use of a survival analysis 
to measure time to culture conversion, median time to culture negativity was 
significantly longer in DM patients than in controls (42 vs 37 days, p=0.03). 
These data suggest the bacillary load to be higher at presentation in TB-DM 
patients, this leads to a longer time to sputum-culture conversion. Whether 
this increased time to culture conversion in TB-DM patient leads to higher risk 
of relapse requires further study. 
 
1.48 Treatment failure and death 
 
Whether DM increases the treatment failure of TB or increase death remains 
unanswered. Study by Lee et al. (2017), compared 119 patients with 
treatment failure to 1119 controls, DM increased the risk of treatment failure 
by 3.9-fold. In an Indonesian study (Alisiahbana et al. (2014), patients with 
higher treatment adherence found at 6-months 22.2% of the patients with DM 
and 6.9% of the controls were positive, with drug resistance was lower in DM, 
therefore treatment failure was not due to drug resistance or non-adherence 
to treatment.  
 
Two retrospective cohort studies, Restrepo et al. (2011) and Uwanipimolkul et 
al. (2014) on patients with PTB in the USA showed a 6.5-6.7 times increased 
risk of death in DM patients compared to non-DM controls. In Wang et al. 
(2016) the 1-year mortality rate was 17.6% in DM patients compared to 7.7% 
in non-DM controls, and death related to PTB was more common in DM 






Studies on treatment failure and mortality rate suggest this to be more likely to 
occur in TB-DM patients. However, there is no suggestive management of 
TB-DM patients, as this could improve treatment response, which remains to 
be investigated, furthermore, deaths reported does not explain if the 
increased severity of symptoms is presented in TB-DM patients or by the 
existence of comorbidities attributable to DM compounded by advanced age. 
 
Furthermore, TB drugs may affect DM treatment, DM is also likely to alter the 
pharmacokinetics of TB drugs. In a study by Wu et al. (2016), DM patients 
with TB had rifampicin serum concentrations that were 53% lower than in non-
DM patients with TB. This low concentration of TB drug may be linked to 
treatment failure or resistance. DM can cause changes in oral absorption, 
decreased protein binding of drugs, and renal insufficiency or fatty liver with 
impaired drug clearance. The effect of DM on TB drug concentration is yet to 
be fully understood.  
 
1.49 National Clinical Evidence for TB-DM screening and management 
 
NICE (TB Clinical Guidelines, 2016) reported patients with DM have both an 
increased risk of developing TB and significant morbidity and mortality. This is 
due to an impaired immune response to TB infection in patients with DM. 
Furthermore, NICE acknowledges treatment course is more difficult with 
poorer treatment outcomes in TB-DM patients compared to those without DM.  
 
NICE reviewed the use of standard treatment regimens to be adapted to 
accommodate DM and the effect of these regimens for treatment of active 
PTB or EPTB. This was based on evidence reviewed from Medline, Embase, 
Medline in Process, the Cochrane Database of Systematic Reviews, the 
Cochrane Central Register of Controlled Trials, the Database of Abstracts of 
Reviews of Effects, and the Health Technology Assessment database. The 
review included randomised, quasi-randomised and non-randomised 
controlled trials, prospective studies, comparing treatment regimens of TB in 
patients with active drug-susceptible TB and DM. The review included 3838 




conditions of interest, no papers relating to the treatment of TB in patients with 
coexisting DM met the inclusion or exclusion criteria (NICE, 2016).  
 
No evidence comparing the effectiveness of different anti-TB regimens in 
patients with DM was identified. However, it was noted that TB treatment in 
DM patients was more difficult due to diabetic complications, such as renal 
failure or due to adverse effect profiles of anti-TB drugs and DM, for example 
neuropathy, or because of drug interactions between treatments used for both 
conditions. As a result, DM patients can be at risk of poorer treatment 
outcomes including treatment failure, relapse or the development of drug 
resistance, in comparison to those without DM (NICE, 2016).  
 
NICE (2016) identified individuals with co-morbidity including diabetes as a 
significant risk factor for TB. NICE (2016) stipulates that coexisting conditions 
should be managed by a specialist multidisciplinary team with experience in 
managing TB and the coexisting condition. However, no further advice was 
given in relation to dual management i.e. screening options, treatment 
management and follow-ups. For instance, as is the case for individuals with 
HIV and active TB, where advice on treatment course, including avoiding drug 
interactions when co-prescribing antiviral and anti-TB medication due to 
interaction is given. In the case of TB-DM, rifampicin is known to accelerate 
the metabolism of oral hypoglycaemic agents, mostly sulphonylureas and 
biguanides, which lowers their plasma concentration and potentially 
therapeutic efficacy. However, such guidance is not available from NICE, 
PHE, Royal College of Nursing, or the British Thoracic Society. 
 
The British National Formulary (BNF) (2020) recognises isoniazid is 
associated with an increased risk of not controlling DM, increasing risk of 
peripheral neuropathy due to overlapping toxicity profiles with isoniazid and 
those with DM should receive pyridoxine when taking isoniazid, evidence of a 
need for advice on drug treatment protocols for those with TB-DM.  
 
UK guidelines (PHE, 2020; NICE, 2016) do not provide guidance on 




those with TB-DM, and on follow-up of DM patients with TB. There is no 
current data on prevalence of TB-DM in the UK. Although PHE (2020) and 
NICE (2016) guidance acknowledges DM as a risk factor for TB, there is no 
guidance on the management of TB-DM patients in the UK and this is an 
unmet need.  
 
NICE (2016) and PHE (2020) encourage an active case finding (ACF) 
strategy to identify and treat individuals with TB. ACF targets high-risk groups, 
which includes professionals at risk of TB (e.g. healthcare workers) close 
contacts of patients with TB (or an active TB case is suspected), individuals 
with social risk factors (homeless people, people with drug or alcohol 
problems, prisoners) and non-UK born individuals from within high TB incident 
regions. However, currently there is no mention of DM screening in TB 
patients.  
 
In the absence of national guidelines on the joint management and control of 
TB and diabetes, the World Health Organisation (WHO) (2014) had 
developed a framework aimed at a guidance programme for clinicians and 
others engaged in the care of patients and prevention and control of DM and 
TB. The framework is based on evidence collated from systematic reviews of 
TB-DM and therefore is a provisional. The framework includes the following 
provisional recommendations: 
 
1. A joint coordination of TB and DM programmes to be established at 
regional and local levels.  
2. Surveillance of TB should be initiated among TB patients in all 
countries. 
3. Surveillance of diabetes should be initiated among TB patients in all 
countries. 
4. At a minimum, individuals with DM should be screened for chronic 
cough (a cough lasting more than 2 weeks) at the time of their 




5. Screening for TB infection on broader indication should be explored as 
part of a research agenda to improve the diagnosis of TB among 
people with diabetes. 
6. A referral system should be established so DM individuals suspected to 
have TB are appropriately referred to TB diagnostic and treatment 
facilities.  
In the latest 2019 WHO report, globally most WHO regions and high TB 
burden countries are not on track to reach the 2020/3 milestone of the End TB 
Strategy. Globally there was a decline of 1.6% per annum from 2000-2018, 
and a 20% decline between 2017 and 2018. A cumulative reduction of 6.3% 
from 2015 to 2018, which is short of the End TB Strategy target (WHO, 2019. 
GLOBAL TUBERCULOSIS REPORT 2019: EXECUTIVE SUMMARY). 
 
PHE (in partnership with NHS England) TB prevention strategy is working with 
commissioners to ensure TB prevention and control programmes target all 
ages. Their strategy programme includes: 
 
• active case finding (contact investigations and identifying latent TB in 
high-risk groups) 
• awareness-raising activities 
• standard and enhanced case management (including providing directly 
observed therapy and free treatment) 
• finding people lost to follow-up and encouraging them back into 
treatment 
• incident and outbreak control 
• monitoring, evaluating and gathering surveillance and outcome data 
 
The TB prevention programmes target specific high-risk groups, such as 
asylum seekers and refugees, under-served children, the homeless, offenders 
and people who misuse substances. They also considered integrating TB and 
HIV services, joint clinics. There was no mention on the management of TB-





Currently there is no monitoring, evaluation or surveillance of TB-DM cases 
nationally or locally. This research will aim to help to establish the prevalence 
of TB-DM in a high TB incidence area. Identify the key characteristics (clinical 
symptoms, microbiological assessment and radiological presentation) to 
develop criteria for screening for DM (including best test method and time) in 
TB patients, assessing treatment efficacy in DM patients with TB to establish 
a clinical pathway between TB physicians and endocrinologists to better 




Although there is substantial evidence to suggest DM is a risk factor for the 
development of TB, it is not yet clear whether DM significantly affects the 
presentation of TB, i.e. increased fever, cough haemoptysis and atypical 
radiological images. There are ambiguous results from limited studies based 
on the UK population. Diabetes is known to alter the pharmacokinetics of 
several anti-TB drugs and the efficacy of TB treatment depends on drug 
plasma concentrations and, therefore, DM is likely to have a negative effect 
on the treatment of TB. Currently, there are no guidelines on the optimal 
treatment duration of TB or screening for DM in TB patients. The overall 
management of DM in TB has no clear guidance available within the UK 
healthcare services. The literature suggests DM treatment in TB disease 
should be aggressive. By having an optimal glycaemic level, patients are 
likely to have better outcomes; therefore, aims to achieve this are paramount.  
 
The latest guidance from NICE 2019 mentions DM on two occasions within 
the guidance. This refers to people with comorbidities or coexisting conditions 
and DM is seen as an immunocompromised condition. There is currently no 
case management of TB-DM, as there is with TB and HIV, in the British HIV 
Association guidelines for the management of TB. This includes diagnosis of 
active TB, where recommendation of performing microscopy on respiratory 
samples followed by molecular testing, e.g. Xpert MTB/RIF. They also 
recommend molecular testing on pulmonary smear-negative samples. In 




standard TB treatment with ART and the use of PI/r rifampicin is substituted 
with rifabutin. In HIV patients with TB meningitis they should receive 
corticosteroids. Furthermore, the guidelines recommend using fixed-dose 
combination therapy, where possible, to enhance treatment adherence. In 
relation to ART treatment, the recommendation with TB patients is to 
commence ART as soon as practically possible, within 8-12 of diagnosis of 
TB and ART to commence within two weeks if the patient CD4 cell count is 
less than <50 cells/ mm2.  
 
In TB-DM this approach to case management is missing and requires 
investigation of the association to guide clinical management of these 
patients.  
 
The clinical case management guide produced and endorsed by the Royal 
College of Nursing, PHE, National TB Programme, does not reference DM as 
a risk factor in its management. The Tuberculosis Coalition for Technical 
Assistance (TBCTA), which collaborates with WHO, has developed 
International Standards for TB Care (ISTC) stating the basic principles of care 
for individuals suspected or having active TB globally (TBCTA, 2006).  
 
The diagnosis of unexplained productive cough in DM patients should be 
tested for TB and any chest findings of TB should have sputum samples sent 
for microbiological testing. However, both HIV and DM patients with TB are 
likely to have atypical presentations. In relation to treatment, it recommends 
adherence to be monitored using DOT and furthermore therapy response to 
be monitored using sputum microscopy at the completion of the intensive 
treatment phase, and at 5 months and end of treatment. A positive smear at 
the 5th month is deemed as failure. In TB and HIV coexisting condition, the 
international standard recommends counselling and testing as a routine, 
managing all patients with TB and HIV infection, cotrimoxazole prophylaxis is 
given and to evaluate when to start antiretroviral therapy (ARV) (BHIVA 





However, for TB-DM patients there is currently no screening for DM, in TB 
cases. There is no pathway to provide the management of the co-existing 
conditions. No recommendations if DM is diagnosed in TB cases as to when 
to commence DM treatment. Lastly, no treatment monitoring of TB medication 
to assess if it if altered by DM or by DM medication.   
 
1.51 Rationale for studying TB-DM association 
 
There is a strong epidemiological association between DM and TB, as 
reviews suggest DM triples the risk of developing active TB infection (Jeon et 
al., 2008). 
 
DM modifies the presenting features of PTB and is associated with atypical 
radiological presentation with more severe TB treatment, including increased 
risk of treatment failure, relapse and death during TB treatment. The current 
estimation by the International Diabetes Federation (IDF) is the prevalence of 
DM will continue to increase globally to 592 million by 2030. In Europe, the 
prevalence of DM was estimated at 8.5% in 2013, with the WHO estimating a 
TB incidence rate of 40 per 100,000 population (74,000 new cases per 
annum) to 592 million by 2035 (WHO, 2016). 
 
The epidemiological association and the effect on the clinical presentation and 
treatment outcome resulting from the interaction between DM and TB are like 
those observed in co-infection with HIV and TB (Harries et al., 2011). 
Although the risk of developing TB because of DM is lower than with HIV, with 
a DM pandemic, the association between TB-DM may come to resemble HIV-
TB association (Lonnoth et al., 2010). As with HIV, DM should be considered 
as an immunosuppressive condition which affects immune function and as a 
result affected patients are less likely to eradicate Mtb when infected, and are 
more likely to have re-activation of Mtb in its latent state.  
 
DM is influenced by the immigration of different ethnic groups, as with TB. A 
study in Italy amongst 974 TB cases, of which 725 patients were non-UK 




common countries of birth being Romania, Bangladesh, Philippines and India. 
In comparison to TB-only cases, TB-DM cases are usually of an older age 
group (median 58.6 years compared to 39.5) and men are more commonly 
affected (77.4% compared to 64.4%) (Odeone et al., 2011). Chest radiograph 
presentation demonstrated greater cavity pattern in TB-DM cases compared 
to TB-only (45% compared to 31.7%) (P= <0.05) (Ebrahimzadeh, 
Mohammadifard and Naseh, 2014). Bacteriological positive sputum smears 
and culture were more frequently reported in the TB-DM cohort (sputum 
smear: 75% compared to 56%, P = <0.05); sputum culture: 83% compared to 
67%).  
 
Research on a high-risk population, such as in the London Borough of 
Newham, would help to assess the attributable risk factors for TB. The Dual 
Epidemic of TB and Diabetes (NICE, Tuberculosis Guidelines NG33, 2019) 
suggest that DM is an important risk factor in England. However, current 
knowledge is limited; only a handful of studies have assessed this 
phenomenon in Europe and fewer in England, and a comprehensive 
description of the epidemiology of TB-DM at a national level is still missing. 
 
To contextualize this review of association between DM and TB, this current 
study will explain the disease as a co-existing condition and assess if any 
significant association is affecting patient clinical outcome. If so, the work will 
be used to implement change in current TB management of those with DM in 
Barts Health NHS Trust. It will be presented in terms of aetiology, diagnostic 
criteria, treatments and the association of these two conditions. The 
predominant focus, which is in London, will provide further insight into the 
importance of analysis and research of the association of DM and TB within 










1.52 Aim and Objectives 
 
The main aim of this research project is to: 
 
Analyse the prevalence of DM among TB patients in Newham and to describe 
the clinical characteristics of the TB-DM population.  
 
1.53 Primary Objectives: 
 
1. To determine the prevalence of DM in TB (TB-DM) patients in 
Newham, with close attention paid towards differences between UK 
born and non-UK born patients.   
2. To analyse the demographic, epidemiological characteristics and 
microbiological features associated with TB-DM compared with TB only 
patients. 
3. To describe the clinical manifestation and TB post-treatment outcomes 
in patients with TB-DM compared with TB-only cases.  
 
1.54 Secondary Objectives 
 
1. To analyse any differences in the chest radiological presentation between TB 
only to TB-DM in PTB patients.  
2. To compare the vitamin D levels between TB only and TB-DM patients 
3. To determine the time for TB culture conversion to negative between 
TB-only and TB-DM patients 
4. To analyse the HbA1c levels between TB-only and TB-DM patients and 








































Chapter 2 - Methodology 
 
2.1  Research design 
 
We employed a retrospective cross-sectional study design, including patients 
diagnosed with TB and those with TB-DM, between 2012 – 2015 in the 
Borough of Newham, East London. DM is thought to be a risk factor for the 
reactivation of TB disease and has been investigated as an independent 
variable in this study. This study assessed the association between TB and 
DM by comparing cases of TB (control group) to TB-DM (case group) cases in 
adults, using secondary data over five years, and each case which was then 
followed up for two years after completion of TB treatment to capture relapse 
or development of MDR-TB. Data was sourced from adults on the London TB 
Register and Enhanced Tuberculosis Surveillance System (ETS) in England 
and patient medical records held at Barts Health NHS Trust. The Cerner 
Millennium System, which contains all patient records (clinic notes, GP notes, 
medications, pathology and diagnostic results) was used to identify those with 
DM. Barts Health NHS Trust, which serves 2.5 million people over three 
London Boroughs, including Newham, was selected as the study population 
due to its ongoing high incidence of TB (PHE, 2017). The data were 
anonymised for ethical reasons, and the datasheet was received in a 
Microsoft Excel format and exported to SPSS for analysis. The doctoral 
research student secured all data by taking out all patient identifiers and used 
unique codes to identify data sets. Quality improvement approval was 
received from the Clinical Effectiveness Group at Barts Health NHS Trust to 
undertake the quality improvement project as a doctoral degree project (see 
appendix 1 and 2). 
 
Analyse the prevalence of DM among TB patients in Newham and to describe 







2.2 Primary Objectives: 
 
1. To determine the prevalence of TB among DM (TB-DM) patients in 
Newham, with close attention paid towards differences between UK 
born and non-UK born patients. 
2. To analyse the demographic, epidemiological characteristics and 
microbiological features associated with TB-DM compared with TB 
patients. 
3. To describe the clinical manifestation and TB post-treatment outcomes 
in patients with TB-DM compared with TB-only cases.  
 
The primary aim of the study was to understand the prevalence of DM in TB 
patients in the London Borough of Newham. The study is to aid our 
understanding whether a true significant association exists between DM and 
TB, and the overall clinical outcome. The study considers the clinical features 
associated with TB-DM and this is to help inform policy change to manage 
TB-DM patients as an entity.  
 
The findings are also likely to highlight future gaps in knowledge, which need 
to be investigated prior to establishing a bi-directional screening programme 
for TB and DM. The study population is racially diverse in the London 
Borough of Newham. Patients who are diagnosed with TB are recorded on 
the London TB Register and ETS in England. The notification records have 
been kept from 2000 onwards, and the register is annually updated to 
consider denotifications, late notifications and other updates.  DM is a risk 
factor for TB and was cited in recent NICE (2016) TB guidelines. However, 
this is not readily acknowledged in widespread clinical practice, nor is there 
guidance on the management of TB-DM cases. This five year (three years of 
active case findings with an additional two years of follow-up of all cases) 
period allows time for any TB relapse or reactivation or development of MDR-
TB to be investigated, post completion of the initial TB treatment. However, 
the DM diagnosis is not registered on any national surveillance system, and 
all the data extracted was from the local hospital and GP databases, using the 





The data collected from the Cerner Millennium System on each case 
included: 
 
1. Sociodemographic information: country of origin, time in the host 
country, age, gender, education and employment. The use of alcohol 
was defined as a heavy drinker (>10 drinks per week or >14 units per 
week), smoking (>10 cigarettes per week), IV drug use and usage of 
illicit drugs (marijuana, cocaine, heroin, methamphetamines, 
hallucinogens, inhalants and other drugs) was recorded. 
 
2. TB risk factors: previous TB diagnosis, contact with a TB case, alcohol 
intake, tobacco use, drug abuse, past or current imprisonment, 
anthropometric measurements (BMI), HIV status and other co-
morbidities, long-term steroid use (inhalation corticosteroids or peri-oral 
corticosteroids), cytotoxic treatment, immunosuppressive medications, 
severe diseases (chronic renal failure, chronic liver disease, 
malignancies, chronic lung diseases), pregnant or lactating women. 
 
3. Clinical symptoms: pulmonary and extra pulmonary symptoms: the 
presence of cough, fever, weight loss, anorexia, haemoptysis, chest 
pain, fatigue and night sweats. 
 
4. Clinical data: pulmonary and extrapulmonary symptoms; TB 
localisation (pulmonary/ extrapulmonary), radiological findings (lung 
lesions and location and the presence of cavity lesions). Radiological 
findings collected from CXR performed at the time of diagnosis using 
the PACS system. CXR results were categorised by the involved field 
and pattern (i.e. upper lung field lesion defined as the presence of any 
lesion above an imaginary line across the diaphragm). 
 
The radiographic presentation was categorised as normal, consolidation, 




• ‘Normal' pattern is defined as the absence of any abnormal lesion on 
CXR or TC. 
• ‘Consolidation' pattern is defined as a mostly homogeneous opacity in 
the lungs characterised by little or no loss of volume, effacement of 
blood vessel shadows and sometimes the presence of an air 
bronchogram. 
• ‘Cavity' pattern is defined as a clear area within the lung that may or 
may not contain a fluid level, and that is surrounded by a wall, usually 
of varied thickness. 
• ‘Miliary' pattern is defined as multiple nodular infiltrates, with 
approximately 3 mm wide distribution and generalised. 
• ‘Pleural effusion' is defined as a normal opacity extending upwards 
from the costophrenic angle in an erect film. 
 
Mtb microbiological examinations (direct microscopy, culture and PCR 
results), Mtb drug sensitivity, previous history of TB, treatment regimes, TB 
drug resistance (any drug resistance, multi-drug resistance; extensively drug-
resistant tuberculosis). DM diagnosis, plasma glucose and glycated 
haemoglobin results, DM treatment history and serum protein levels. 
 
Death during treatment was recorded as death due to any cause during 
treatment. Death due to TB was attributed to being caused by TB based on 
two of the following criteria: death certificate with TB as the leading cause of 
death; or clinician who identified TB as a probable cause of death; or positive 
AFB smear or culture at the time of death.  
 
2.3  Ethical considerations 
 
The principal concern of this research was maintaining the confidentiality of 
patient data. No personal identifiers were recorded to capture patient-level 
data as personal identifiers were encrypted at data collection level. The study 
relied entirely on secondary data. Therefore, no social or psychological effects 




Health NHS Trust and London TB Register and ETS System in England, 
patient identifiers were anonymised during data collection. The doctoral 
student did this by removing all identifiers when the datasheet was completed; 
only relevant data were extracted. The Clinical Effectiveness Group 
Department, Barts Health NHS Trust granted permission to use the 
information because of the potential to inform the future TB program (Quality 
Improvement Registration (QIP) reference number 7489, approved 
23.08.2016, provided by the Clinical Effectiveness Group Department. This 
study involved the collection of data from routine information systems and was 
analysed to address the study objectives. All the information was kept no 
longer than required for the doctoral thesis, and all data are kept secure on an 
individual server with password protection, which can only be accessed by 
authorised researchers. No hard copies have been kept. As this is a quality 
improvement project it did not need to be submitted for Research Ethics 
Committee (REC) approval. However, the project is conducted within an 
ethical framework, at a practical level this means ensuring the project follows 
legislation and guidelines of; Caldicott Principles (1997); Data Protection Act 
(2018); NHS Confidentiality Code of Practice (2003); HQIP guide to managing 
ethical issues (2017). All QI projects are registered centrally with an allocated 
supervisor and in a Directorate to ensure Directorate priorities are met and 
components required for the project are available. A regular QI governance 
meeting is used to track projects and provide feedback and implement 
learning into practice.  
 
2.4  Study population 
 
The study population was obtained from the London TB Register and (ETS) in 
England and electronic medical records, using the TB and DM (type 1 and 









Table 2.1  ICD code for TB and DM classification 
Diabetes Mellitus Tuberculosis 
ICD10 & E10-E14 ICD10  
The codes are the agreed global codes for these conditions. This was used to 
pull data for each patient from the local systems. These codes were given by 
qualified clinical coders (WHO, 2010). 
 
2.5  Dependent variables included  
 
TB infection was the dependent/response variable of interest.  
 
2.6  Independent variables including DM  
 
The independent variable of interest was DM. The test used to diagnose DM 
was the level of DM control by measuring blood HbA1c levels. This test 
reflects the plasma glucose level for the previous 120 days, and the results 
are reported as a percentage (Sherwani et al., 2016). The clinical diagnostic 
criteria for DM is HbA1c of 6.5% or higher, 5.7%-6.4% indicates pre-DM, and 
less than 5.7% is normal.  This pre-diabetic group was excluded from the 
study, as this group does not meet the inclusion criteria (NICE, 2017).  
 
2.7  Covariates 
 
The covariates in this study were chosen based on their potential significant 
confounding effects. The covariates reported in this study included gender, 
age, country of birth (UK or elsewhere), ethnicity, previous BCG vaccination 
history, previous TB diagnosis, prior contact with TB patients, HIV status, 
other immunosuppressive conditions (including drugs), smoking status, 
alcohol use, history of imprisonment, social risk factors, and type of participant 
(contact or new entrant), this information being reported and recorded by a 






2.8  Statistical analysis 
 
SPSS version 25 was used for the analysis of study data. All datasets were 
quality checked for any duplicate records, and any duplicates found were 
removed. The dataset collected included demographics, social risk factors, 
examination and laboratory results. All variables in SPSS were renamed, 
coded and appropriately categorised for analysis, and irrelevant data were 
omitted (see appendix 3).  
 
The frequencies of each variables as calculated using univariate analysis to 
characterise the distribution of TB and TB-DM and any potential risk factors in 
the study population. The chi-squared test was used to assess the association 
of DM with all variables, including covariates (ethnicity, gender, age etc.) to 
TB, comparison of clinical and radiological findings between TB and TB-DM, 
and the rate of TB-DM association in UK and non-UK cohorts.  
 
The relationship between the predictors and the response variables was 
further assessed using a binary logistic regression to produce unadjusted 
odds ratios and confidence intervals. Adjusted odds ratios and confidence 
intervals were used to determine the association between DM and TB, 
accounting for significant covariates and confounders and effect modifiers, 
which were obtained using multivariate logistics regression.  SPSS performed 
an automatic stepwise selection process (utilising a P-value <0.05 as 
significant) to observe the effect of each covariate on the relationship between 
DM with TB in multiple logistic regression.  The acceptable level of error was 
0.05 and a P-value of <0.05 was significant when a two-tailed T-test was 
applied for continuous variables. As two significant groups were analysed, the 
TB-DM and TB only group, a chi-square test was performed for the 
categorical variables. The odds were used over the risk ratio to report the 
odds ratio in this study as they reflected the study objectives. Where records 
have been incomplete or values missing for any one of the stratification 
variables (age, gender, place of residence, and year of admission), subjects 





2.9  Calculating the prevalence of TB-DM 
 
The prevalence of health outcome is derived from the proportion of individuals 
with health outcomes in a population (Setia et al., 2016). This was determined 
for TB-DM in a sample of the population which was divided by the total 
number of the TB population and expressed as a percentage.  
 
 
2.10  Chi-square Test 
 
Statistical analysis included the use of Pearson’s chi-square test which 
examines the independence variables. The test is used to determine if there is 
a statistically significant difference between the expected frequencies and the 
observed frequencies to illustrate a relationship between two categorical 
variables (McHugh et al., 2013). Fisher's exact test is used when the sample 
size is modest, and the evaluation is not appropriate. This test calculates the 
probabilities of all possible tables together with all the observed row and 
column totals (Howell, 2014, McHugh et al., 2013). 
 
2.11  Fisher's Exact Test 
 
Fisher's exact test is used to test the association between two binary 
variables in the 2 x 2 chi-square test and is usually used for smaller sample 
sizes (McDonald et al., 2015). Fisher's exact test determines the association 
between two categorical variables. The chi-square test is asymptotic (i.e. it 
depends on a large-scale approximation) and so the more significant the 
sample size, the better it will perform; it is not valid for small sample sizes. A 
small sample size is defined as several less than 40. Fisher's exact test was 
chosen as it is designed for nominal level data. However, the test will be 
underpowered if the associations are ordinal. Fisher's exact test, as with the 
Number of people with TB-DM 




chi-square, is based on significance and provides no further quantification of 
the size of the effect: for example, the degree/strength of association.  
 
2.12  Inclusion criteria 
 
Adult patients (age >18 years) with a diagnosis of TB during the period 2012-
2015. 
TB case: a patient with Mtb isolated from a clinical specimen by culture, or 
through methods such as molecular gene probes (confirmed case), or a 
patient for whom a physician has diagnosed TB and decided to start a full 
course of anti-tuberculosis therapy. 
 
2.13  Exclusion criteria 
 
•    < 18 years of age, 
•    No data on glycaemic control: patients without a previous diagnosis of DM 
will be excluded from the analysis if: a) no blood glucose tests are available, 
or b) they had only one fasting blood glucose level result ≥126 mg/dL (7.0 
mmol/L). 
 
2.14  Study procedures 
 
TB cases were identified from the London TB Register and the ETS system in 
England.  
Patients were classified into the TB-DM group if: 
 
•    They had a previous diagnosis of DM type 1 or type 2 DM with an earlier 
physician diagnosis of DM before TB diagnosis and currently receiving 
treatment for DM, i.e. insulin or oral hypoglycaemic agents) 
OR 
•    They were diagnosed with DM type 1 or type 2 at the time of TB (a 
physician diagnosis based on WHO 1999 (30), 2006 (31) and 2011 criteria 




HbA1c result ≥ 6.5% or FBG of ≥126 mg/dL (7.0 mmol/L) during TB 
treatments.  
To consider the risk of TB stress-induced hyperglycaemia: 
a.    FBG of ≥126 mg/dL (7.0 mmol/L) (fasting is defined as no caloric intake 
for at least the previous eight hours), 
OR 
b. One oral glucose tolerance test (OGTT) ≥200 mg/dl (11.1 mmol/l) (two 
hours post-glucose load of 75g oral dose in all adults; the dose should be 
drunk within five minutes), 
OR 
c.   In a patient with classic symptoms of hyperglycaemia or hyperglycaemic 
crisis, a random plasma glucose (RPG) ≥200 mg/dl (11.1 mmol/l), 
AND 
d.   One HbA1c result ≥ 6.5% FBG of ≥126 mg/dL (7.0 mmol/L) during TB 
treatment. 
 
Stress-induced hyperglycaemia, corticosteroid-induced hyperglycaemia and 
other reasons for impaired glucose metabolism abstracted from the medical or 
laboratory records were evaluated in conjunction with clinician/clinical 
supervisors. 
 
2.15  Sample size 
 
The sample size for this cross-sectional cohort study was 168 TB-DM cases 
and 321 TB-only cases. The minimum total sample size required was 384. 
This was calculated using Cubenmax Systems Calculator (latest release 
2020). 
 
It is not practical or feasible to study the whole population in any study 
including this study, which is based in the London Borough of Newham with a 
population size of 325,005. Therefore, a set of participants were selected over 
a period from the population, which is less in number compared to the whole 




drawn from. Therefore, a true inference can be made about the population 
(Olayinka, Anthonia, and Yetunde, 2013). 
 
In this study, the population of interest is the London Borough of Newham, the 
target population is those diagnosed with TB, in whom the incidence of DM is 
to be investigated. The sample subset group is TB-DM of the target 
population which is included in the study. The calculation of an adequate 
sample size is important as the calculation for optimal number of participants 
is required to be able to arrive at a scientifically valid result (Olayinka, 
Anthonia, and Yetunde, 2013).  
 
Cubenmax System Calculator utilises the Yamaro Yamane formula, nf= 
n/(1+n/N) where nf is the desired sample size as the study population is less 
than 10,000 and the desired sample size of the` population is greater than 
10,000 and N is the estimate of population size. N in this study is the number 
of patients with TB only and TB-DM at commencement which was 489, n = 
Z2pq/d2 where z is the standard estimate and = 1.96, P is prevalence given as 
0.5 is this study, q = 1-p and d is precision at 0.05. the calculated nf adjusted 
for 90% response rates was 384, which is the minimum sample size. 
Therefore, the 489, patient cohort recruited for this study is statically 










The table is a guide for determining the sample size required with different 
precision levels where confidence level is 95% and) P=0.05, using Yamaro 
Yamane sample size calculation. (Olayinka, Anthonia, and Yetunde, 2013). 
 
2.16 Internal validity of the study  
 
This refers to ensuring the findings of the study are correct for the population 
studied. This includes considering selection bias and confounding limits, 
appropriate study design, study setting and methods, which is crucial for the 
validity of a study (Kadam & Bhalerao, 2010). The cross-sectional design 
used in this study has the limitation that it only provides associations between 
factors and outcomes, which are described, as opposed to making a causal 
relationship.  
Table 2.2 Sample size for +/-3%, +/-5%, +/-7%, and +/-10%. Precision 




2.17  Selection bias in the study 
 
The selection bias refers to when a study population is not fully representative 
of the population. The population for this study in Newham had the highest 
rate of TB in England, but the DM rate remained within the national average, 
which is comparable, although a possible bias is selecting an at risk group for 
TB, which is the non-UK born patients. To mitigate this, random sampling of 
TB cases were selected over the study period, increasing diversity of the 
study group. The diversity of the population would reflect London’s diversity, 
allowing comparison to be made with a broader region. Persons at-risk (drug 
abusers, poor social housing, poor access to health, and economic bias) may 
be more common in the Borough of Newham compared to more affluent 
boroughs, which may lead to bias. Furthermore, inpatient TB cases likely to 
receive more thorough examinations leading to TB and DM diagnosis quicker 
than outpatients. This likely to affect time of diagnosis, treatment 
commencement, a better dual management of TB-DM which likely to affect 
overall outcome.    
 
Any missing values in the data collection phase are likely to introduce bias; 
therefore, an adjustment was made to the statistical analysis to omit samples 
with missing numbers and tested to ensure no significant differences resulted 
between individuals with missing values and those with values. In variables 
with less than 10% of the sample, these were analysed using Fisher’s Exact 
test, or if data was missing more than 40% and was an important variable, this 
factor was used for hypothesis generation (Madley-Gowd et al., 2019).  
 
The loss to follow-up is also likely to have caused a selection bias. As this 
was a longitudinal study, loss of participants to follow-up is expected to have 
occurred. To minimise this, data from the London TB Register and ETS 
System in England was used, which recorded loss of monitoring: this rate was 
low at 2%. Most those that were lost to follow-up either died or they 






2.18  Information bias 
 
Information bias occurs when data obtained in the study is inaccurate 
(Althubaiti, 2016), e.g. information about symptoms and exposure factors. 
This inaccuracy could be either intentional or unintentional; however, as this 
data was captured before the research was undertaken, as both national TB 
surveillance and London Enhance Surveillance System collect data on key 
variables by case workers. As a result, the information is prospectively 
collected at time of diagnosis, reducing the information bias in this study. 
However, it is to be mindful the questions require patients to provide honest 
and accurate response which always poses a potential bias.  
 
2.19  Study population 
 
An underpowered study increases the risk of type 2 errors (false-negatives). 
The sample size of TSPOT, IGRA and TST analyses was too small to explore 
potential risk factors associated with positive samples (TSPOT, IGRA, TST). 
There were also too few TB/HIV co-infection cases to compare TB-DM and 
TB-DM-HIV cases adequately. To have an optimal sample size of TB-HIV-DM 
cases, more participants should have been recruited from neighbouring 
boroughs. 
 
2.20  Test procedures and interpretation of results 
 
All routine tests were conducted by biomedical scientist (BMS) staff at the 
Royal London Hospital Pathology, Microbiology & Virology and Biochemistry 
Departments. All results were entered onto Winpath, a pathology software 
used by pathologists to view results in detail and the Cerner Millennium for 
staff to view across the Trust. T.SPOT.TB. tests were done by Oxford 








2.21 Confounding Variables 
 
A confounder also referred as confounding bias occurs when an investigator 
tries to determine the effect of an exposure on the occurrence of a disease (or 
outcome), however, in fact is measuring the effect of another factor, a 
confounding variable. In medical research investigating disease aetiology and 
casual relationship, a confounder is an undesirable, as it obscures the real 
effect of an exposure. As a result, confounding is managed through 
adjustment of the confounding variables. A confounding factor arises when a 
factor is associated with both the exposure (treatment) and the outcome.  
 
For a confounder to be considered as a confounding variable to be a potential 
confounder, it requires having the following characteristic; 1) the variable must 
have an association with the disease, that is, it should be a risk factor for the 
disease; 2) it must be associated with the exposure, that is, it must be 
unequally distributed between the exposed and unexposed groups; and 3) it 
must not be an effect of the exposure. 
 
As a confounding variable can obscure the real effect, it is required to be 
removed from investigations as much as possible to obtain real effect as 
much as possible. Like other types of bias found in research, in most cases 
bias can be controlled in study designs phase which can be managed through 
randomisation, restriction and matching.  In randomised studies, patients are 
assigned randomly to exposure categories. In studies which investigates the 
effects of an intervention, it is possible to reduce the confounding by 
randomisation, this is by assigning patients to an experimental group or to a 
control group. Randomisation helps to prevent selection bias by the 
investigator. Randomisation process ensures that any differences between 
two groups are due to chances and not due to the choice of an investigator. 
Thus, any differences in the potential confounders between two groups may 
still exit after randomisation, they are likely to be reduced as much as 
possible. Furthermore, subjects in randomisation are assigned to a stratum, 
i.e. treated and untreated individuals who roughly share the same 




overall effect is weighted average across the strata. A disadvantage is the 
lack of efficiently to remove any differences between treatment groups and a 
low number of strata may cause residual confounding. 
 
Restriction refers to when subjects with certain value/ characteristics for a 
potential confounder are selected (e.g. gender, age), whilst matching involves 
the selection of the groups to be compared to a comparable group (e.g. 
exposed vs not exposed).  Another method of controlling confounding 
variables, post data collection in analysis phase is by adjusting the variable 
using stratification or multivariate analysis. 
 
Another method of control of confounders at the study design phase is 
through matching. For instance, in a cohort study, the participants in the 
exposed and unexposed groups could be matched in pairs for potential 
confounders. For example, a study on the relationship between diabetes and 
ischemic heart disease, for each ‘exposed participant with diabetes mellitus 
the investigator may select an ‘unexposed’, that is, nondiabetic patent of the 
same age. In this way, the potential confounding effect of age on outcome will 
be reduced. In case-control design, matching is frequently used. The 
advantage of this approach is it is more efficient in providing comparable 
treatment group. The disadvantage is the treated individuals may not have 
much match with the untreated individual, leading to a biased result.  
 
An approach for controlling confounding after the completion of a study data 
analysis is stratification. In this method, the study population are divided into 
stratum subgroups, for example age can be divided into subgroup levels and 
relative risk of each stratum calculated. To calculate a summary statistic that 
describes the effect of variable and adjusting for confounder (i.e. age), one 
could use either polling Mentel-Haenszel procedure or standardisation. Both 
methods aggregate information over all strata by taking weighted averages of 
stratum-specific relative risks to calculate an overall ‘adjusted’ effect size. It 
may also be one potential confounder is indeed confounding a relationship of 
interest.  This adjustment for confounding by a variable does not always 




confounding when the number of confounding factors is limited. increasing the 
number of these factors will rapidly increase the number of strata, as the 
number of categories is multiplied.  
 
2.22 Multivariate analysis 
 
A multivariate analysis is used to control for confounding, this avoids the 
limitation of stratification, as it obtains the possibility to adjust for many 
confounding variables in just one model. Multivariate analysis estimates the 
ORs or hazard ratio (HRs). The control for confounding by multivariate 
analysis uses the same principles as stratification, i.e. factors of interest are 
investigates whilst the potential confounders are held constant.  
 
In this study univariate and multivariate logistic regression analysis was 
performed to examine each factor for its association with the outcome (DM) 
using Pearson’s chi-square test. Secondary to univariate analysis, multivariate 
analysis was undertaking controlling confounders (age and gender) with the 
statistical significance was set at p value <0.05. for north models, the risk was 
calculated and summarized as odds ratio and 95% CI was set.  The two 
variables considered to be confounding variables as they both were known to 
be risk factors for the outcome of interest. DM especially T2DM is related to 
older age due to lifestyle change and later manifestation. Furthermore, male is 
more common to be diagnosed with TB. 
 
2.23  T-SPOT. TB Procedure 
General Principle 
T-SPOT (Oxford Immunotec, Abingdon, UK) works using an enzyme-linked 
immune-spot (ELISPOT) technique based on enumeration of activated T-cells 
responding to stimulation by specific antigens (ESAT-6 and CFP10) and 
resulting in IFNγ secretion. The stimulation by ESAT-6 and CFP10 antigens 




During the procedure, the peripheral blood mononuclear cells (PBMCs) are 
separated from the whole blood sample and incubated with antigens to allow 
stimulation of any sensitised T-cells. The secreted IFNγ is captured by 
specific antibodies on the well membrane.  
A second antibody, conjugated to alkaline phosphatase and directed to a 
different epitope on the (cytokine) IFNγ molecule, is then added and binds to 
the cytokine captured on the spot of insoluble precipitate at the site of the 
reaction. Each spot represents an individual’s cytokine-secreting T-cell and 
the number of spots obtained provides a measurement of the abundance of 
Mtb effector T-cells in the peripheral blood.  
Blood is collected in one 8ml or two 4ml CPT tubes. The white cloudy band of 
PBMCs was collected using a pipette and transferred to a 15-ml conical 
centrifuge tube, Blood was stored at room temperature and assayed within 
eight hours. The 8ml of CPT tubes was centrifuged at 1600xg for 28 minutes. 
The T-STOP. TB assay requires 2.5 x 105 viable PBMCs per well. A total of 
four wells were used for each patient. A manual count was done using a 
Neubauer haemocytometer. The plates were removed from the incubator and 
to each well was added 200 μl PBS solution, which is washed a further three 
times. A 50 μl of conjugate was added to each well and incubated for one 
hour. A substrate solution of 50 μl was added to each well for seven minutes. 
The plates were washed with distilled or deionised water to stop the detection 
reaction, allowing at least four hours drying time. A test result is positive if 
wells show > 6 spots. 
2.24  Mtb microbiological examinations 
General Principle 
 
Microscopy of stained sputum smears is a technique based on the 
Mycobacterium's cell wall components being rich in lipid complexes 
preventing access to aniline dyes, but when stained with carbol-fuchsin or 
fluorochromes, they are not easily decolourised, even with alcohol-acid 
solutions. All Mycobacterium species retain this characteristic, and it is not 




Royal London Hospital Microbiology Services protocol used 100 fields with a 
light microscope, using 1000x magnification. If there was an AFB count of less 
than 10 in 100 fields, then the number of AFB were counted within the actual 
slide. For a high positive, the examination of only 20 to 30 fields was 
sufficient. By examining specimens using a microscope the objective of 
staining is to discover acid-fast bacilli. The discoloration stains both living and 
dead (viable and non-viable) bacilli. This semi-quantitative evaluation reports 
the number of acid-fast bacilli found out of specimens in stained smears. 
 
Table 2.3 Result interpretation using Bright field (1000x magnification: 1 
length = 2 cm = 100 High Power Fields (HPF)): 
IUATLD/WHO 
scale 













1 length = 30 









Zero AFB / 1 
length 
Zero AFB / 1 
length 
Zero AFB / 1 
length 
Scanty 
1–9 AFB / 1 length  
or 100 HPF 
1–29 AFB / 1 
length 
1–19 AFB / 1 
length 
1+ 
10–99 AFB / 1 
length or 100 HPF 
30–299 AFB / 1 
length 
20–199 AFB / 1 
length 
2+ 
1–10 AFB / 1 HPF 
on average 
10–100 AFB / 1 
field 
on average 
5–50 AFB / 1 field 
on average 
3+ 
>10 AFB / 1 HPF 
on average 
>100 AFB / 1 field 
on average 
>50 AFB / 1 field 
on average 
 
2.25  Smear microscopy procedure 
 
The property of acid-fastness is due to the presence of mycolic acids in the 
cell walls of mycobacteria. The primary staining is conducted using fuscin, 
which binds to the mycolic acids in the cell wall (Wanger et al., 2017). 
Thereafter, decolourisation occurs using acid alcohol, which does not affect 
the primary stain from the cell wall mycolic acids while allowing the 
mycobacteria to retain the purple/blue stain colour, which is known as acid-





Using the Ziehl-Neelsen (ZN) technique for Mtb, slides were prepared in a 
class 1 biological safety cabinet. For each sample, a new, clean, grease-free 
slide was used, with each specimen and laboratory number recorded. A 
smear was prepared directly from a fresh sample (without any prior 
centrifugation) using an applicator stick and by selecting the purulent particles 
of sputum. The smear was an approximate size of 2-3 cm in length with 1-2 
cm width, which allowed 100-150 fields to be counted in one smear. A 
thorough spreading was done before staining to allow air-drying at room 
temperature. The prepared slide was passed over a flame 2-3 times for 
approximately 2-3 seconds to heat-fix. The heat-fixed slide was covered with 
carbol-fuchsin using a Bunsen burner; the slides were heated until a vapour 
rose. The stain remained on the slide for ten minutes for the carbol-fuchsin to 
penetrate and stain the cell wall. The dye was gently washed from each slide 
with a stream of cold water until all unbound stain was washed away. Each 
slide was covered with acid alcohol for three minutes. The slides were rinsed 
again with water and the excess water was removed. The slide was then 
covered with methylene blue counterstain for one minute. The slides were 
rinsed with water and air-dried (RHL Microbiology BMS Protocol).  One length 
of smear (2cm) was examined, or 100 fields, with a light microscope, using 
1000x magnification. 
 
2.26  Culture test for Mycobacterium tuberculosis  
General Principle 
 
Bacteriological culture provides a definitive diagnosis of TB and possesses 
higher sensitivity than sputum microscopy. This allows detection of a very low 
number of bacilli (approximately ten bacilli/ml of sputum compared to at least 
5000 bacilli/ml of sputum for microscopy). Culture is also used to test for 
extrapulmonary TB. Specimen processing for Mtb was carried out in a 
biological safety cabinet, biosafety level 3 (BSL3), with the growth procedure 
performed in a class 2 biological safety cabinet using a Mycobacterium 
Growth Indicator Tube (MGIT). All cultures were incubated at 35-37oC and 




after 8 to 12 weeks of growth. The MGIT tubes contain a fluorescent 
compound embedded in the tube which is sensitive to the presence of oxygen 
dissolved in the liquid culture during the continuous incubation at 35-37oC. BD 
BACTEC monitors the tubes every hour for increasing fluorescence. The 
presence of fluorescence above a significant threshold identifies a positive 
tube.  
 
2.27  PCR detection of mycobacterium complex 
 
The Xpert MTB/RIF assay (Cepheid) does not require isolation of 
Mycobacterium and provides rapid diagnosis and predicts resistance to 
rifampicin using a cartridge-based system on clinical specimen either 
processed or unprocessed. The Xpert MTB/RIF assay test for the presence or 
absence of Mtb complex DNA using a semi-quantitative method. This 
estimates the bacillary load as well as provides results of RIF (rifampicin) 
resistance is present or absent. PCR can be carried out on all respiratory 
samples and other specimens where rifampicin resistance in Mtb continues to 
be investigated. The Xpert MTB/RIF assay is a nucleic acid amplification 
(NAA) which can identify possible multi-drug resistant TB (MDR-TB) that is 
resistant to both isoniazid (INH) and RIF, two of the most effective TB drugs 
(CDC, 2013). The Xpert MTB/ RIF assists in the identification of possible drug 
resistant TB (MDR-TB). The RIF resistance is a predictor of MDR-TB because 
of the resistance to RIF, in most cases, co-exists with resistance to INH. 
 
2.28  GeneXpert MTB/RIF for Mtb 
 
This test is used to detect Mtb and for the detection of rifampicin resistance. 
Using the GeneXpert cartridge, the sample is drawn i.e. (process or 
unprocess sputum, fluids) using a sterile transfer pipette, into the open port of 
the XpertMTB/RIF cartridge. The cartridge lid was closed and the test starts. 
A trace call should be considered as a real positive result, in line with clinical 
decisions. A second trace call is sufficient to make a diagnosis of PTB unless 
there is a recent history of TB alongside other clinical information.  A Rif 




Rif DETECTED result, with a high suspicion of MDR-TB, indicates MDR-TB 
treatment should be considered. An Rif INTERMEDIATE result indicates the 
MTBC concentration was very low; as a result; resistance could not be 
determined (Cepheid, 2019 https://www.cepheid.com/uk/cepheid-
solutions/clinical-ivd-tests/critical-infectious-diseases/xpert-mtb-rif). The test is 
based on real-time PCR for detecting Mtb DNA complex in samples and if 
rifampicin (RIF) resistance is present identified through the mutations of the 
rpoB gene in samples from at risk individuals of RIF resistance (Lawn and 
Nicol, 2011).  
 
2.29  Vitamin D  
 
25 (OH) and 1,25 (OH)2 D were analysed by the Biochemistry Department at 
RLH using an Abbot Architect i2000SR with a Chemiluminescent microparticle 
immunoassay (CMIA). A 7.5 ml of clotted blood sample was collected for 
analysis. The defined reference guide from the RLH laboratory is: 
1.    Vitamin D levels <25 nmol/L indicates vitamin D deficiency.  
2.    Vitamin D levels 25-50 nmol/L suggests vitamin D insufficiency.  
3.    Vitamin D levels > 50 nmol/L indicates adequate vitamin D levels.  
 
2.30  Radiology findings of TB patients 
 
A qualified radiologist interpreted chest x-rays and CT scans, along with chest 
physicians and infectious diseases doctors and the findings were recorded on 
the London TB Register and ETS in England and in their medical notes. Any 
atypical images and reports identified during the data gathering were 
discussed with the clinical supervisor for clarification. All were reported on the 
Cerner system. Each case was further evaluated into appropriate categories 
by the researcher and cross-examined with clinical notes for the severity of 
symptoms and confirmed by a clinical supervisor or lead clinical physician for 










































3.0  Chapter 3 - Results 
 
During the 5-year study period, 489 patients with PTB and EPTB were 
included in this research. Of these, 84 (17%) cases had been previously 
diagnosed with DM before TB diagnosis, and only 5% had been previously 
diagnosed with TB.  All data were analysed using statistical tests chi-square 
and Fisher's exact test for differences in sociodemographic and clinical 
characteristics between the TB-only and TB-DM patients.  
 
Drug sensitivity and patterns of Mtb isolated from patients with TB-only and 
TB-DM were compared, using microscopy, culture and drug sensitivity testing. 
In patients with PTB, the association with DM and the severity of the disease 
(indicated by chest x-rays), delayed sputum conversions (after 30 and 60 
days) after treatment commencement and symptoms were reported. The 
study also estimated the median sputum conversion by days using the Kaplan 
Meier survival plot to assess the association of sputum conversion between 
TB-only and TB-DM cohorts.  
 
Clinical outcomes at the end of treatment were deemed as either failure or 
cured by measuring the AFB microscopy or culture-positive at six months or 
during treatment, or resolution of signs and symptoms of TB.  
 
3.1  The prevalence of TB-DM in Newham 
 
The TB-DM patients’ ages ranged from 27 to 49 years, with a median of 36, 
with 85.3% of the cases being non-UK born with 63% being male and 37% 
being female. The HIV prevalence in the study population was 2.5%.  From a 
total study population of 489, 168 patients were diagnosed with DM, with an 
overall prevalence of 28.5% (CI 95% 24.3-33.0) (Table 3.1).  Amongst the 168 
TB-DM cases, 3.88% were newly diagnosed DM cases at the time of TB 
diagnosis. Newly diagnosed DM patients were more frequently diagnosed at 
the time of TB diagnosis in non-UK born than UK born patients. However, TB-




(p=0.08) (Table 3.2). Information on DM treatment was available for all 168 
TB-DM cases, of which 94% were in treatment, with only four cases treated 
with insulin and the remainder/majority with oral hypoglycaemic drugs. The 
DM prevalence in the general UK population is estimated at 3.9%, whereas in 
this study, the London Borough of Newham had a DM prevalence rate of 































Table 3.1  The prevalence of Diabetes Mellitus Among Patients with TB Diagnosed in Newham, 2012-2017. 






































a International Diabetes Atlas, 2014. Active study period was from 2012 to 2015, with 2-years additional follow-up period. No. 






































































Gender       
Male 207 (65) 106 (62)     
Female 113 (35) 63 (38) 
0.949 (0.643 – 
1.400) 
0.866 




































1.697 (1.080-2.667) 0.02 
  










































2.394 (1.081-5.303) 0.054 
  
Yes 4.0 (1.5-10.5) 0.071 






0.479 (0.162-1.419) 0.176 0.5 (0.2-1.6) 0.193 Yes 
No 







































* Fisher Exact Test was used to test the association between the two categorical variables when the sample size was less than 5; **adjusted for gender, 
age and HIV status. OR, Odds ratios, a measurement of association between exposure and an outcome.  The OR represents the odds that an outcome 
will occur given an exposure, compared to the odds of the outcome occurring in the absence of that exposure; TB, tuberculosis ; DM, diabetes mellitus; 
CI, confidence interval. 
 
The odds ratio (OR) is used to measure the association between an exposure and an outcome, in this study between variables and TB-DM. To analyse 
the association between TB-DM and demographic and clinical characterise, the study compares TB-DM cases and TB-only control. The OR were used 
to compare the relative odds of the occurrence of the outcome of interest (TB-DM) given exposure to each of the variable (age, gender, alcohol intake). 
The OR is determined by whether an exposure is a risk factor for TB-DM outcome, and the magnitude of risk factors for outcome is measured as: OR=1 
Exposure does not affect odds of outcome; OR>1 Exposure associated with higher odds of outcome; OR<1 Exposure associated with  lower odds of 
outcome. 








































3.2  Age 
 
The age cohort was stratified into those <55 years and those >55 years, this 
was done to assess whether older age is identified as a risk factor for TB-DM 
comorbidity and in agreement with recent systematic reviews (Moreno-
Martínez et al., (2015); Cordeiro da Costa et al., (2016) Caraffa et al., (2016). 
In the TB-only cohort, 297 (92%) who were diagnosed with TB were aged 
under 55 compared to 119 (70.9%) in the TB-DM group. The age stratified by 
either greater than or less than 55 years, in the TB-only cohort, 8% had TB 
and were less than 55 years. In comparison to TB-DM, where 29.1% of the 
cases were over the age of 55 years, and a significant factor to TB-DM (P= 
<0.05). Older age has been documented as a risk factor for TB-DM 
comorbidity, and with agreement with recent systematic review this 
association may reflect the current distribution of DM among the general 
population of Newham. Furthermore, older age > 55 years in the non-UK born 
DM population is approximately three times greater than UK born population 
in this group (Ref).  
 
3.3  Gender  
 
In the TB-only cohort, 207 (65%) were male compared to 113 (35%) female, 
compared to the TB-DM cohort, where 106 (62%) were male and 63 (38%) 
female. Statistically (P-value 0.920), no association was found between either 
group. However, the odds ratio suggests an increased risk of developing TB 
in men (OR 1.0; CI 0.5-1.8). 
 
3.4  Previous TB diagnosis 
 
A total of 17% of the total study population were known to have been 
diagnosed previously with TB. Statistically, there was no significance between 
the TB-only and TB-DM cohorts that had previously been diagnosed with TB. 
 
3.5  Co-morbidities 
 
In the TB-only cohort, 79 (34%) reported having at least one co-morbid risk 




significant association (P-value 0.009) observed between the two groups in 
the presence of co-morbid risk factors.  Within the TB-DM cohort, 149 
individuals had reported co-morbidities, which included individuals who were 
on long-term systemic steroids, suffered from chronic renal failure, chronic 
liver disease, chronic lung disease, malignancy, or were on anti-TNF 
treatment for rheumatoid arthritis and ulcerative colitis.  
 
3.6  Fever 
 
In the TB-only cohort, 189 (33%) presented with fever at the time of TB 
diagnosis compared with the TB-DM cohort, where 93 (41%) presented with 
the symptom. Statistically (P-value 0.02), this was significant, where fever 
presented more commonly in the TB only group. 
 
3.7  Cough 
 
A total of 241 patients from the study population presented with cough as a 
symptom of TB. Of these, in the TB-only cohort, 152 (55%) had cough 
compared to 89 (41%) in the TB-DM cohort. Statistically (P-value 0.203), 
cough is not a significant factor in either group.  
 
3.8  Weight loss 
 
56 (26%) of the individuals in the TB-DM cohort presented with weight loss as 
a symptom on presentation compared to 121 (43%) in the TB only cohort. 
Weight loss was not a significant factor associated in this study.  
 
3.9  Haemoptysis 
 
Only 13 (5%) in the TB-DM cohort compared to 26 (10%) in the TB-only 
cohort presented with haemoptysis as a symptom on presentation. 
Statistically (P-value 0.069), there is no significant association of haemoptysis 





3.10  Night sweats 
 
51 (23%) in the TB-DM cohort presented with night sweats as a symptom on 
presentation compared to 102 (37%) in the TB-only cohort. A statistically (P-
value <0.05) significant result was observed between the TB and TB-DM 
cohorts. The TB-DM cohort was more likely to present with night sweats.  
 
3.11  Smoking 
 
When comparing smoking between the two groups, in the TB-only group, 36 
(16%) patients were considered heavy smokers and met the smoking criteria 
compared to 43 (4%) in the TB-DM group. Statistically (P-value 0.319), no 
significant difference was observed between the two groups.  
 
3.12  Heavy drinking 
 
34 of the 489 individuals included in the study were classed as heavy 
drinkers, of which 11 were from the TB-DM cohort and 23 from the TB-only 
cohort. When comparing to see whether drinking increased TB risk (P-value 
0.07), no significance was observed in this study population.  
 
3.13  HIV 
 
Only a total of 14 cases from the total study sample population were known to 
be HIV positive. In the TB-only cohort, six were known to be HIV positive 
compared to eight in the TB-DM cohort. Statistically, no significant (P-value 
0.193) risk was associated with HIV, and HIV in the presence of DM did not 
increase the risk of TB. Similarly, the OR value of 0.479 does not indicate an 
increased risk between the HIV-positive patients and the TB-DM cohort. 
 
3.14  Persons who inject drugs (PWID) 
 
In the TB-DM group, 24 patients were known to be an IV drug-taker, with 12 in 




used, which resulted in a significant result with a P-value of 0.03. The result 
suggests IV drug use is an independent risk factor in the presence of DM to 
increase the risk of TB. However, the OR value of 6.1 (0.7-48.1), with such a 
wide range, indicates the lack of precision in the interpretation of the result 
and it should be taken with caution.  
 
3.15  Homelessness 
 
A total of 11 (4%) individuals from the total population were known to be 
homeless. Of those, four patients reported to be homeless within the TB-only 
group compared to 7 in the TB-DM cohort. Statistically (P-value 0.885) no 
significant difference was observed between the two groups. This may be the 
result of small numbers in the study population.  
 
3.16  Prison 
 
Only two individuals from the TB-only cohort had a history of imprisonment. 
Statistical analysis could not be performed.   
 
3.17  Known contact with TB 
 
A total of 152 cases reported having direct TB exposure, of which, 111 (61%) 
were in the TB-DM cohort and 41 in the TB-only cohort. Statistically, no 
significance was observed (P-value 0.446).  
 
3.18  BCG 
 
A total of 328 of the 489 cases were known to have been vaccinated against 
TB, of which 111 (61%) were from the TB-only cohort and 217 (76%) were 
from the TB-DM cohort, either in the UK or home country. Statistically, no 
significant difference was observed between the groups with or without BCG 
vaccination. Thus, vaccination does not provide additional protection against 





3.19  Relapse 
 
A total of 23 relapses was reported in the total study population, of which 13 
were in the TB-only cohort and 10 in the TB-DM cohort. Statistically (P-value 
0.275), there was no increased risk of relapse of TB in patients with DM. 
 
3.20  Microbiology and radiological characteristics 
 
In the TB-DM cohort, a total of 68 (41%) PTB cases were identified and 100 
(54%) EPTB cases. In the TB-only cohort, 151 (47%) PTB cases were 
identified and 170 (53%) EPTB cases. Statistically, there was a significant 
difference observed between the two groups (P-value 0.03). The association 
between DM and radiological characteristics showing the presence of cavities 
was significantly associated with DM comorbidity (OR 1, 95% CI 0.9-1.6; P-
value <0.05) (Table 3.3). No difference in drug resistance was observed 
between both cohorts. 
 
Table 3.3 Analysis of Radiological and Microbiological 
Characteristics of TB and TB-DM cohorts 

































































































* Adjusted for age and gender. TB: Tuberculosis infection; DM: Diabetes 





3.21 Comparison of culture conversion time in intensive phase of 
treatment 
 
This study consisted of 489 patients who had begun anti-TB therapy, with a 
total of 219 PTB confirmed cases with positive culture for TB. Prior to anti-
tuberculosis treatment (ATT), 151 patients were identified in the TB-only 
cohort compared to 68 patients in the TB-DM cohort. In the 1-month of TB 
treatment, 35%, in the TB-only cohort, had a negative smear after completion 
of the1st month ATT compared to 32% in the TB-DM cohort. After 2-months of 
ATT, in the TB-only cohort, 89% were smear-negative compared to 85% in 
the TB-DM cohort (P-value <0.05). Within the two-month intensive treatment 
phase, TB-DM had a slightly slower conversion rate when compared to the 
TB-only cohort (table 3.4). 
 
Table 3.4  Analysis of positive sputum culture pre-anti tuberculosis 
treatment (ATT), and after 2-months ATT initiation. 
 































135 (89%) 30 58 (85%) 40 






3.22 Sputum Culture Conversion – within the intensive treatment 
phase (after 2 months of treatment initiation) 
 
A Kaplan Meier curve was used to show the culture positive cases which 
convert to negative culture by end of day 60, post commencing treatment. The 
plot illustrates the time after initiation of treatment in the initial intensive 
treatment phase.  
 
The Kaplan-Meier survival curve was used to illustrate the difference in time 
for sputum culture conversion from positive to negative and being clear of Mtb 
in the sputum. Using the Kaplan Meier curve for culture conversion by 60 
days after commencement of treatment shows the TB-DM to have a slower 
rate of smear-positive conversion rate compared to the TB-only cohort log 
rank test P=<0.05, (figure 3.1).  The presence of DM decreases the 
conversion rate as the TB-DM cohort has a lower rate of conversion, reflecting 
higher bacillary load.  Comparison of time to culture conversion among TB-
only patients and TB-DM patients by 30 days. The TB-only cohort median 
conversion was 10 days compared to 16 days in the TB-DM cohort.  
 
These results illustrate how the TB-DM cohort are less likely to have a 
clearance result (negative sample) for TB and a reduced estimate of survival 
compared to the TB-only cohort. By day 60, the TB-DM cohort still had a 
higher bacillus load and were more infectious with TB, posing a risk to others, 
as well as being less likely to be able to clear Mtb. Therefore, by the end of 
the two-month’s intensive phase of treatment, the potential levels of bacilli 
load in the culture were greater in the TB-DM cohort. The result would imply 
an aggressive initial phase of treatment in TB-DM patients with anti-TB 
medication and ensuring optimal control of DM is essential for a better 
outcome.  
 
However, it is important to note that sputum culture conversion is a clinical 
tool used to predict the therapeutic efficacy in TB patients. A non-conversion 
of sputum smear to negative culture at the end of the intensive phased of 




with increased treatment failure associated with death. The results from the 
study suggest sputum culture conversion after the first two months of 
treatment may be a predictor for treatment success in the TB-DM cohort. 
Lung cavitation and sputum culture conversion is also available to be used to 
monitor TB-DM patients’ outcome. As this was a retrospective study, to limit 
selection bias, all cases were followed-up to ensure accurate TB diagnosis 
and treatment completion as well as relapses and drug resistance recorded. 
Non-differential misclassification of information can lead to information bias by 
clinical practitioners when entering data into the clinical system, including 
confounding variables such as smoking and drinking during treatment, which 
are likely to result in misclassification due to lack of information. Factors 
commonly associated with delayed sputum conversion include male gender, 
older age and AFB density (Gunda et al., 2017).  A smear non-conversion is 
more likely to occur with those aged 40 and over and who have poor 
compliance with treatment adherence. This study also assessed the chest X-
ray as the presence of cavities is more common in TB-DM cohort relating this 
to the culture conversion rate, TB-DM patients are likely to be infected for a 
longer period. This likely increase the risk of treatment failure and mortality 
rate.  Further limitations in this study include the fact that this is a single 
centre study; therefore, the results from are unlikely to be generalizable. 
Furthermore, being a retrospective study increases the likelihood of data 





Figure 3.1 Kaplan-Meier - AFB Sputum Culture Conversion – within 2-
months’ TB treatment initiation 
 
Comparison of time to culture conversion among TB-only patients and TB-DM 
patients at 60 days after commencement of anti-TB treatment.  
 
3.23  Acid-Fast Bacilli (AFB) distribution profile 
 
When comparing the AFB smears in sputum between the cohorts, in the TB-
DM cohort 15% had a scanty positive result, 30% was positive for AFB 1+, 
17% was positive for AFB 2+ and 38% positive for AFB 3+. In comparison, the 
TB-only cohort had 51% as scanty positive, 18% as AFB 1+, 11% AFB 2+ and 
20% AFB 3+, with a chi-square P-value of 0.019, being significant (figure 3.2). 
The result demonstrates how TB-DM patients is more likely to be infected with 
greater severity, along with increased time for culture conversion. This reflects 
a higher bacterial burden and, theoretically, would imply the intensive 
treatment phase likely needs to be increased or better glycaemic control 









Sputum AFB smears were graded following CDC guidelines: those with a 3+ 
were defined as high AFB smear grade. By examining the baseline smear 
results among patients with TB-DM and the TB-only cohort, it was found that 
a greater proportion of AFB-positives were among TB-DM, which is 
statistically significant using the chi-square test (P-value <0.001). 
 
3.24  A comparison of drug sensitivity between TB-only and TB-DM 
patients 
 
In the TB-DM cohort, out of 168 isolates, 163 (98%) were fully sensitive to 
first-line therapy and five reported as MDR-TB. In contrast, in the TB-only 
cohort, a total of 321 (98%) isolates were sent for culture testing: 312 (98%) 
were fully sensitive with 9 (2%) MDR-TB reported. There was no significant 
observed difference between the two groups in culture sensitivity patterns (P-































3.25 Vitamin D Levels in TB-DM vs TB only cohort 
 
The mean vitamin D level in the TB-DM cohort was 26.90 ng/mL and in the 
TB-only cohort, it was 25.61 ng/mL. The vitamin D level was measured using 
a 25-hydroxy vitamin D concentration in blood samples. A level of 30 ng/mL to 
50 ng/mL is in the normal range for healthy individuals. A level of less than 20 




A total of 137 patient samples reported Vit D levels during initial diagnosis or 
treatment phase. In the TB-DM cohort, a mean Vit D level of 26.90 ng/mL (SD 
3.6, range 1-70) was reported. In contrast, the TB-only cohort reported a 
mean vitamin D level of 25.61 ng/mL (SD 3.684; range 1-100). Statistically, 
there was no significant difference in vitamin levels between the TB-DM and 
TB-only cohorts. The TB-DM cohort had a mean serum vitamin D level of 





















Figure 3.3  Vitamin D Levels in TB-DM vs TB-only Group 
 
 
The graph compares the number of cases of Vit D levels falling into the 
normal level category, insufficient category, deficient category, and severely 
deficient category 
(http://www.bartsendocrinology.co.uk/resources/CEG+Vitamin+D+guidance.p
df).  A level of less than 9.9ng/mL is considered severely deficient. A level 
between 10-19.9ng/mL is considered deficient. A level between 20-29.9ng/mL 
is considered insufficient. A level of 30 to 39 ng/mL is considered adequate. A 
level between 40 to 59 ng/mL is considered optimal. A level between 60 to 
100 ng/mL is considered therapeutic. A level greater than 100 is considered 
excessive. Statistically, no significance (P-value 0.58) was observed between 














3.26 HbA1c Levels in TB-DM vs TB cohorts 
 
The HbA1c levels is higher in the TB-DM cohort compared to the TB-only 
cohort and is statistically significant (P-value <0.05). A level of 7 mmol/L 
(6.5%) of more is considered to have diabetes. A total of 168 HbA1c results 
was available at the time of diagnosis of TB, excluding stress-induced 
glycaemia. The HbA1c level was taken at the same time as when the AFB 
samples were collected, reflecting true infectivity.  HbA1c levels provide the 
average blood glucose levels for the three months prior to diagnosis or while 
individuals were symptomatic at initial diagnosis. In the TB-DM cohort, 115 
cases had reported HbA1c levels with an average mean reading of 7.63% 
(SD +/- 5.6; range 4-13). In the TB-only cohort, 54 reported HbA1c levels on 
presentation or during the infectious phase. The average HbA1c level 
reported was 5.53% (SD +/- 5.02, range 5-8), the P-value (<0.05) (figure 3.4) 
(table 3.6) suggested this is a significant independent factor for developing 
TB.   
 TB-Only 
n = 78 
TB-DM 

















N (%) with normal level 
(≥30ng/mL) 
19 (24%) 18 (31%) 
N (%) with insufficiency 
level (20-29.9ng/mL) 
16 (20%) 18 (31%) 
N (%) with deficiency 
level (10-19.9ng/mL) 
25 (32%) 15 (24%) 
N (%) with severe 
deficiency level 
(<9.9ng/mL) 





By applying chi-square statistical analysis, hyperglycaemia levels were found 
to be significant (P-value <0.05) between the TB-DM and TB-only cohorts. 
Transient hyperglycaemia frequently occurs in TB patients who have 
commenced anti-TB medication. However, the results excluded transient 
hyperglycaemia post-TB treatment completion. When comparing the HbA1c 
levels between the two cohorts, the TB-DM cohort had a far more 
uncontrolled level (mean HbA1c of 7.63%, range, 4-13%). This was in 
comparison to the TB-only cohort level (mean HbA1c level 5.53, range 5-8%) 
and suggests that a controlled glycaemia level is likely to contribute to the 
clinical outcome, as well as the severity of symptoms. The normal range is 5-
7%, HbA1c (Diabetes UK, 2019).  
 
Previous studies have shown that TB induces stress hyperglycaemia (due to 
general inflammatory factors triggered by active TB), commonly occurring in 
the first few months of commencing anti-TB medication. This is followed by a 
return to an euglycemic state (Kumpatla et al., 2013; Menon et al., 2016). In 
this study, euglycemic cases were excluded and completed a 2-year follow-
up, which presented with 27 cases of post-completion of TB treatment to have 
been diagnosed with DM and commenced on DM medication. This, therefore, 
rules out any transient hyperglycaemia caused by anti-TB medication, 
especially in the early phases of hyperglycaemia induced by rifampicin 
administration or using steroids. This further reinforces the need to have a 
glucose measurement done at the time of TB diagnosis and the 
commencement of anti-TB medication to confirm DM diagnosis.  Therefore, 
hyperglycaemia is an early marker for abnormal metabolic state and probable 












Table 3.6 HbA1c Levels between TB-only and TB-DM cohort 












7.63% 5-8, SD +/- 5.61 
 
 
Figure 3.4  HbA1c Levels in TB-DM vs TB-only cohorts 
 
TB-DM cohort mean HbA1c level recorded was 7.63% (range, 3-13, SD 5.61) 
compared to TB without DM mean HbA1c of 5.53% (range, 5-8, SD 1.32), chi-
square P-value <0.05. A level less than/equal to 5.8% (40 mmol/mol) – 
requires ruling of hypoglycaemia. HbA1c levels between 5.9 - 6.6% is 




considered poor; 7.7 – 8.6% is considered less than poor, and a level 
between 8.7 – 13.0% is very poor.  
 
3.27  Clinical outcome post-completion of TB treatment 
 
Comparing the clinical outcome post-treatment, no statistical significance was 
observed between the two cohorts. In the TB-DM cohort, 158 out of the 168 
successfully completed their treatment. In comparison, in the TB-only cohort, 
303 out of 321 successfully completed their treatment. By the end of the 6th 
month of the anti-TB period, of all 489 enrolled in the study, 461 had 
successfully completed their treatment. In the TB-DM cohort, 7 (4%) patients 
died during their course of treatment, the same number as in the TB-only 
cohort 7 (2%) (table 3.7). The proportion of deaths observed in the TB-DM 
patient group was higher compared to the TB-only cohort. The lost to follow-
up and transferred out of study numbers were relatively similar in both 
cohorts.  
 
















TB-DM 158 (94%) 7 (4%) 2 (1%) 1 (1%) 
0.475 
TB only 303 (94%) 7 (2%) 7 (2%) 4 (1%) 
 
Within both groups, 94% completed treatment successfully within six months 
of anti-TB treatment. No significance was observed in relation to mortality or 
treatment failure rate. 
 
3.28 Comparing time of TB diagnosis between TB only and TB-DM 
 
This study observed that TB diagnosis was much later in the TB-DM cohort 




evaluated the effect of duration of a diabetes diagnosis on the risk of TB 
disease, this result suggests: 
 
1. DM alters the presentation of TB, leading to a miss-diagnosis 
2. DM increases the risk of reactivation of latent TB, as T2DM 
predominantly presents in older age, therefore those with latent TB and 
who develop DM, lowering their immunity leading to activation of latent 
TB.  
 
It is unclear whether the predisposition to Mtb infection and severity of illness 
is increased in the presence of DM, as a result of defective immunity in 
individuals with DM. This would imply TB disease can be impacted by this 
chronic condition. In addition, this is very likely to be further influenced in non-
UK born individuals living in the UK, as they are more likely to become obese, 
suffer with DM and have high blood pressure, rather than the native UK 
population (Murphy, Robertson, and Oyebode, 2017). The result may reflect a 
late diagnosis of DM in the home country and in the host country (due to 
access to healthcare). The result also showed the diagnosis of DM in the 
younger population is observed in natives rather than in non-UK born 
individuals, this may reflect a population trend of DM onset because of 
changes in lifestyle in non-UK born or natives. 
 
Table 3.8 Year before TB diagnosis is made in TB-only and TB-DM 
cohort 
 





TB Only 9.38 
 
The median time (in years) for diagnosis of TB with those with DM is 17.28 
years after entry into the UK. In comparison with the TB-only cohort, who do 











There is a widened superior mediastinum. The lungs and pleura appear 









Lung fields are emphysematous. Old calcific granuloma seen in the left upper 
lobe. The present x-ray shows a soft tissue density on the right side between 
the anterior ends of the third and fourth ribs. There is some prominence of the 
right hilum as before and there could be underlying hilar lymphadenopathy on 









A minute (sub-centimetre) subpleural granulomatous process is seen within 
the lateral aspect of the upper lobe of the right lung.  Otherwise, the scanned 
lung fields appear clear. Multiple pathologically enlarged mediastinal lymph 
nodes readily noticed, particularly in the paratracheal and tracheo-caval 
regions.  The nodes in the aortopulmonary window and subcarinal regions are 
also seen enlarged. The enlarged nodes appear to be matted with no cystic 
degeneration or calcification seen within. No pleural or pericardial collections 
seen. Few sections passing through upper abdomen showed no focal hepatic 








There is a large right pleural effusion. There is consolidation and atelectasis in 










There are nodular opacities seen in both lung fields and the possibility of 



















There is bilateral small moderate pleural effusions some patchy parenchymal 








Lower thoracic spine fixation noted. No lung parenchymal abnormality of note. 









There is a miliary nodular shadowing in both lungs suspicious of miliary TB. 












No parenchymal nodules, consolidations or evidence of collapse is seen. 
Cardiac, mediastinal and hilar contours appear unremarkable. No pleural 









No lung mass or consolidation. No pleural effusions. There are mild 










There is segmental collapse seen in the left upper lobe. Rest of the lung fields 











Mild diffuse accentuation of bronco-vascular markings with basal peri-
bronchial thickening.  No pneumonitic patches or cavitary lesions.  Clear 
costophrenic recesses. Heart does not appear to be enlarged. Unfolded aorta 

































Chapter 4 - General discussion 
 
Primary Objective: 1 
 
4.1 Determining the prevalence of DM among TB (TB-DM) patients in 
Newham, with a focus on differences between UK-born and non-UK born 
patients.   
 
The global estimated number of TB cases was 10 million in 2018 and 1.2 
million deaths are directly attributed annually to TB (WHO, 2019). The global 
prevalence of DM is estimated to be 415 million, with 7 million new cases 
diagnosed each year and 5 million deaths associated with DM (IDF, 2015). 
The converging epidemics of TB and DM suggest DM could increase the risk 
of active TB by 3-fold because of uncontrolled DM leading to increasing 
reactivation of latent TB, increasing immune-susceptibility and development of 
MDR-TB as insufficient initial treatment.  
 
At the national level, the information on TB-DM co-epidemic is unknown, 
although the rate of TB has not been declining according to previous targets 
set by the WHO. The WHO strategy aims for the elimination of TB (defined as 
incidence of <1 per 100,000 people) in low-incidence countries. The incidence 
of TB, in England, has fallen from a peak of 8,280 in 2011to 4,655 in 2018, to 
reach the WHO End TB Strategy target of a 90% reduction in new 
notifications by 2035 (PHE, 2018) further approaches and changes in practice 
is required. In 2015, PHE and NHS England launched the Collaborative 
Tuberculosis Strategy for England 2015 to 2020, which aimed at decreasing 
TB on a year by year basis until its elimination. To achieve this, the following 
actions were given priority: improving access to health services and earlier 
diagnosis of TB, an increase in the quality of diagnostic equipment, carry out 
thorough contact tracing of known cases, improve BCG vaccination uptake, 
reduce MDR TB, implement new entrant latent (LTBI) testing and treatment 





This is the first study in the UK to report the TB-DM rate as a tandem 
condition in a high TB burden population with increasing public health 
problems, using real-world data and follow-up of cases. The study includes 
the use of patient-level data from routinely recorded data on demographics, 
clinical course and outcome. The study assessed each patient’s diagnosis 
alongside standard definitions, the treatment course of each patient using 
real-time clinical records, hospital visits, DM diagnoses, laboratory test 
interpretations, radiological assessments, and treatment efficacy and 
outcomes, with a 2-year follow-up.  Recent data indicates that TB infection in 
Newham is above 40 per 100,000 compared to the rest of London (2017), 
which is a rate of 21.7 per 100,000. The latest DM incidence in the UK is 
estimated to be 3.9 million (6% of the UK population are classed as diabetic) 
(IDA, 2015) and the incidence of DM in the Borough of Newham is 22,904 for 
adults over the age of 18 years, which represents 6.7% of Newham’s 
population. Therefore, the DM rate in the borough of Newham is comparable 
to the national average, thereby not posing a threat of being selected or 
biased.  
 
The result from this study shows the prevalence of TB-DM in Newham is 
28.8%, the average time to TB diagnosis post entry to the UK was 17.28 
years in the TB-DM cohort compared to 9 years in the TB-only cohort (p- 
<0.001), with 89% of TB-DM cases being non-UK born patients. This 
significant finding suggests TB-DM groups are diagnosed with DM much later 
in adult life, and those non-UK born individuals also present with TB 
symptoms much later after entry into the UK, compared to the TB-only group 
(P-value <0.001). This may be a result of DM impacting upon the increased 
reactivation of latent TB in those already infected from a high-risk country. 
Furthermore, in the UK-born cases it is likely DM increases the risk of 
acquiring TB, as a result of immune deficiency and this is seen later in life, 
most likely as T2DM is an age related condition, therefore further studies are 
needed to target this group.  This result would suggest a significant proportion 
of TB cases may have been prevented if they had been screened for TB on 





The study also identified over 80% of all TB cases were diagnosed in non-UK 
born patients, with male patients (over 60%) being more commonly diagnosed 
in both UK and non-UK born populations. When analysing the prevalence of 
DM in TB cases, 168 cases had been diagnosed with TB-DM, with 3.8% of 
these being diagnosed as new DM cases, post-TB treatment. The result 
strengthens our knowledge that DM is an independent risk factor for an 
increase in TB cases in the London Borough of Newham. When comparing 
the age at which TB was diagnosed in the study population, the mean age 
was 36 years. The study found the mean age of TB only cases to be 
diagnosed at a younger age (mean: 38 years), compared to TB-DM cases 
(mean age: 45 years) which was more frequently diagnosed in those over the 
age of 55, and older age was a risk factor in the TB-DM cohort. This reflects 
T2DM which is mostly also age related.  
 
A screening for DM as part of LTBI screening should be considered. It is 
plausible that the presence of DM, coupled with latent TB, increases the risk 
of active TB, a likely reason for the continuously high TB incidence in the 
London Borough of Newham and requires further investigation. It is possible 
that non-UK born individuals from a large TB incidence country to have active 
TB upon arrival in the UK or have LTBI, which reactivates post-arrival 
because of socio-economic risks including poor housing centres and 
overcrowding, or they could obtain TB through local transmission from 
individuals in the host nation. 
 
Systematic reviews suggest DM increases the risk of TB, caused by immune 
dysfunction in diabetics, this current study strengthens our knowledge that the 
association between DM and TB exists, with certain characteristics: age, 
fever, weight loss being more common in TB-DM cases. Higher mycobacterial 
load, due to an increased clearance time in patients, all likely associated with 
poor glycaemic control, and immune deficiency, which in turn is related to DM 
diagnosis and medication adherence, which then affects clinical outcome. The 
results from this study highlight the need to investigate the management of 




directional screening, monitoring TB drug adherence and therapeutic effects, 
especially drug-drug interactions with hypoglycaemia agents.  
 
It is likely, as can be seen in results reported here, that non-UK born citizens 
are at higher risk of TB due to increased exposure in their home country or 
due to the other reasons mentioned. This places individuals at risk of LTBI to 
progress to active TB; hence, the late diagnosis of TB after entry into the host 
country. Migration has been shown to be a driver of TB in low incidence 
countries, with most TB cases attributed to reactivation of latent TB acquired 
in the country of birth (Dale et al., 2018). The results also suggest higher 
infectious risk, in the TB-DM cohort, through increased cavitation and late 
sputum conversion, which are significant factors. Furthermore, 5% of all those 
treated in the TB-DM cohort had relapsed compared to 1% in the TB-only 
cohort, which likely implies treatment failure is higher in the TB-DM cohort 
leading to an increased mortality rate as reported here. 
 
Loutet et al., (2018) undertook a pilot study in Newham, which was 
undertaken to evaluate a national roll-out of an LTBI treatment and screening 
service in a high TB incidence population. Within the study period (2012-
2014) the authors discovered over the 3-year period that the TB incidence 
was 100 per 100,000 population, which was greater than the London average 
of 35.4 per 100,000 population. The pilot study revealed over 80% of TB 
cases in Newham (including TB-DM cases) were in people from the non-UK 
born population.  They reported the treatment of LTBI was a significant 
mechanism to suppress the incidence of TB in Newham. A total of 5,591 
patients in Newham were screened for LTBI screening. The age ranged from 
16-35 (71%) and 54% male. Of those offered LTBI, 1,254 (22.4%) declined to 
be screened. The result showed individuals from Sub-Saharan Africa were 
most reluctant to undertake LTBI testing, when compared with individuals 
from the Indian sub-continent (adjusted OR 0.6 (95 percent CI, 0.4-0.9) and 
adjusted OR 0.7 (95% CI, 0.6-0.8) (Loutet et al., 2018). Their results showed 
an immediate impact of the LTBI screening programme on managing TB 
incidence, by actively identifying active cases and reducing transmission of 





This current study found 85.3% of all cases occurred in non-UK born men with 
a mean age of 36 years (range 27.5-49.9). This study is comparable to that of 
Loutet et al. (2018), and highlights that there is an opportunity to actively find 
cases and treat, in addition to managing DM cases (known and new cases) to 
provide a better treatment outcome for patients and effectively contribute to 
TB elimination.  
 
Although there is no UK-based comparable studies, a study by Restrepo et al. 
(2014) in Texas, USA to estimate the contribution of confirmed DM cases to 
TB rates, where both conditions were prevalent, was undertaken. This was a 
prospective study using TB clinics in the Texas-Mexico border area with a 
total of 333 TB cases enrolled in the study, 233 of whom met the study 
criteria: 61 in South Texas and 172 in north-eastern Mexico. All cases had 
pulmonary TB. The result estimated the prevalence of DM among the TB 
patients to be 39% in Texas and 36% in Mexico. DM contributed to 25% of the 
TB cases, whereas HIV contributed to 5% or fewer, with a median time until 
DM diagnosis of seven years. This study is suggestive of a missed 
opportunity for TB prevention (Restrepo et al., 2014). In comparison to the 
Restrepo study, TB-DM patients in this study had a time of 17.28 years (see 
table 3.8) until DM diagnosis, a decade difference in active TB presentation in 
the TB-DM cohort compared to the TB only patients. This might be related to 
TB exposure and other environmental and societal factors.  However, the TB-
DM prevalence in this study was 28.5%, which is comparable to the findings 
by Restrepo et al. (2014) who cited in their study a direct association between 
TB and DM is likely. 
 
The findings from this current study and previous studies have found DM to 
be associated with older age, which is a well-known risk factor for DM but not 
for TB. A likely explanation of why TB-DM is common in non-UK born 
nationals is that those individuals from high TB burden countries are at risk of 
having latent TB upon entry into the UK and poor glycaemic control has a 
negative impact on immunity: hence, an increased risk of latent TB becoming 




risk factors for PTB among DM patients. Their study included 160 patients 
organised into two groups: the first group of 80 patients with TB-DM and the 
second of 80 patients with DM and chest disease other than TB. They 
reported the mean age of the TB-DM group to be 52.90 years, with the DM-
only group having a mean age of 54.57 years with a p-value of 0.32. They 
showed no significant difference between the two cohorts in relation to 
mortality rate, cure rates, relapse and resistances.  Ponce-de-Leon et al., 
(2004) studied TB and DM in Mexico using a study size of 581 patients. They 
reported that the mean age of TB-DM was 51.5 years compared to 44 years 
in non-DM-TB patients. Nissapatorn et al. (2005), who looked at TB and DM 
in the South Asian population in Malaysia, found a TB-DM group age of 51.5 
years compared to 37.5 years in the non-DM-TB group, using a sample size 
of 1651 patients.  
 
In this study, when comparing age, the TB-DM cases are likely to be older by 
10-20 years than those with only TB. This indicates an association with DM, 
especially T2DM, which is more prevalent globally and amongst those at an 
older age. It is also likely to be associated with social risk factors including 
lifestyle habits i.e. diet and inactivity. The male dominance in both TB-only 
(65%) and the TB-DM cohort (62%) has also been reported by Nissapatorn et 
al. (2005), who found 69.3% of their study population with TB-DM to be men. 
TB is more likely to be observed in men due to occupational exposure, 
although further investigations into occupational exposure in men and the 
impact of comorbidity of TB-DM in relation to occupational exposure is 
required (Davidson et al., 2016).  
 
In relation to DM diagnosis in TB patients, the result from this study reflected 
a high percentage of non-UK born to have TB at a much later age than those 
with only TB in the Newham population. This late diagnosis of DM could be 
due to two causes: 
1. These individuals already have prediabetes, whereby the blood sugar 
level is high, but lower than the threshold for diagnosing DM, and this 




2. The risk factors for DM include age (40 and above), body mass index 
(25 and above), Asian ethnicity and having high blood pressure. Age 
and ethnicity are implicated in this study with DM being more 
commonly diagnosed in non-UK individuals, who have a major shift in 
lifestyle once resident in the UK compared with in their country of birth 
(Mainous et al., (2014). This increases the risk of prediabetes and DM.  
 
One explanation for this is a likely late diagnosis of diabetes in the home 
country, or that it reflects a population trend of earlier onset of DM, especially 
type 2 DM, due to the rapid changes in lifestyle experienced by non-UK born 
in the host country.  
 
Furthermore, local transmission in the Borough of Newham within 
communities, may have also contributed to the higher incidence of TB cases 
observed in such a diverse migrant population with a range of ethnic groups. 
These ethnic groups are more likely to live in densely populated areas with a 
higher concentration of their own ethnic communities, which increases the 
spread of TB. In addition, having multi-generations living together as opposed 
to a nuclear family setting increased TB transmission (Hayward et al., 2018).  
 
Furthermore, the results of TB-DM prevalence in Newham is the first study to 
be done in the UK and in any London Borough. It is likely the social and 
clinical observations seen in patients with TB-DM in Newham could be 
representative of other London Boroughs or cities in the UK, which have 
similar demographic characteristics including a densely populated non-UK 
born population. It is documented that more non-UK born individuals are 
entering the country due to globalisation, conflict and for financial reasons, 
this has led to non-UK born individuals seeking permanent residence in the 
UK, and a significant proportion of these non-UK born residents are from high 
TB burden areas, including Sub-Saharan Africa and the Indian Subcontinent 
(ISC) (Restrepo and Schlesinger, 2014; Pande et al., 2018). As a result, TB 






The results from this study show the average age at diagnosis of TB in the 
TB-DM cohort is 17 years compared to 9 years in the TB only group 
(p=<0.001), with poor glycaemia control (average HbA1c levels of 7.63%), 
age over 55 years could be because DM is playing a role in late TB diagnosis. 
It has been reported in previous literature that DM can decrease the immune 
response, which facilitates either the primary infection with Mycobacterium 
tuberculosis or reactivation of latent TB, by altering the components of the 
immune system, including altered levels of specific cytokines and chemokines 
(Nathella and Babu, 2017). Activation of latent TB in affected individuals, is 
more common in non-UK born patients, especially those from a high TB 
burden country. Furthermore, non-UK born cases with active TB, which had 
not been diagnosed, are likely to reflect the increased numbers. However, 
since 2012, the UK Home Office has introduced pre-arrival screening for 
active PTB for all long-term visa applications from endemic countries; those 
with active TB are denied entrance. Therefore, the arrival of non-UK born 
individuals with active TB alone is not likely to be significant to the overall TB 
burden seen in the UK and reported here in Newham. It is likely that poor 
glycaemic control leading to immune suppression is allowing the activation of 
latent TB, which is common in non-UK born individuals travelling from high-
incidence countries.   
 
As non-UK born cases are observed as a key risk factor for developing TB, it 
is advisable to investigate the mechanism leading to this susceptibility 
including urbanisation, modernization, changes in nutrition and lifestyle 
including lack of physical activity, stress and behavioural changes which are 
commonly experienced by non-UK born who likely have come from a poverty-
ridden rural area to urban obesogenic environment. All these factors further 
the risk of obesity and diabetes which is commonly seen in inter and intra-
country non-UK born in developed and developing countries (Tomas et al., 
2013).  Research by Hanif and Susaria (2018) on the association between 
migration and diabetes, in Asian Indians living in the UK have shown a 
common non-UK born likely to be obese, have higher blood pressure, 
increased cholesterol and blood sugar levels. Furthermore, non-UK born who 




immigrant siblings living in India (Ebrahim et al., 2010).  The result from this 
study found men are at higher risk of TB-DM, which is likely to coincide with 
the exposure to TB through lifestyle change, living in poor housing and 
overcrowding, increasing obesity because of a change in lifestyle and barrier 
to access healthcare facilities either in birth country or host country. 
 
The incidence of TB in 2018 was 4,655 (8.3 per 100,000 population), to meet 
WHO End TB Strategy target of 90% reduction of new notification by 2035, 
further effort is required, including understanding the variation of TB 
prevalence and patient profiles across the country, focusing on people with 
social risk factors. This study focuses on DM as a risk factor with the aim to 
implement policy change to manage co-existing conditions better and to 
subsequently reduce TB burden. The prevalence data from this study shows 
85.3% of all TB cases are reported in non-UK born patients, although we 
found no statistical association, DM is a significant variable between UK born 
and non-UK born populations. But as mentioned, reactivation of LTBI maybe 
a cause, but this requires further investigation. The results show TB-DM 
cohort are diagnosed later than the TB only cohort, from a health policy 
perspective it would be  beneficial to highlight both DM and TB in high risk 
groups within the population which is those over the age of 55 years, non-UK 
born and male are being at higher risk of TB and DM. Health providers, both 
primary care and secondary care, should consider this at risk group and look 
at implementation of TB or DM screening, if either condition is present. 
Further consideration of dual management of TB-DM, with referral to 
specialist care as early as possible and education on lifestyle behaviours.   
 
Actively screening for TB in DM patients is not routinely conducted in the UK 
or globally, partly related to resource available to enable for universal 
screening and cost implications. This is likely to be difficult to implement in 
low-burden countries as a routine but likely to be beneficial in clusters of high 
incidences in the UK. This is unlikely to be implemented in non-UK born 
individuals from host countries, prior to entrance into the UK, mostly due to 
cost and further investigation is required especially from a endocrine 




logistically or financially, as DM clinics are not set up with an x-ray facility and 
sending patients for x-ray without clinical reason is not evidence based. 
Therefore, a screening programme targeted at non-UK born individuals with 
DM from ethnic groups disproportionately affected by TB and DM would prove 
useful, based on this research reported here. 
 
Currently, screening for and treatment of LTBI in DM patients is not clinically 
recommended in any guidance. Screening for TB disease is recommended for 
persons migrating from countries with a high TB incidence. It would be 
beneficial to investigate the screening and treatment of LTBI and active TB, in 
addition to, testing for DM in positive TB cases. Current practice is those 
tested positive for TB to be screened for HIV, the same practice should be 
applied to DM. 
 
The findings from these results imply TB is being diagnosed sometime after 
non-UK born individuals’ arrival in the UK, suggesting that differential 
exposure among non-UK born individuals is a vital risk factor for TB. 
Approximately 13% of the UK foreign non-UK born population are from a 
country where TB prevalence is >250 cases per 100,000. Following the 
Second World War, a significant number of non-UK born cases came from the 
Commonwealth and British Empire; likely due to Britain's labour deficit for 
post-war reconstruction and political turbulence after decolonisation (i.e. the 
creation of Pakistan). Many Commonwealth nations have a high prevalence of 
TB: in Africa, 275 per 100,000 inhabitants in 2015; at South East Asia, 246 
per 100,000 (WHO, 2018). Non-UK born individuals from high TB incidence 
countries are more likely to have been exposed to Mtb and have an increased 
risk of acquiring LTBI.  
 
In 2016, 17.2% of all TB cases reported in England had travelled outside the 
UK (excluding Western Europe, USA, Canada, New Zealand and Australia) 
within the last two years prior to TB diagnosis. In addition, 7.3% of all TB 
cases in England had received an overseas visitor from high incidence 
countries; and with 23.3% of non-UK born cases having travelled to a high-




Epidemiological evidence indicates that travels to countries with high TB 
prevalence increases the probability of acquiring LTBI, with a threat 
associated with a greater TB burden along with more travel in the destination 
country. The second and third generation of non-UK born individuals (born in 
the UK but with parents born overseas) are at a lower risk of TB compared to 
first-generation non-UK born individuals, however, remain at greater risk when 
compared with the general population. This would imply that vulnerability to 
Mtb from the nation of origin and the higher incidence of TB among ethnic 
minority groups in comparison to the overall population are most likely to be 
related to transmission over the migrant populations especially when travel to 
family back in home country (Hayward et al., 2018). 
 
Laboratory studies also provide support for the biological plausibly of TB-DM 
and DM-LTBI association. After the inhalation of Mtb bacilli, alveolar 
macrophages in the lung are the very first line of defence from mycobacterial 
invasion. A failure to clear Mtb from the alveolar macrophages can result in 
bacterial replication and increase spreading (Gomex et al., 2015). In animal 
studies, DM mice have demonstrated that a delayed and diminished innate 
immune reaction to the invasion of Mtb; evidence for diminished innate 
response was also found in human DM patients (Vallerskog, Martens and 
Kornfeld, 2010). DM patients show deficiencies in serum complement factors, 
allowing Mtb to interrupts the mononuclear phagocytes and attain intracellular 
survival. However, further laboratory investigation is required to characterise 
the immunological responses in DM patients with Mtb (Gomex et al., 2015).  
Non-biological plausibility exists, including DM patients being more likely to 
access healthcare services, therefore being at increased risk of contact with 
Mtb exposed patients. DM patients are more likely to be exposed to Mtb in 
healthcare settings, but this requires further investigation (Pan et al., 2016).  
 
This study identifies over a quarter of TB diagnosed in patients in Newham to 
have DM as a co-existing condition, therefore, this is the first London-based 
prevalence study to measure the association of TB-DM using primary data. 
The findings strengthen and builds on previous studies and knowledge on the 




studies on DM impact on lowering the immune response. The results have 
shown some symptoms are more prominent or severe in TB-DM patients, 
because of altered immunity. Radiographic presentation was shown to differ 
in TB-DM cases in their presentation, with greater cavity involvement and 
presentation more common in the older age group compared to the TB only 
group. Likewise, with HIV infection, theoretically it can be assumed DM is 
linked to increase the risk of developing to active TB from LTBI, due to 
immune suppression, although more investigation is required. Therefore, 
future studies should focus on the impact of a targeted screening for TB in DM 
cases, DM in TB cases, and LTBI screening among the DM population or DM 
screening in LTBI and TB cases in those high risk individuals (older age, non-
UK born males).  
 
This prevalence study consisted of 85.3% of all TB diagnoses to be in non-UK 
born individuals within the study population. This reflects the Newham 2011 
Census data (Aston-Mansfield, 2017), whereby 83.3% were from a non-White 
British ethnic group. This would identify BAME groups to be at risk group of 
TB-DM, furthermore, non-UK born individuals who have come and settled and 
are an at risk group of LTBI, are probably more likely to progress to active TB 
disease in the presence of DM and may explain the late TB diagnosis or 
presentation in the TB-DM cohort, this requires further investigation. In 
addition, health policies should highlight at risk groups of TB, including DM as 
a risk factor. New arrivals to the UK and healthcare workers from high TB 
incidence countries should have screens for TB and DM to help tackle the TB 
burden in the UK. However, migration alone should not be considered as a 
sole target for prevention as other factors affect the progression to active TB, 
including genetically acquired susceptibility, co-morbid factors including DM, 
vitamin D deficiency, HIV, societal factors (homelessness, prison history, 
alcohol and drug misuse), which are all documented to be key risk factors 
(Hayward et al., 2018).  
 
Therefore, biological and anthropological factors influence the risk of TB and 
its progression. TB incident in Newham maybe due to local transmission 




conditions, which likely to encouraged transition, or reactivation of LTBI (Ho, 
2004).  
 
The results from this study are consistent with others in which DM (especially 
uncontrolled DM) increases the TB risk and progression, affecting clinical 
presentation and microbiological outcome. The general population of Newham 
has a DM prevalence of 8.57% (Diabetes UK, 2019). This study highlights the 
potential association between DM and active TB due to dysfunctional 
immunity. When comparing crude data on TB and DM rates in London, the 
three top London Boroughs with the highest TB incidence also have the 
highest level of DM rates, Newham (DM, 8.57%) (TB, 46.9 per 100,000); 
Harrow (DM, 9.58%) (TB, 24.8 per 100,000); Brent (DM, 8.91%) (TB, 33 per 
100,000). The lowest rates of TB and DM in London, Richmond upon Thames 
(DM, 3.7%) (TB, 7.1 per 100,000); Camden (DM, 4.01%) (TB, 9.2 per 
100,000) (Diabetes UK, 2019; PHE 2018). 
 
The findings from this study is suggestive of non-UK born individuals having a 
higher incidence of TB, which is explained by the differential exposure to TB 
both pre-migration and familial links with their country of birth, this is in line 
with literature reviews on TB-DM. But this alone does not drive the incidence 
of TB in hot spots as seen in Newham. Non-UK born individuals face many 
disadvantages, including risk of exposure to TB, vulnerability to infection (local 
transmission or link to home country i.e. travelling back, or living in an 
overcrowded housing) development of disease related to poor nutrition and 
barriers to accessing healthcare) (Fogel, 2015). The results suggest DM is a 












Primary Objective 2 
 
4.2 Social, clinical characteristics and microbiological features 
associated with TB-DM compared with TB only patients 
 
4.3 Social risk factors 
 
Social determinants and clinical risk factors are important in the epidemiology 
of TB and are considered as part of global initiatives, such as the End TB 
Strategy, the global strategy and targets for TB prevention (Barron et al., 
2018). These determinants link poverty and low socio-economic status to the 
factors which directly increase the risk of being infected (exposure to an 
infectious source) or developing TB (impaired immunity). There is substantial 
evidence to link TB disease and socio-economic factors. Further to these 
issues, it is vital to understand the local, regional and global risk factors of 
social determinants in anti-TB drug resistance, and to measure the health 
status and performance of local healthcare systems which deal with the TB 
burden and associated risk factors (Barron et al., 2018; Taneu et al., 2017).  
 
From this study, social risk factors, including smoking, heavy drinking, 
homelessness, imprisonment and known contact with TB cases, did not show 
any additional risk of developing active TB in either the TB-only group or the 
TB-DM group, as previous studies have reported. This study does report 
those who inject drugs to be at significant risk (p-0.04, OR, 0.836-50.36) in the 
TB-only group and TB-DM group. However, the number of PWID is too small 
to make any significant conclusions. Therefore, social risk factors do not 
increase the risk in the TB-DM cohort compared to the TB-only group in our 
study population of Newham. Social risk factors for acquisition of TB are likely 
the same in the DM group as in the general population.  
 
It is well documented that there is an association between deprivation and TB 
disease, as those in economically disadvantaged groups are at the highest 
risk, with poor living standards and nutrition being the main risk factors 




urban environment poverty, homelessness and overcrowding is important in 
controlling the spread of Mtb. In London, the TB notifications rates increased 
by 12% for every 1% rise in the number of people living in overcrowded 
conditions. Furthermore, social determinants are entwined with ethnicity; 
socio-economic disparities lead to inequalities in health. Referring to the 
findings in studies of non-UK born patients combined with the economic 
issues of unemployment, low income and poor housing conditions, non-UK 
born individuals are more likely to face homelessness and overcrowding. 
Cigarette smoking plays a role in the pathogenesis of TB infection and is 
related to ciliary dysfunction, a weakened immune response and to defects in 
the immune response of macrophages, this is without or with a decrease in 
the CD4 count in smokers, increasing susceptibility to TB infection (Silva et 
al., 2018). The alveolar macrophages bind into the bacillus through the match 
receptors 1,3 and 4. Lymphocytes release cytokines that are activated whilst 
recruitment other alpha lymphocytes. A cytokine is macrophages TNFα, which 
can be released by macrophages following exposure to Mtb antigens. The 
TNFα activates macrophages and dendritic cells. In smokers, smoking, acting 
through the α7 cigarette receptor reduces the production of TNFα by the 
macrophages, thus preventing its protective action and being susceptible to 
TB (Silva et al., 2018). 
 
Globally, it is estimated that 10% of all TB cases are related to alcohol 
misuse. In this study only 34 patients met the drinking criteria, with 10% in TB 
only group and 4% in TB-DM group (P-value 0.054). Statistically no 
significance was observed between both the groups.  In a cohort study, which 
assessed the TB treatment outcome in Tomsk, Serbia, found that 60.2% of 
their TB patients had a lifetime alcohol use disorder (AUD) and 72% of AUD 
cases were male increasing the risk of TB treatment failure and relapse (Shin 
et al., 2011). In a prospective study in New York City by Silva et al. (2018), 
AUD patients reportedly had an incidence of 464 cases/100,000 person-
years, which is nine times the incidence found for the age-matched general 
population. Alcohol and TB have been long linked, despite the fact that it is 
still not known if there is a higher risk of TB as a result of alcohol misuse per 




deficiency, or societal aspects, such as overcrowding or homelessness. 
Although, in vivo and in-vitro studies have demonstrated that alcohol use is 
significantly linked to the disturbance of the immune response and increased 
susceptibility to respiratory disorders, including TB. It is possible this study in 
Newham cohort may have under reported AUD incidence for various reasons 
including participant’s honesty, how the data was captured, and if interview 
bias was a factor during data capture phase.  
 
In 2015, it was estimated a quarter of a billion-people aged between 15 and 
64 years of age use at least one illicit drug (Peacock et al., 2018). The impact 
of drug use on health continues to be devastating, with an estimated figure of 
207,400 drug-related deaths in 2014 (European Drug Report, 2015). The link 
of drugs with TB is through the presence of illicit drug users infected with Mtb 
in families and communities; this is a crucial risk factor in the transmission of 
TB. Individuals who inject drugs, infection with TB and the progress to active 
TB are encouraged by several variables: insecure lifestyles, crowded housing 
situations, isolation and accumulation of individuals inside for the usage of 
medication, smoking, malnutrition and acute cough. In this study we found 
individuals who inject drugs to be slightly higher in TB-DM group (7%) 
compared to TB-only (3%) (P-value 0.04, CI; 6.490 (0.836-50.36)).  
 
A London-based case-control analysis of patients with PTB reported 19 (86%) 
of 22 crack cocaine users were smear-positive, in comparison to 302 (36%) of 
833 non-drug-using patients. The smear positive at the time of diagnosis of 
PTB was 2.4 times greater in people who had been on crack cocaine (Story et 
al., 2008). In-vitro studies show cocaine decreases immune reactions, 
including chemokine and IFY-y responses, that are required against TB 
infection. Overall, cocaine usage attenuated the potential for monocytes and 
alveolar macrophage mechanisms, resulting in failure to respond to a 
challenge that was mycobacterial (Kiboi, Nebere and Karanja, 2016). 
 
In 2015, foreign nationals accounted for 13% of the UK population; 47.9% of 
ethnic minority groups lived in overcrowded housing (Hayward et al., 2018). In 




black Caribbean ethnic group, who had at least one social risk factor - 
homelessness, imprisonment, drug or alcohol misuse - higher than in any 
other ethnic group. Evidence suggests that being socio-economically 
disadvantaged is likely to be an important factor in explaining the high 
incidence of TB in Newham.  
 
In relation to gender, the result of this study agrees with others, with a 
preponderance of males in both the TB-DM (65%) and TB-only group (62%). 
This potentially reflects the results of smoking and alcohol consumption. Koh 
et al., (2017) reported the synergistic effect of smoking and alcohol misuse to 
TB infection. The metabolism of ethanol produces acealhydehyde and or 
reactive oxygen species. The oxidative stress and a suppressed immune 
response is the suggested mechanism for the increase risk developing TB. 
Although this study could not find any significant difference between the two 
genders, it detected an increased risk of TB-DM in the case of women (P-
value 0.866; CL, 0643-1.400).  
 
Studies have shown smoking to cause increased TB disease due to the 
chronic exposure to cigarette smoke, which reduces the expression of surface 
proteins related to antigen presentation by pulmonary macrophages, a 
method of defence against Mtb invasion (Hayward et al., 2018). This study did 
not find smoking to be a significant factor in TB-DM development.    
 
Primary Objective 3 
 
4.4 Clinical symptoms 
 
Clinically, this study found additional co-morbid risk factors (arterial 
hypertension, chronic renal disorder, peripheral vascular diseases and chest) 
alongside DM to be significant comparing the TB-DM group and the TB-only 
group (p-0.007; OR, 1.0-2.6). The result also found TB-DM patients were 
more likely to present with fever, night sweats and weight loss than the 
patients in TB wrongly.  Symptoms of cough and haemoptysis did not differ 




studies.  The results of this current study can be compared to Paralija and 
Mujakovic’ (2018), which studied the impact of DM on PTB clinical 
presentation. In their study, they found cough to be the most common 
symptom in both groups, but more so in participants with DM (P-value 
<0.001). 29.9% of the DM cohort had haemoptysis compared to 13.4% in the 
non-DM cohort (P-value <0.001), with 41.2% of DM patients having an 
extensive form of PTB compared to 24.8% in those without DM (P-value 
<0.01). This study reported comparable findings: the DM group is likely to 
present with more extensive clinical symptoms compared to the non-DM 
group. Dousa et al., (2019) retrospective unmatched case-control study in a 
Qatar national hospital found the common presenting symptoms in TB-DM 
patients were cough, fever and weight loss. There are still disparities in 
clinical symptoms between studies regarding the exact presentation DM is 
likely to influence. The results from this and previous studies indicate the level 
of severity of symptoms overall are greater in patients with DM, and no 
specific symptom is more common than any other. In theory those with DM 
would benefit from better management of their DM during TB treatment to 
reduce these associated symptoms.  
 
4.5 Glycaemia levels in TB and TB-DM cohort 
 
DM is thought to be a risk factor for the development of active TB, especially 
where there is a high burden of TB. Glycaemia control is, therefore, a 
potential variable for modifying the risk of TB. In this study, of the 489 
participants, 168 (34.35%) were DM positive, of which 3.88% were diagnosed 
with DM (new DM) after TB treatment. At baseline, the median HbA1c levels 
for the TB group without DM was 5.53% (SD +/- 1.32, range, 5-8%) compared 
to the TB-DM group with 7.63% (SD +/- 5.61, range, 3-13%). The 489 study 
participants had a follow-up after two years of completion of TB treatment, 
with overall incidence of DM in TB positive cases of 28.5 (95% CI; 24.3-33.0). 
The study reports DM to be present in 1 in 3 cases of TB, increasing the risk 
of active TB with poor glycaemic control. The TB-DM cohort, overall, had poor 
glycaemic control, ranging from hypoglycaemia to hyperglycaemia (SD +/- 




median at poorly controlled levels. In contrast, the TB without DM cohort 
presented more controlled glycaemic levels (SD +/- 1.32, range, 5-8%) 
(HbA1c diabetes with a level of > 48mmol/mol or over).   
 
Previous observational studies have shown the risk of developing TB to be 
greater in patients with diabetes, to some varying degree. Lee et al. (2016) 
studied glycaemia and the risk of TB using a cohort of 123,546 participants in 
a community health screening service in northern Taiwan, from 2005-2008. 
The glycaemia amount was quantified with FPG at the time of screening. 
Follow-ups were obtained by the cohort until 2012 to get re-occurrence of TB. 
They noted that DM patients with poor glycaemic control (FPG 130 mg/dl) had 
a substantially higher danger of contracting TB in contrast to people without 
diabetes. The risk of TB in DM patients with good glycaemic control (FPG < 
130 mg/dl) did not differ significantly in the non-DM patients. They estimated 
7.5percent (95% CL, 4.1-11.5%) of the prevalence of TB from the analysis 
population could result from poor glycaemic control. 
 
Studies on the association between TB and glycaemia control have resulted 
in inconclusive findings, a likely reason could be explained by the different 
levels of glycaemic identification, reporting and management in different study 
populations. Lee et al. (2016), used a cohort study approach to assess the 
association in older population in Hong Kong. They reported patients with a 
haemoglobin (A1c) (HbA1c) >7% units more likely to develop active TB than 
individuals without DM (adjusted hazard ratio (aHR) 2.56), compared to those 
with a controlled glycaemia level (HbA1c <7%). Baker et al. (2012) studied the 
association between TB and DM using DM-related complications as a proxy 
measurement for DM severity. They reported TB increased the DM severity. 
In a UK population-based study, a study by Pealing et al. (2015) investigated 
the association between DM and the risk of TB in a UK GP cohort to identify 
high-risk groups for latent TB screening (Pealing et al., 2015). Using the data 
from the UK Clinical Practice Research Datalink, 222,731 patients with 
diagnosed DM between 1990-2013 and 1,218,616 control patients without DM 
were matched for age and gender. They found the level of HbA1c was not an 




several factors that were not adjusted for, including BMI, smoking status and 
alcohol use.  The overall glycaemic control was good in the diabetic patients, 
with two-thirds of the patients having an HbA1c of < 7.5%. However, both 
Pealing et al. (2015) and this current study did not find social variables as 
significant risk factors. 
 
In this study of the Newham cohort, the results evidenced a poor control of 
blood glucose levels to be a significant factor for TB (TB-DM). Therefore, the 
findings from this present study, together with previous research, suggest that 
a poor glycaemic control could potentially modify and increase the risk of TB 
among DM patients or progress the TB disease with more severe clinical 
outcomes. Furthermore, the current study findings concluded that glycaemia 
control is associated with an increase in the risk of active TB, and these 
findings are unlikely to be biased. This is because the distribution of all major 
risk factors for TB was similar in both cohorts (TB-only and TB-DM group) 
(good glycaemic control versus poor glycaemic control), although the 
possibility of confounding by other covariates not studied cannot be ruled out. 
Second, TB patients were likely to develop transient hyperglycaemia before 
receiving anti-TB treatment, which could have affected their glycaemia levels. 
However, all the known DM patients had their glycaemia levels measured 
prior to TB treatment, and the long follow-up period (two years) minimised the 
chance of reverse causality caused by transient hyperglycaemia. Similarly, 
most of the DM patients in this study had been previously known to have had 
DM; people with long-term DM are more likely to have poor glycaemic control 
than those with new onset. Therefore, the results from this study likely reflect 
the long-term DM condition and poor glycaemic control. Overall, the evidence 
from this study supports a probable causal effect of glycaemic control on the 
development of active TB.  
 
Currently no one mechanism on the association between TB and DM has 
been documented. Laboratory studies imply that both innate and adaptive 
immunity are elevated in the Mtb infection as a first line defence but those 
with DM have an impaired function of both the innate and adaptive immune 




Kornfeld, 2014). An improved glycaemic control is likely to restore the immune 
function and reverse the risk of TB. The phagocytic function is affected in DM 
patients with poor glycaemic control, which is significantly elevated when 
glycaemia control is improved. In another study granulocyte adherence was 
noted in patients with DM. After 1-2 weeks of being on the lowering of fasting 
blood sugar and diabetic treatment, with granulocyte adherence improved 
(Chaudhury et al., 2017). Yamashiro et al. (2005) discovered that diabetic 
mice had a reduced reflection of Th-1-related cytokines in response and 
insulin treatment significantly enhanced the synthesis of these cytokines. 
Gomez et al. (2013) found the attachment and ingestion of Mtb in human 
monocytes were reduced in DM that in non-DM cases. Poorly controlled DM 
was a significant predictor of lower interaction between monocytes and Mtb. 
 
This study highlights how poor glycaemic control is a major risk factor for TB, 
and that poorly maintained levels are likely to drive TB cases. In a modelling 
study by Pan et al. (2015) it was reported that prevention of DM could save 
millions of active cases of TB and TB deaths in high burden countries over the 
next two decades. This study supports this view; in addition to the prevention 
of DM, improving glycaemic control in DM patients may be beneficial in TB 
control in practice. The management of TB-DM should include prevention of 
DM through better lifestyle changes, bi-directional screening of TB and DM 
and early screening of DM, followed by close monitoring of glycaemic control 
in active TB and LTBI cases.  
 
Furthermore, most TB-DM patients in this study were on oral metformin, 
which is known to provide a protective cover to the host’s immune system and 
reduce Mtb growth and mortality rates, with a lower occurrence of cavitation in 
the lungs (Ayelign et al., 2019). However, this study was not designed to 
explore the effects of metformin on survival rate, but evidence suggests those 
on oral DM medication with good glycaemic control had a better TB treatment 
outcome (Riza et al., 2014). The control and management of DM would 






Secondary Objective 1  
 
4.6 Radiological features 
 
The findings from this study are consistent with many others, demonstrating 
that abnormal CXRs are more frequent in DM patients compared to non-DM 
patients. CXRs in the TB-DM group tended to be more abnormal than seen 
with classic TB features, including greater lower lobe involvement and 
cavitation as opposed to the common findings of segmental or lobar airspace 
consolidation, pulmonary infiltrates, cavitary lesions, ipsilateral hilar and 
mediastinal lymphadenopathy and pleural effusion (Huang et al., 2017).  
 
The result from this study indicates DM has the potential to manipulate the 
radiological features of PTB. This current study found a significant difference 
in CXR presentation between TB-DM and TB-only group. The radiological 
manifestations in TB-DM in those with poor glycaemic control (HbA1c >6.5%) 
were more likely to display cavitation. 
 
The mechanisms underlying the atypical findings in PTB remain unclear. In-
vitro studies utilizing hyperglycaemic mice discovered immune disorder, which 
is likely to impact upon TB susceptibility (Nathella et al., 2017). Perez-
Guzman et al. (2001) reported a lesser number of non-lymphocyte leukocytes 
were reported in DM-PTB patients, but statistically, this did not give rise to the 
irregular radiological findings. Furthermore, no differences in the counts in 
peripheral blood were seen between TB non-DM patients and the TB-DM 
patients. They did report an increased frequency of lung lesions in patients 
that were older compared to younger aged patients. They suggested a 
physiological dysfunction with an elevated ventilation/perfusion (V/Q) ratio and 
a consequent increased alveolar oxygen stress (PAO2) which might inhibit the 
development of Mtb in the lower lung fields of DM patients, however the 
correlation between pulmonary physiological dysfunction and lower lung 





This finding is consistent with Chiang et al. (2006), who studied the 
association between glycaemic control and radiological manifestation using 
CT scans of the thoracic region. They reported, statistically, a higher 
prevalence of abnormal findings and lesions involving all lobes of the lung in 
DM patients. Their study cohort included 41 PTB-DM cases with an HbA1c 
value >8% with an abnormal CXR. Eleven of the participants received CT 
scans. The scans were expected to provide a more detailed and thorough 
diagnostic report. However, a straightforward diagnosis of PTB by the reading 
physician was only made in four of the eleven patients. This suggests the 
limited role of thoracic CT scans in aiding the diagnosis in TB in poorly 
controlled DM patients. Furthermore, the findings from this study presented a 
greater number of EPTB to be frequent in TB-DM patients. This more 
probably explained as DM likely to affect the immune response to Mtb as a 
result more EPTB reported.  
 
The findings from this study strengthens the argument that those with 
uncontrolled DM (HbA1c >6.5%) are more likely to present with cavity lesions 
and nodular lesions, results which are significant. In relation to pulmonary TB 
cases in the TB only group, they represented approximately half of the study 
population (47%), with 3% EPTB. This contrasts with the TB-DM cohort, 
where PTB contributed to 41% of the cases, with 54% EPTB. DM, therefore, 
is likely to influence TB dissemination, whereas in TB cases without DM, 
patients are likely to localize TB within the lungs. Furthermore, clinically it 
would be appropriate to consider TB-DM cases who present with PTB to be at 
risk of EPTB and vice versa, TB-DM patients who present with EPTB should 
be tested to exclude PTB. As part of the differential diagnosis of other lower 
respiratory infections, a CXR should be done even in potential patients at low 
or no risk of TB. A CXR should be thoroughly examined by a reading 
physician, considering the DM history in the diagnosis for TB. These findings, 
along with previous studies, suggest Mtb strains might affect the radiological 







Secondary Objective 2  
 
4.7 Vitamin D 25(OH)D and TB  
 
Calcitriol is an inactive form of vitamin D 25(OH)D which can induce 
antimicrobial activity as seen in in-vitro testing, and evidence suggests 
individuals with TB have a lower level of vitamin D 25(OH)D compared to non-
TB individuals (Kota et al., 2011). Similarly, the literature suggests an altered 
vitamin D homeostasis is likely to be vital in the development of TB, with a 
deficiency in vitamin D in TB-DM also likely to have adverse effects compared 
to TB cases without DM (Hassanein et al., 2016).  
 
In this study, the aim was to provide novel evidence for the association of 
25(OH)D between TB patients with DM and those without. In the TB-only 
group, the median level of 25(OH)D was 25.61 ng/mL (95% CI, 15.90-35.33). 
In contrast, the 25(OH)D level was slightly higher in the TB-DM group (median 
level (26.9 ng/mL (95% CI, 19.28-34.51). This study found no statistical 
difference in the 25(OH)D levels between these two groups, but both were 
lower than the normal range. 
 
The association between TB and DM has been demonstrated in many 
studies. Zhao et al. (2018) reported patients with TB-DM had significantly 
lower serum vit D levels compared to those without DM, and DM is an 
important independent risk factor for vit D deficiency. The data collected from 
178 TB-DM patients reported 149 (84%) to have vit D deficiency (91 (51%) 
with vit D levels of 10-19.9 ng/ml and 58 (33%) with severe deficiency (<10 
ng/ml)  suggesting vitamin D is a potential mediator in the association 
between DM and TB; however, this is inconsistent according with these 
results. However, both cohorts had levels of vitamin D that are lower than 
normal, with only 24% in the TB-only group having levels within the normal 
range compared to the TB-DM group, with 31% having levels within the 
normal range. This is consistent with other studies. Choudhary et al. (2013) 
studied vitamin D status in patients with T2DM and PTB. The study involved 




patients had PTB and 40 patients both PTB and T2DM. Vitamin D levels were 
taken from all four groups. The mean difference in vitamin D levels were not 
statistically significant between the groups with TB, DM, and TB-DM, but the 
prevalence of severe vitamin D deficiency was higher in the group with both 
TB-DM (45%) as compared to TB-only (26.66%) and DM (17.39%) and 
healthy controls (7.69%). The prevalence of severe vitamin D deficiencies 
with T2DM was thought to be a predisposition risk for PTB.  
 
The findings reported by Koa et al. (2011) reported normal levels of vitamin D 
were related to better clinical outcomes for TB patients, with quicker sputum 
culture conversions from positive to negative, which implies vitamin D 
potentially plays a significant role in Mtb clearance and immune function. 
Severe cases of hypo-vitaminosis D have been reported to be more prevalent 
in diabetic patients with PTB (Wang et al., 2018). Herrera et al. (2017) 
compared vitamin D and its relationship with phagocytosis of Mtb. They 
showed that 54% of the study population with T2DM had inadequate serum 
levels of vitamin D, and these results agreed with this research.  Boillat-
Blanco et al. (2016) found vitamin D was inversely associated with TB and 
DM, using a case-controlled approach in Dar es Salaam, Tanzania.  
Glycaemia and complete vitamin D 25(OH)D were quantified at enrolment. 
The prevalence of low 25(OH)D was similar in TB patients and controls 
(25.8% versus 31.0%, p=0.22). At the subgroup of patients with persistent 
hyperglycaemia, the percentage of individuals with low 25(OH)D tended to be 
greater in TB patients (50% versus 29.7%, p = 0.20). A low 25(OH)D might 
increase TB risk in patients with DM. Further research should investigate the 
association between TB-DM and vitamin D levels, its association between 
treatment outcome.  
 
Future trials should inquire whether the association between TB and vitamin D 
levels including hyperglycaemic patients and outcome. In addition to whether 
therapy with vitamin D can be more beneficial in TB-DM cohorts. 
 
Therefore, a vitamin D supplementation as adjuvant therapy in TB in selective 




only group. This is to counter the inflammation-influenced hyperglycaemia 
(stress-induced hyperglycaemia) and is also likely to affect 25(OH)D levels 
(i.e. through induction of 25(OH)D metabolism or transient changes in the 
blood levels of proteins (vitamin D-binding protein (VDBP) bound to 25(OH)D) 
(Boillat-Blanco et al., 2016).  
 
4.8 HIV and TB-DM 
 
TB is one of the leading causes of illness in HIV infected individuals living in 
developed countries (Restrepo and Schlesinger, 2014). The management of 
individuals co-infected with HIV–TB-DM is complicated regarding the 
underlying immune suppression, drug-drug interactions and side effects 
(Moneira et al., 2018).  
 
In this study, a total of 14 patients from the total study population had a co-
infection with HIV, representing 2.5% of the total study population. In the TB-
only cohort, eight reported co-infection with HIV, in comparison to the TB-DM 
cohort, where six co-infected with HIV. These were not statistically 
significantly different (P-value 0.479).  
 
In a similar study by Schepis et al. (2017), they found both HIV and DM 
increased the risk of developing TB. Using a retrospective study of 2,395 
patients diagnosed with TB in seven European countries, 292 (12%) were 
infected with HIV. The HIV-TB co-infected cohort compared to the TB-only 
patients were younger, more likely to be male, UK-born and to have other co-
morbidities. The overall prevalence of DM among the 2,395 TB patients was 
7.7%, with DM prevalence amongst TB-only patients and TB-HIV co-infected 
being 7.8% (164/2103) and 7.2% (21/292). No evidence of significant 
association was found between HIV infection and DM. In the 292 TB-HIV co-
infected patients, DM was associated with cavities and night sweating, 
persistent cough, weight loss, haemoptysis and fever. In comparison to this 
study, we found TB-DM and HIV co-incidence in the study population to be 
2.5%, where Schepis et al. (2017) reported 12.2%. However, in this study the 




significant association was found with HIV and DM.  However, the increasing 
prevalence of diabetes among HIV individuals was linked to an ageing 
population likely to foster a recrudescence of TB-DM associated HIV. 
 
It is known that drug-drug interactions of HIV and TB medication can be more 
toxic and the side-effects increased (Gengiah et al., 2011).  These occur 
because of induction or inhibition of metabolic enzymes in the liver or the 
intestine (Siberry et al., 2013). The most prominent family of enzymes is 
cytochrome P450 (CYP). For example, CYP is involved in the metabolism of 
drugs, action includes protease inhibitors and non-nucleotide reverse 
transcriptase inhibitors (NNRTIs), which make up the core of most highly 
active antiretroviral therapy (HAART).  Rifamycin is also the medication 
transporter P-glycoprotein from the intestinal cell wall and liver and is a 
powerful inducer of CYP3A4. Rifampicin is the most potent inducer of this 
isoform of CYP3A4 and has several interactions with anti-HIV, including, 
leading to a decrease in the serum concentration of drugs (Tiberi et al., 2017). 
Rifampicin induces a broad change to gene expression and induces CYP1A2, 
CYP2C8, CYP2C9, CYP2E1, 2Ca9, P-glycoprotein activity and transferase 
enzymes.  Rifabutin is a less potent inducer of CYP3A4; consequently, any 
CYP3A4 inhibitors increase the concentration of rifabutin, but may have no 
impact on rifampicin metabolism (Tiberi et al., 2017). Thus, when rifabutin is 
administered its concentration and of its metabolism can improve its toxicity. 
 
Although this study did not find a clear association between TB-DM and HIV 
probably due to low numbers of HIV cases, previous studies have shown a 
trilateral overlap of these three conditions. Oni et al. (2017) undertook a cross-
sectional study in Cape Town, South Africa. They enrolled participants who 
were screened for DM and, using fasting plasma glucose, measured oral 
glucose tolerance and glycated haemoglobin (HbA1c). The study population 
included 414 TB and 438 non-TB patients and found DM was associated with 
TB (OR 2.4, 95% CI 1.3-4.3; p=0.005), and that there was an association with 
HIV-1 infected individuals (OR 2.4, 95% CI 1.1-5.2; p=0.030). Significant 
affiliation with TB (OR 2.3, 95% CI 1.6-3.3; de:<0.001) was found. The results 




regulation (65.2% among TB cases) and a significant association with TB (OR 
2.3, 95% CI 1.6-3.3; P-value <0.001) was found. DM was present in TB 
cases, and more commonly so in HIV infected patients, which further 
strengthens the need for screening for DM. Moriera et al. (2018) studied the 
effect of hyperglycaemia in TB-HIV patients in Brazil between 2010-2015. 
They used a retrospective cohort of adult patients who had TB and HIV co-
infection and commenced TB treatment. with 414 euglycemic patients 
(87.5%), 49 with hyperglycaemia (10.3%) and 10 patients with known DM 
(2.1%). The DM patients were older compared to the euglycemic and 
hyperglycaemic patients (47.9 vs 37 vs 39.7 years, respectively, P-value 
0.001). The DM patients were more likely to have cavitation in their chest x-
rays compared to the hyperglycaemic and euglycemic patients (50% vs 
23.4% vs. 15.2%, P-value 0.007), respectively). The hyperglycaemic patients 
had more new-onset of DM following the completion of TB treatment 
compared to the euglycemic (22 vs. 1; P-value <0.0001). Hyperglycaemia 
occurs more frequently in HIV infected patients who have commenced TB 
treatment and increases the risk of adverse TB events. In this study, due to 
small numbers in the HIV cohort HbA1c levels could not be compared to TB-
DM cohort or TB-only cohort to investigate the association between 
hyperglycaemia and adverse TB events. This can be implemented in future 
studies.  
 
The interplay between TB and DM in HIV infected individuals is unclear. 
Further research into TB-DM-HIV is required including screening for DM in 
patients with HIV and TB, treatment course (duration of treatment), and 
clinical outcome. In summary, hyperglycaemia is likely to be common and TB 
results are expected in HIV/TB outbreak areas. 
 
4.9 Comparing treatment outcome between TB only and TB-DM 
patients 
 
Furthermore, this study did not find DM to be negatively associated with poor 
TB treatment outcome, other studies reported DM to adversely affect 




DM have a higher bacterial load and a dysfunctional immune system 
(Alisjahbana et al., 2007). In this study, we found a higher bacterial load in 
TB-DM cohort with a longer time for sputum culture to convert from a positive 
to a negative, thus implying longer treatment is required in the initial intensive 
phase of treatment or aggressive treatment with higher dose of anti-TB 
therapy. Studies have shown DM to be linked to treatment failure and 
increase relapse including a meta-analysis which indicated a 1.7 times greater 
treatment failure in TB-DM patient compared to those without DM (Baker et 
al., 2011). If the TB treatment failure is related to DM it is important to 
understand the mechanism for this to initiate action against the treatment 
failure. The common treatment of susceptible TB cases includes the use of 
rifampicin, isoniazid, pyrazinamide and ethambutol for first 2 months 
(intensive phase) then in the continuation phase using only rifampicin and 
isoniazid for 4 months (Alfarisi et al., 2018) (see appendix 7). If it is thought 
that the drug concentration is lower in DM with a high HbA1c, then a 
treatment consisting of higher dosage is required. Furthermore, if the 
treatment is related to combination of variables including weight, age, glucose 
control then increasing the duration of treatment is likely to improve treatment 
outcome.  
 
In this current study, the effect of DM on the pharmacokinetics (PK) and 
pharmacodynamics (PD) of anti-TB medication were not reported. Studies 
based on the PK and PD show inconsistent results including reporting of low 
serum concentration of anti-TB medication in TB-DM cohort and others show 
no difference (Salindri et al., (2016); Viswanathan et al., (2014)).  
 
Alfarisi et al. (2018) used a large prospective cohort study to assess the 
effects of DM (HbA1c value) on first-line TB drugs PK and PD, and comparing 
drug dosage with clinical outcome including microbiological outcomes. Using 
newly diagnosed patients with TB (n=142) and TB-DM (n-101) patients on 
standard fixed-dose three times a week, the PK was assessed during the 
intensive and continuing phase. The result found a significant reduction on the 
maximum concentration (Cmax) value of isoniazid and pyrazinamide but not 




associated with a reduction of pyrazinamide concentration (P-value 0.03) 
(Alfarisi et al., 2018). A higher dose of rifampicin and isoniazid was associated 
with a quicker culture negative time in TB-DM cohort. They found DM and a 
high HbA1c levels increased the risk of not achieving therapeutic target for 
pyrazinamide whilst DM appears to be affected the PK- PD relationship for 
isoniazid and rifampicin.  
 
Although in this study the PK-PD relationship was not studied it is important to 
note the role of DM in reducing or slowing the absorption of anti-TB drugs. 
Whether the lower drug concentration is a result of confounding effect of 
prescribing fixed drugs opposed to adjusting for weight. DM is known to 
affects P-glycoprotein transporter expression and activity, likely to affect TB 
drug absorption. If patients with TB-DM are to receive a higher dosage of anti-
TB drugs the outcome remains unknown and further investigation is required. 
However, ensuring an adequate therapeutic dosage is important including in 
DM cases. As a result, therapeutic dose monitoring is essential in patients 
with DM as well as HIV and any co-morbid factors which may influence 
absorption or any medication likely to interact with TB medication (see 
appendix 5). Further to this quality improvement study, a further study has 
been approved to assess the therapeutic dosing of TB medication for patients 
with DM and ensuring it remains within the therapeutic range.  
 




Sputum conversion is a method which acts as an indicator of pulmonary TB 
treatment efficacy (Restrepo & Schlesinger, 2014). An early conversion is 
important to help prevent the transmission of infectious TB bacilli, reduce 
hospitalisation and the cost related to infection prevention and control. A 
delayed sputum conversion is also suggestive of drug resistance (Takasaki et 





In this study, the findings revealed a significant difference in conversion time 
of sputum and AFB density (P-value <0.001). TB-DM conversion was slower 
in the intensive phase of the treatment compared to TB without DM. DM was 
associated with a delayed sputum conversion, which likely affects treatment 
outcome. The results found a higher initial sputum AFB smear grading among 
patients with TB and DM alongside the delayed sputum culture conversion 
within the intensive phase of anti-TB treatment. These findings reflect those of 
Dousa et al. (2018), who compared the impact of DM on the clinical and 
radiographic presentation of PTB and bacteriologic response during anti-TB 
treatment between 2008 to 2011, in a retrospective case-control study from a 
large national hospital from a total study population of 134 adults with TB and 
DM. They found patients with DM had a higher initial sputum AFB smear 
grade and were less likely to have cavity lesions on initial chest radiographs 
compared to patients without DM. They found 71 (53%) cases from the study 
population remained sputum culture-positive after two months of anti-TB 
treatment compared to 36 (27%) patients without DM.  Ratnawati et al. (2019) 
studied the association between HbA1c levels and TB to determine the impact 
of HbA1c levels on sputum conversion time in Indonesian patients with PTB. 
They included only adults (>15 years) with no previous DM diagnosis. This 
was a prospective cohort study of new PTB cases, with a study population of 
123 new PTB patients, which found 12 patients had HbA1c levels >47.5 
mmol/mol. More than half (56.1%) of the patients had smear-positive AFB and 
11 patients (8.9%) remained AFB smear-positive after two months of being on 
anti-TB treatment. Statistically, there was a significant association between 
HbA1c levels >47.5 mmol/mol and sputum conversion for more than two 
months, with a relative risk of 6.3 (1.9-396), P-value 0.01).  
 
The findings from the current study agree with previous studies showing that 
an increase in HbA1c levels is likely to affect the risk of sputum smear 
conversion failure. In relation to bacterial load, this study reported a significant 
difference in bacterial load through AFB density between the TB-DM and the 
TB without DM groups. The TB-DM group had a higher grade of AFB 1, 2 and 
3 compared to the TB without DM, who were AFB (+/-), and scanty growth 





Bouti et al. (2013) studied the factors influencing sputum conversion time in a 
Moroccan population. Findings reported AFB 1+ sputum smear on eight 
patients (6.7%), AFB 2+ sputum smear in 19 patients (16%), AFB 3+ sputum 
smear in 37 patients (31.1%) and AFB 4+ sputum smear in 55 patients 
(46.2%), with approximately 96.6% conversion within eight weeks. This study 
found that TB patients with an HbA1c level of 6.5% had a higher risk of 
sputum conversion time of > 2 months compared to those with HbA1c levels 
less than 6.5%. The results of this study are consistent with the previous 
studies, including that by Kulsum et al. (2017), which found high HbA1c levels 
among T2DM patients increased (by two or three times) the risk of sputum 
smear conversion failure. Despite all this evidence, the possible association of 
DM to prolonged sputum conversion remains conflicting. The effect of 
controlling HbA1c levels using medical intervention in the improvement of 
sputum conversion times is still not fully understood.  
 
The Kaplan Meier curve for culture conversion indicates TB-DM patients have 
a higher TB bacillary count and are more infectious within two months of the 
intensive treatment phase, as culture conversion is slower. The findings 
demonstrate a higher bacillary load in the presence of DM, rendering the TB-
DM cohort more infectious. Viswanathan et al. (2014) assessed the effect of 
DM on TB treatment outcome and sputum conversion using a population 
sample of 245. They found the overall treatment success to be 93.5%; at the 
end of the intensive phase of treatment, 14.7% remained sputum-positive in 
the TB-DM group (64.2 +/- 10.5) compared to 3.5% in the TB only group (61.5 
+/- 7.5) (P-value <0.001).  
 
Sputum smear conversion after two months of anti-TB intensive treatment is 
an important determinant of treatment success: a predictor for relapse and the 
infectivity of the disease. A total of 89% (30 time to culture conversion 95% 
CI; 8.211-23.789) had culture conversion in the TB-only group compared to 
85% (40 time to culture conversion 95% CI; 8.54-51.45) in the TB-DM cohort 




DM was statistically significant (P-value <0.001) and impacts on the patient’s 
sputum smear conversion after two months of anti-TB treatment.  
 
Future studies should compare the benefits of longer treatment courses for 
the TB-DM cohort. Holtz et al. (2006) found that treatment outcomes were 
statistically significantly worse for patients who did not convert their sputum 
positivity within two months of treatment. The cure rate was higher among 
patients who were smear-negative at the second month of follow-up.  
 
In addition, TB-DM patients with poor adherence are at more risk of sputum 
non-conversion compared to those adhering to medication and those without 
DM. This is supported by Burman et al. (2018). In their study, they found 
patients who took treatment irregularly were 9.9 times more likely to have a 
relapse than those who were adhering to treatment.  
 
Sputum culture conversion is also used routinely as an indicator of the 
progress of treatment of TB (Akalu, Muchie & Gelaye, 2018). The results 
confirmed that sputum culture conversion is a useful interim indicator of 
treatment outcome for individuals with TB and that it is an appropriate first 
goal of therapy. The results support the literature which states that those 
individuals who achieved early sputum culture conversion were more likely to 
have a successful treatment outcome. The results demonstrate how a better 
control of glycaemia levels is more likely to increase sputum conversion to 
negative within the intensive phase, which, in turn, increases better treatment 
outcome (end of intensive treatment phase, time to culture conversion, 
median, days, TB non-DM 30 (95% CL, 3.9-36.01) vs TB-DM 40 (95% CI, 
8.54-51.45).  
 
4.11 Confounding variables 
 
Confounding influences occur when a risk factor is associated with both the 
comparison variable and the outcome of interest. In this study, age and 
gender was considered as a key confounder as active TB is evidently higher 
in the male population and DM is related to older age.  The risk of developing 




risk factors imply the progression from exposure to infection, where those with 
high bacillary load in the sputum and the proximity of individuals are key risk 
factors for development of infection (McDonald, 2014). Endogenous factors 
lead to the progression from infection to active TB and well-established risk 
factors include HIV, malnutrition, age, and gender. 
 
Confounding refers to a situation when one finds a spurious association or 
missed a true association between an exposure variable and an outcome 
variable, because of a third factor (McDonald, 2014). A confounding variable 
is a factor associated with both the exposure variable and the outcome 
variables. In observational research, confounding is an intrinsic limitation. To 
identify a confounder, the usual method is to check for a potential confounding 
factor is, first, to find out if the assumed confounding factor is associated with 
both the outcome variable and exposure variable, and secondly, to compare 
the associations before and after adjusting for the confounding factor. In this 
study, the confounding variables were considered at the analysis stage and 
this could have been tackled using either a stratification method or a 
multivariate approach (McNamara & Martin, 2018).  
 
Multivariate analysis was considered over stratification, as the stratification 
method is effective when dealing with dichotomous confounding variables as 
the data can be separated into 2 or more distinct strata sets. Stratification is 
more difficult to achieve in continuous datasets, such as age, therefore, the 
adjustment for confounding factors would not reliably remove the confounding 
effect of that variable (McNamara & Martin, 2018). Furthermore, there may be 
residual confounding when there are relatively few strata of continuous 
variables (i.e. in this study age was stratified into 2 strata: <55 yr and > 50 yr). 
Using a stratification method, this could be improved by increasing the 
number of age strata; however, this then would have required to inflate the 
number of observations in each stratum. The major disadvantage of this 
approach of stratification is the inability to deal with multiple confounding 





The multivariate analysis estimates the association between several 
independent variables (potential risk factors) and 1 dependent variables 
(outcome; TB-DM). This method was implemented as it utilises all study data 
and examines multiple variables, both continuous and dichotomous. It allows 
the estimation of the effect of an exposure variable on a given outcome 
variable, after controlling for the confounding effect of other included variables 
(e.g. age and gender) (McNamara & Martin, 2018).  
 
4.12 Clinical recommendations 
 
To manage TB and DM in tandem, the detection of both is necessary. As this 
study has reported, the prevalence of DM among TB patients is over 25%, 
with those who are older more likely to be susceptible to a TB-DM coexisting 
condition. Therefore, screening for DM in TB patients is necessary, although 
not straightforward as different measurements are used. This study used 
HbA1c but HbA1c requires further evaluation in different settings and patient 
populations. In general, point of care HbA1c in combination with age and 
high-risk groups (non-UK born) is an approach which is sensible. 
 
Using 2018 national data on TB and DM rates, the yield of TB screening 
among patients with DM is low. The prevalence in England for DM is < 25 per 
100,000 (PHE, 2018), which would mean at least 1000 people with DM would 
need to be required to be screened to detect a single case of TB. By using a 
risk stratification approach (history of TB, smoking, socio-economic variables, 
severity of symptoms, ethnic background) could help to prioritise a subgroup 
of DM patients for TB screening. 
 
Screening and treatment of LTBI have been recommended, aimed at high-risk 
groups of developing active TB disease, like HIV infected individuals including 
those between the age of 16 to 35 years old who have recently arrived in 
England from high incidence countries, where TB incidence is 150 per 
100,000 population or over (PHE, 2015. Latent TB testing and treatment for 
non-UK born. A practical guide for commissioners and practitioners). Applying 




TB, especially if it is targeted where a high proportion of TB cases arise from 
reactivation among non-UK born individuals with DM and an increasing age 
for screening. As observed in this study, this group is likely to be an 
appropriate population as a focus for LTBI screening. Currently, there is no 
evidence that LTBI screening is effective in reducing TB burden among DM 
patients, as no studies have been conducted. 
 
Furthermore, in this current study, the TB-DM patients were found to have 
higher initial cavities and residual lesions of the lung, which are all risk factors 
for prolonged time-to-smear conversion. The results from this current study 
will help to improve the planning and implementation of TB treatment courses 
and their length and overcome the delay in sputum conversion or in 
prolonging a treatment course. Therefore, early recognition and diagnosis of 
TB-DM can provide clinicians with the opportunity to identify patients who may 
benefit from a more thorough investigation, aggressive therapy and 
management of both TB and DM, including accelerated testing procedures, 
and timely utilization of behavioural therapies for treatment compliance. 
Frequent observation of sputum cultures in patients with risk of late sputum 
conversion will help to manage treatments in TB-DM cases and reduce the 
risk of infection to others. Reducing the time to sputum culture conversion is 
an important infection control measure, because individuals with TB and 
positive sputum cultures are infectious and likely to transmit the disease to 
other individuals (Restrepo & Schlesinger, 2014). 
 
All TB patients should be screened for DM routinely as is currently undertaken 
with HIV patients. Such screening would likely yield new undiagnosed 
individuals with DM, which will allow them to be referred to specialists for care 
to manage their DM, leading to increased TB treatment success.  
 
The timing of screening is essential; it is predicted that blood glucose can be 
affected by TB (stress-related hyperglycaemia). However, glycosylated 
haemoglobin is less affected than fasting blood glucose. Screening for DM at 
the time of diagnosis of TB is likely to be positive for stress-related 




Screening later, after initial TB treatment, is a possibility, but this would miss 
early intervention, which is critical considering the evidence in literature review 
that DM increases the risk of early TB and the mortality rate.  However, 
transient hyperglycaemia may require treatment to increase better TB 
outcomes. Screening at the time of diagnosis is preferable as patients are still 
available at the healthcare setting and early diagnosis of DM and initial care 
can result in better outcomes. 
 
DM can also be screened during the TB intensive treatment phase (2-8 
weeks), by which time the stress-related hyperglycaemia would have receded 
and a more accurate DM diagnosis can be made, which reduces the 
likelihood of false-positive results.  
 
Screening for DM can be offered at the end of the TB continuation treatment 
phase. This would provide an accurate result and reduce false-positive results 
to almost zero. But a late DM diagnosis would negatively affect the improving 
TB treatment outcome. 
 
Those TB cases with transient hyperglycaemia should be re-tested at the end 
of TB treatment. This would ensure a more accurate diagnosis of DM. It is 
also likely those TB patients with transient hyperglycaemia to revert to normal 
levels after TB treatment, but there is a risk of developing future DM, and this 
should be emphasised to encourage a healthier lifestyle to reduce the future 
risk of DM through dietary changes, increased physical activity, smoking 
cessation and reduced alcohol intake. 
 
If a patient is diagnosed with DM at the time of TB diagnosis, they should be 
managed by the TB clinic (with specialist advice, if required) for at least the 
first two weeks of TB treatment and until the end of the initial intensive 
treatment phase. This will ensure the patient is no longer infectious by the 
time the patient returns to the endocrinology clinic. If the patient has severe 






During TB treatment in DM patient regular dosing to ensure therapeutic levels 
are achieved as DM directly affects absorption of TB drugs or indirectly 
through drug-drug interaction causing suboptimal therapeutic levels 
increasing risk of treatment failure, developing drug resistance and relapse. 
Target level to be achieved between 9-24 mg/L. A sub therapeutic level is <4 
mg/L, where a change of dosage is necessary. Dose levels should be 
checked 6 hours’ post dose in DM patients (see appendix 5).  
 
4.13 The current TB clinical policy and change in practice 
 
The current TB clinical policy supports the implementation of the Collaborative 
Tuberculosis Strategy for England: 2015 to 2020 to achieve year-on-year 
reductions in TB incidence and eventual elimination of TB and incorporated 
NICE Guidelines, NG33, Tuberculosis, 2016.  
 
This study reported risk factors such as symptoms based on clinical notes, 
which were reported at the time of diagnosis, without a formal template of 
diagnostic criteria. There could be methodological challenges including the 
practitioner not accurately documenting symptoms, and a prospective study 
using a strict criterion for TB and DM assessment would avoid this issue and 
provide assurance. Furthermore, this study used a single HbA1c reading 
around the time of diagnosis, a measurement which might mis-classify 
individuals as either DM or non-DM patients.  Future studies should include a 
DM diagnosis which is confirmed with a repeat HbA1c test unless clinical 
symptoms and plasma glucose levels >11.1 mmol/1 (22 mg/dl) are present 
during treatment course. In addition, adjustment for potential confounders is 
also a limitation. In this study, gender and age were adjusted for estimates. 
Further adjustments including smoking, drinking, imprisonment is likely to 
provide a stringer estimate than those controlled for age and gender alone 
McNamara & Martin, 2018). Furthermore, biased estimates were likely to be 
associated with those with renal impairment and all co-morbidities should be 
separately calculated or use Charlson Comorbidity Index (CCI). Current 
scoping work being conducted with Endocrinologists at Barts Health NHS 




underway. In addition, a current change in practice to routinely send for 
HbA1c testing prior to commencing of TB treatment should be instigated. 
 
DM can affect TB clinical and treatment outcomes, but it can also interact with 
TB transmission, TB acquisition, TB reactivation in those latently infected 
(Awad et al, 2019). In addition. The type of DM may have different outcomes, 
in this study DM included T1DM and T2DM, thereby limiting our ability to 
assess the association of DM types.  
 
Furthermore, the optimum treatment strategy for concurrent TB and DM 
remains unknown. In general, patients with TB and DM are not treated 
differently to those with TB only, in practice. However, evidence from the 
literature shows an increase in rate of TB treatment failure in patients with DM 
due to excessive TB (Pizzol et al., 2016), although not reported in this study. 
There are still uncertainties in the optimal DM treatment in TB-DM cases, 
including avoiding sulphonylurea derivatives and treating DM with diet, 
lifestyle changes, metformins and insulin. A successful treatment can only be 
achieved by ensuring good compliance to treatment for both TB and DM.  
 
Currently, there is insufficient evidence to support changing the recommended 
TB standard treatment to one specific for clinical management of TB-DM 
cases. According to WHO (2011), the TB treatment regimen to be prescribed 
is the same as for patients without DM, whilst it is vital to provide clinical 
management of DM in TB patients for individuals with poor glucose control. 
There are no randomised trials which evaluate an adequate TB-DM treatment 
regimen, neither is there enough evidence on drug-drug and drug-disease 
interactions in TB-DM patients to provide specific guidance.  
 
An optimal TB-DM management and integration of services could lead to the 
earlier commencing of treatment for DM, and improved health outcomes for 
those with co-existing conditions (Zheng et al., 2017). Prospective studies 
specifically designed to address the differences between DM and non–DM TB 
patients and the interactions of drug-disease and drug-drug in TB and DM 





Further studies assessing TB treatment compliance and DM diagnosis in TB 
patients are required. A prospective cohort study design would be beneficial 
and enable a reduction in bias by implementing randomisation sampling 
techniques to manage cofounding variables. Utilisation of pre-questionnaires 
to be used by clinicians to record patient responses to treatment, assessment 
of clinical signs and symptoms, body weight to improve data reporting and 
regular follow-up sputum smears during the treatment course introduced. As a 
clinical change to practice, therapeutic dose monitoring in high risk groups 
have been recommended including DM as routine practice (see appendix 4).  
 
Future studies should focus on measuring the effects of DM in patients with 
TB and investigate the association with treatment outcome, through potential 
effects on treatment compliance. Drug-drug interactions, drug side effects, 
glycaemic control, weight gains during treatment and patient cell-mediated 
immune responses need to be assessed. This should be a prospective cohort 
study using a multi-centre approach. Participants should include all new cases 
commencing a TB treatment regime and should be followed-up each month 
until treatment completion. At the end of TB treatment, follow-up for a further 
two years at six-monthly intervals for assessments of lung function and 
recurrent TB should be included. Participants should also provide regular 
blood samples for HbA1c measurement, as a marker for glucose 
dysregulation and probable DM. At baseline, participants should provide a 
venous blood sample, to assess immune responses to TB. At the end of the 
treatment, participants should be assessed for lung function using spirometry 
at 6-month intervals.  This will allow measurement of adverse treatment 
outcomes including relapse and recurrent active TB.  
 
For development of policy/clinical guidelines, glycaemia levels require further 
assessment, as it is likely that DM could present at any time during treatment 
for TB. Thus, HbA1c testing at more time points or following recognised 
treatment for DM should be undertaken (Sherwani et al., 2016). An 
exploratory analysis will need to be performed to assess the effect of degree 




current study, improvements in clinical management have been suggested 
and have been implemented locally, including routine testing for HbA1c on TB 
diagnosis and a new Trust TB policy recognising DM as a formal risk factor 
with greater emphasis on management of DM in TB patients.   A further 
quality improvement project on monitoring TB treatment dosage in high risk 
groups has been implemented to provide a better outcome in at risk groups, 
this includes DM.  Future work for bi-directional screening have been 
suggested, with endocrinologists to contribute to further study of the 






Current practice, change in practice, and future studies in treatment of TB-DM patients 
  




Main risk factor for active TB in the UK: 
• Place and date of birth 
• Caucasian population; increasing prevalence with age 
• Afro-Caribbean, non-UK born; highest prevalence in the 
young, 
• Indian subcontinent; highest prevalence in middle age 
• HIV/AIDS 
• Heavy alcohol consumption and smoking 
• Medical factors – DM, end-stage renal failure, malignant 
disease, systemic chemotherapy, steroids and TNF-α 
antagonists, e.g. infliximab, vitamin D deficiency 
 
DM in TB patients is a 
major risk factor, as is 
HIV. This is now in the 
Trust reviewed TB policy, 
which was introduced 

























The diagnosis is usually made in one of three ways: smear 
or culture of sputum or histology with identification of 
caseation granulomas. Individuals suspected to have active 
TB should be referred for a medical assessment this 
includes: 
• Medical history 
• Physical examination  
• Chest x-ray  






Diagnostics of TB includes sputum smear and culture 
microbiology and chest x-rays to aid TB diagnosis where 
high clinical suspicion. If a person does not have signs of 
active TB, a Mantoux test or an IGRA test can be used to 
diagnose latent TB. Although in patients with HIV or 
HbA1c to be included 
into the battery of 
samples taken 
undertaken at time of TB 
diagnosis or 
commencement of TB 
medication.  
 
Logistically screening for 
DM in TB patients should 
be done at time of 
diagnosis or commencing 
of TB medication. 
 
Evaluation of dose 
monitoring of TB 







This is to assess 
specific subset 
of DM patients 




immune-suppressive condition specialist advice should be 
sought i.e. HIV specialist. Nucleic acid amplification 
techniques using Xpert MTV/RIF assay to detect MTB and 
identify rifampicin resistance and WHO recommends the 
use of this in areas with high rates of HIV. Furthermore, 
blood tests include FBC, liver function tests, urea, 
electrolytes and creatinine, HIV and HCV and vitamin D. 
 
In HIV patient tuberculin skin test, maybe falsely negative 
and radiological changes may be atypical. WHO guidelines 
recommend isoniazid chemoprophylaxis for HIV-infected 
patients, with positive or unknown skin tests in the absence 
of active TB disease.  
 
Other tests include bronchoscopy, biopsy from extra 
pulmonary sites, gastric washings, urine, CT scans, bloods, 













• Microscopy for AFB 
• Mycobacterial culture on solid or liquid media 
• Antimicrobial susceptibility testing of TB complex 
• Direct molecular testing of clinical samples by PCR for TB 
complex and resistance to rifampicin such as Cepheid’s 
GeneXpert. 
• Genotypic identification of isolates from culture 
• Whole genome sequencing for speciation 
 
• TB-DM to be tested for 
MTB/ Rif for resistant TB. 
• Evaluating use of WGS 






Local referral can be made to TB services from primary and 
secondary care, 
 
All patients with suspected TB should be referred to TB 
services and must be seen within two weeks of referral 
being made. In urgent PTB patient should be seen within 
two working days of referral. 
 
 All TB cases 
with a  DM 
diagnosis 
should be 
referred to a 
specialist 
secondary 
cases. If DM is 











4.14  External validity 
 
This refers to the generalisability of the study findings to the general 
population (Kukull & Ganguli, 2012). Although some limitations were found, 
the internal validity is adequate, which is a prerequisite for external validity. 
Results from the laboratory were quality-assured and all clinical details, 
including treatment, were approved by trained physicians. The conclusions of 
the study can be generalised to both the London population and England, 
more widely.  
 
4.15 Limitations of the study 
 
This was a retrospective cross-sectional study approach so the non-
availability of data in some instances is a limitation; currently, there is no 
mandatory surveillance database for reporting DM in TB cases. A prospective 
cohort study would improve this but would fall to similar limitation including 
patients not attending appointments.   
 
Although each culture-positive sample was tested for Mtb, this study did not 
determine the cluster outbreaks which would have provided further insight into 
the transmission of TB or a reoccurrence in individuals. Future studies should 
incorporate strain-typing results to identify clusters. 
 
There is the potential for misclassification of DM within the study, as routinely 
collected clinical data without validation; this includes hospital and primary 
care correspondence. It is likely that misclassification was minimal as DM is 
an indicator condition within UK primary and tertiary care; therefore, practices 
have incentives to maintain accurate diabetes patient registers. 
 
The retrospective nature of the study cannot control exposure and relies on 
accurate recordings; therefore, some cases of primary care may have been 
omitted, especially around DM care or any pre-diabetes risk factor which can 




including alcohol intake and cigarette smoking, was based on data entries 
entered by the TB nurses into the London TB Register and, potentially, some 
may have been omitted or patients not declaring certain data. To overcome 
this, it would require working with other professionals i.e. for alcoholic abuse 
likely to receive input from alcohol liaison team, to gain accurate information.  
 
4.16 Future research recommendations 
 
Future investigations should focus on clinical trials to examine the benefit of 
prolonged or intensified TB treatment for TB-DM patients, and clinically 
relevant interventions with respect to the management of cardiovascular risk, 
optimal timing and dosages.  
 
An investigation into mathematical and economic models to estimate the 
costs and potential impact of different interventions, i.e. screening TB patients 
for DM and vice versa, intensified treatment and treating of LTBI, should be 
undertaken.   
 
Future studies should consider reviewing the treatment guidelines by 
incorporating bidirectional screening and the cost-effectiveness of treating 
patients with TB and DM. Future research should examine TB cases 
nationally; in this research, there was no difference in outcomes on death, 
relapse or reinfection, which was expected as the patients were recruited from 
one main centre. Future investigations should focus on clinical management 
and clinical trials to examine the benefit of prolonged or intensified TB 
treatment for TB-DM patients, and clinically relevant interventions with respect 
to the management of cardiovascular risk, optimal timing and methods of 




Currently, there are no national figures for the prevalence of TB-DM, and this 
is the first study to make an estimate of the number of TB-DM patients in a 




In 2018, the population of Newham was 352,005, with a large proportion of 
the adult population from the Black and Asian minority ethnic community 
(BAME) (70%), followed by White British (15%) and White Other (14%). Eight 
percent of the population over the age of 18 years are recorded to have DM 
compared to England’s average of 6.4% (Newham Adult JSNA 2019). It is 
estimated that 78% of the diabetic population has been diagnosed by primary 
care and about 7,000 individuals are living with undiagnosed DM in the 
Borough of Newham.  33,000 individuals are expected to live with non-
diabetic hyperglycaemia, and this is likely to influence the DM prevalence 
rising to 12,000 from 8,000 over the next 10-15 years. The rate of TB in 
Newham remains around 47 per 100,000 population (PHE, 2018) compared 
to England’s average of 9.2 per 100,000 (PHE, 2018). The prevalence of TB-
DM in Newham is 28.5 per 100,000. Therefore, introducing DM screening in 
TB patients, monitoring of TB drug levels in DM patients, screening of HbA1c 
prior to Tb treatment, these measures to increase better TB treatment 
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Appendix – 1 – Quality Improvement Registration Form 
 












































































Appendix 3 – Data collection variables 
 
Section 1 “Sociodemographic data” 
 
Center free text field (specify) 
ID Patient Code institute code and 4-digit progressive serial number 
 
Hospitalized from – to  date field: format DD MM YY- DD MM YY 
Date of birth date field: format DD MM YY 
Country of birth date field: format DD MM YY 
Length of stay in the host country numeric field 3 digits (months) 
Gender curtain drop-down menu (one choice): 1) F (female), 2) M (male) 
Education curtain drop-down menu (one choice): 1) none (no formal 
education), 2) primary education (≤ 7 years), 3) higher education (>7 years  
including vocational training, secondary, high school and college/university). 
Employment curtain drop-down menu (one choice): 1) street seller, 2) 
self-employed (sales person, craftsman), 3) employee, 4) caretaker, baby-
sitter, 5) housekeeper, 6) health care worker, 7) student, 8) restaurant staff, 9) 
farmer, 10) construction worker, 11) industry worker, 12) other, 13) 
unemployed. 
 
Section 2 “Clinical data” 
ID Patient Code institute code and 4-digit progressive serial number 
 
Weight numeric field 3 digits (kilograms) 
Height numeric field 3 digits (cm) 
Tobacco use curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Tobacco intake numeric field 3 digits (cigarettes per day) 
 




Alcohol intake numeric field 3 digits (drinks per week) 
 
Drug abuse curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Type of drug free text field (specify) 
 
 
HIV+ curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Date diagnosis date field: format DD MM YY 
CD4+ at diagnosis numeric field 3 digits (cell/mm3) 
Date date field: format DD MM YY 
Last CD4+ numeric field 3 digits (cell/mm3) 
Date date field: format DD MM YY 
 
Previous TB disease curtain drop-down menu (one choice): 1) yes, 2) no, 
3) nr 
Date diagnosis date field: format DD MM YY 
 
Previous TB contact curtain drop-down menu (one choice): 1) yes, 2) no, 
3) nr 
Date date field: format DD MM YY 
 
Comorbidities curtain drop-down menu (multiple choice): 1) long term 
steroid (inhalation corticosteoids or peroral corticosteroids), 2) cytotoxic 
treatment, 3) immunosuppressive medications, 4) chronic renal 
failure;5)chronic liver disease, 6)chronic lung diseases), 7) haematological 
malignancies. 8),other malignancies; 9), silicosis; 10) gastrectomy 11)anti-




Pregnant or lactating women curtain drop-down menu (one choice): 1) 
yes, 2) no, 3) nr 
 
Symptoms curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Persisting cough curtain drop-down menu (one choice): 1) yes, 2) no, 3) 
nr 
Fever curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Weight loss curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Anorexia curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Hemoptysis curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Chest pain curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Fatigue curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Night sweating curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Other free text field (specify) 
 
Tuberculin skin test curtain drop-down menu (one choice): 1) negative, 
2) positive, 3) nr 
Date date field: format DD MM YY 
 
IGRAs curtain drop-down menu (one choice): 1) negative, 2) positive, 3) 
indeterminate, 3) nr 
Type curtain drop-down menu (one choice): 1) QFT, 2) TSpot-TB 
Date date field: format DD MM YY 
 






Chest X-Ray curtain drop-down menu (one choice: 1) yes, 2) no, 3) nr 
Date date field: format DD MM YY 
 
CT (computed tomography scans) curtain drop-down menu (one 
choice): yes/no/nr 
Date date field: format DD MM YY 
Normal curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
 
Cavity curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Localization curtain drop-down menu (one choice): U=upper M= middle 
L=lower 
 
Consolidation curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Localization curtain drop-down menu (one choice): U=upper M= middle 
L=lower 
 
Miliary curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
 
Plural effusion curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Localization curtain drop-down menu (one choice): M=monolateral 
B=bilateral 
 
Sputum smear microscopy curtain drop-down menu (one choice): 1) 
yes, 2) no, 3) nr 
Result curtain drop-down menu (one choice): 1) negative, 2) positive, 3) nr 





Sputum culture curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Result curtain drop-down menu (one choice): 1) negative, 2) positive, 3) nr 
Date date field: format DD MM YY 
 
Other material smear microscopy curtain drop-down menu (one choice): 
1) yes, 2) no, 3) nr 
Result curtain drop-down menu (one choice): 1) negative, 2) positive, 3) nr 
Date date field: format DD MM YY 
 
Other material culture curtain drop-down menu (one choice): 1) yes, 2) 
no, 3) nr 
Result curtain drop-down menu (one choice): 1) negative, 2) positive, 3) nr 
Date date field: format DD MM YY 
 
PCR curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Result curtain drop-down menu (one choice): 1) negative, 2) positive, 3) nr 
Date date field: format DD MM YY 
 
Anti -TB Drug Resistance curtain drop-down menu (one choice): 1) yes, 
2) no, 3) nr 
Method curtain drop-down menu (one choice): 1) culture (proportion) 2) 
molecular (specify),  
Any drug resistance curtain drop-down menu (one choice): 1) yes, 2) no, 
3) nr 
Resistant to curtain drop-down menu (multiple choice): 1) isoniazid, 2) 
rifampicin, 3) pyrazinamid, 4) ethambutol, 5) streptomycin, 6) amikacyn, 7) 











Previous DM diagnosis curtain drop-down menu (one choice): 1) yes, 2) 
no, 3) nr 
Type curtain drop-down menu (one choice): 1) type1, 2) type 2, 3) nr 
Date date field: format MM YY 
 
New DM diagnosis curtain drop-down menu (one choice): 1) yes, 2) no, 
3) nr 
Date date field: format DD MM YY 
 
Signs and symptoms of DM curtain drop-down menu (multiple choice): 
1) polyuria, 2) polydipsia, 3) poliphagia, 4) weight loss in the last 2 months 
 
Glycemia 1 numeric field 4 digits with one decimal point (mg/dl) 
Date date field: format DD MM YY 
 
Glycemia 2 numeric field 4 digits with one decimal point (mg/dl) 
Date date field: format DD MM YY 
 
Glycemia 3 numeric field 4 digits with one decimal point (mg/dl) 
Date date field: format DD MM YY 
 




Date date field: format DD MM YY 
 
Oral glucose tolerance curtain drop-down menu (one choice): 1) yes, 2) 
no, 3) 
OGTT results numeric field 4 digits with one decimal point (mg/dl) 
Date date field: format DD MM YY 
 
 
DM treatment curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
Oral hypoglycaemic agents curtain drop-down menu (one choice): 1) 
yes, 2) no, 3) nr 
Insulin curtain drop-down menu (one choice): 1) yes, 2) no, 3) nr 
DM treatment change due to TB drug interaction curtain drop-down 
menu (one choice): 1) yes, 2)  no, 3) nr. If yes specify interaction: free text 
field (specify) 
Vitamind D Levels 1 numeric field 4 digits with one decimal point 
(ng/mL) 
Date date field: format DD MM YY 
Albumin Levels 1 numeric field 4 digits with one decimal point (g/L) 

















Appendix 4 – Differential characteristic between TB and TB-DM cohort 
 
 
Characteristics TB TB-DM 
Age 
Equally to occur in all age 
groups 
More common with older 
age 
Gender Men more likely affected Men more likely affected 
Symptoms (cough, fever, 
haemoptysis, weight 
loss, night sweat) 
Symptoms range from 
non-specific to severe 
Symptoms more severe 
PTB / EPTB Involves both 
Significantly higher EPTB 
involvement 
Chest x-ray 
Upper-lobe infiltrates with 
less cavitation 
Greater cavitation 
AFB Smear Grade 
Less higher grade 
positivity 
Greater higher grade 
positivity 
Culture conversion & 
infectivity 
< 2months for culture 
conversion, less infectious 
>2 months for culture 
conversion, more 
infectious 



























Appendix 5 – Therapeutic Drug Monitoring for Antimicrobials in 
Tuberculosis 
 
This is a quality improvement project undertaken to improve the therapeutic 
drug monitoring (TDM) for TB patients prescribed rifampicin and isoniazid 
containing medication, and other antimicrobials (levofloxacin, moxifloxacin 
and linezolid). This is secondary to evidence to suggest that TB patients with 
co-morbidities, including DM are likely to have a different pharmacokinetics to 
these drugs, leading to under-dosing, reduced effectiveness and higher rates 
of treatment failure.  Under-dosing should also be considered in any patient 
with suspected treatment failure irrespective of whether they have 















































All patient diagnosed with TB 
Glycaemia test for all TB cases 
Does patient have diabetes mellitus. See 
diagnosis criteria. 
 
• FOLLOW-UP: According to TB 
schedule. Repeat glycaemic test  if 
DM symptoms present in intensive 
phase (2-8 weeks) and at end of 
continuation phase. 
• Does patients have DM? 
 
• Commence and continue TB management 
according to regimen  
• Close monitor of DM symptoms: Polyuria? 
Polydipsia? Polyphagia? Weight loss? Blurred 
vision? Numbness/tingling?  
• Adherence to TB medications 
 
Refer to DM clinic for DM work 
up (Based on Trust guideline) 
Is DM diagnosed?  
• Continue TB management 
• Assess social risk and advice lifestyle 
including smoking cessation, alcohol 
drinking, physical exercise, healthy diet   
• Monitor DM symptoms regularly 
• Adherence to TB medications 
Commence DM management according to Trust 
guideline: close monitor of  poor blood sugar 
control. 
• Continue TB management: close monitor of poor 
TB treatment adherence. 
• Education and counselling: TB & DM treatment 
adherence and psychological support. 















a) a fasting plasma glucose concentration 7.0 
mmol/L (whole blood > 6.1 mmol/L) or  
c) two hour plasma glucose concentration > 11.1 
mmol/L two hours after 75g anhydrous glucose in 
an oral glucose tolerance test (OGTT)  
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Included in policy: 
For the groups listed below, failure to follow the policy may result in 
investigation and management action which may include formal action in 
line with the Trust's disciplinary or capability procedures for Trust 
employees, and other action in relation to organisations contracted to 
the Trust, which may result in the termination of a contract, assignment, 
placement, secondment or honorary arrangement. 
All Trust staff, working in whatever capacity, other staff, students and 
contractors working within the Trust. 
Other staff, students and contractors working within the Trust  
Exempted from policy:  No staff groups are exempt from this policy  
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1.0 INTRODUCTION AND AIMS OF POLICY 
1.1 The aim of the policy is to prevent and control Mycobacterium 
tuberculosis (MTB) infection within the Trust, providing a safe working 
enviroment for both workers (HCWs), their patients, and visitors. Due to the 





London and the UK as a whole, it is essential that staff are provided with clear 
guidance so that all patients with suspected or confirmed Tuberculosis will be 
appropriately assessed and managed to reduce the risk of transmission to 
other patients and staff in accordance with national and local guidelines. All 
clinical staff are involved in the assessment, treatment and management of 
patients with Tuberculosis.  
TB is not uncommon and there is a small but constant risk of hospital-
acquired infection in both patients and staff. Early identification of TB in 
patients or staff, and implementation of this infection control policy involving 
TB specialist nurses and appropriate management of TB cases is essential in 
the prevention of transmission. 
2.0 SUMMARY 
2.1 The policy describes how to apply the prevention and control measures 
to prevent cross infection of MTB to  patients, staff and the general public 
within our Trust. It outlines appropriate isolation and respiratory precautions 
for all patients with suspected or confirmed tuberculosis (TB). This policy 
identifies the specific management of infectious patients with MTB disease, 
contact tracing and notification. The document outlines the neccessary 
diagnosis, specimen collection methods and the safe transportation of 
patients within the hospital.  
 
• Pulmonary TB is described as smear positive when Mycobacterium 
tuberculosis bacteria are visible by microscopy of sputum smears.  
 
• Pulmonary TB with three negative sputum smears is minimally infectious and 
described as “smear negative”.  
 
• Non-respiratory tract TB is NOT infectious to others (unless aerosolized 
under unusual circumstances).  
 
• Patients or staff may be particularly at risk if they are immunocompromised, 
through having illnesses such as HIV infection, chronic renal failure and 
diseases that require treatment with immunosuppressive drugs.  
• Early identification, involving TB specialist nurses and appropriate 
management of TB cases is essential to the prevention of transmission.  
Note: These guidelines specifically address the infection control issues of 
respiratory tract tuberculosis, that is laryngeal tuberculosis and pulmonary 
tuberculosis, the principal infectious forms of the disease. Transmission of TB 
is primarily person-to-person through the inhalation of infectious droplets 
coughed into the air by an individual with pulmonary or laryngeal TB.  
 
Symptoms of TB include: Chest pain, persistent cough, weight loss, 
drenching night sweats and fevers, fatigue, haemoptysis and an abnormal 






Tuberculosis is a notifiable disease requiring notification to Public Health 
England (TB nursing service will notify cases accordingly). 
 
In cases of Paediatric TB consider the risk of the same infection in the carer’s 
/ parents – this will mean isolating the child until a risk assessment is 
undertaken by the clinical team caring for the child.  
The BCG (Bacillus Calmette-Guerin) immunization provides a degree of 
protection (10-30%) against TB, however, it most definitely cannot be relied 
upon as a method of prevention. BCG vaccinated staff or carers will still need 
to adopt our Trusts infection control measures detailed in this policy. The 
same also applies for persons having had TB previously.  Previous TB 
disease does not offer protection to new infection. In 2005 the UK moved from 
a school-aged universal BCG vaccination policy to a targeted policy towards 
children at high risk. Many health care workers will have evidence of 
vaccination, but regardless all staff, who have contact with patients or clinical 
specimens, require Occupational Health assessment. Any doubts regarding 
staff immunity should be discussed with the Occupational Health Department. 
Remember that TB is common in patients presenting at Barts Trust and may 
occur in the presence of other diseases. If a patient is suspected to have 
smear positive pulmonary TB, or laryngeal TB, admit to a side room. Do not 
admit them to an open ward until the diagnosis has been excluded (send 
sputum for AFB and await result before de-isolating from a side room with 
respiratory precautions). Infectious TB can often be identified rapidly by 
microscopy of sputum but the clinical history and the chest X-Ray 
appearances often indicate that a high level of suspicion is required. 
3.0 Definitions 







A ventilation system that generates negative 
pressure to allow air to flow into the isolation 
room but not escape from the room. Prevents 
contaminated air flow leaving the room and 
entering other clinical areas and the number 
of air changes per hour is recommended as a 
minimum of 10 changes of room air per hour. 
 
Smear positive TB bacteria are seen on microscopy of 
sputum.   
Smear negative and culture 
positive 
TB bacilli are not seen on the sputum smear, 
but are grown on culture of the sputum/ tissue.  
Susceptible (or fully sensitive) 
TB 
Mycobacterium tuberculosis sensitive to first-
line drug therapy 
  
MDR TB Multi Drug Resistant TB. 
Tuberculosis that is resistant to at least 
isoniazid and rifampicin. 
XDR TB Extensively Drug Resistant TB. 
MDR TB with additional resistance to 






PTB Pulmonary TB, affecting the lungs. 
Extra-pulmonary TB Extra-pulmonary TB, also referred to as 
‘closed TB’, mostly affecting organs other than 
the lungs. 
MTB Mycobacterium tuberculosis 
4.0 INTRODUCTION 
4.1 Tuberculosis (TB) is the leading cause of death in the world from a 
bacterial infectious disease, affecting approximately 10 million people a year 
and is the 9th most common cause of death worldwide. It is estimated that up 
to to one-third of the entire world’s population has latent TB infection with 10% 
of infected persons developing the disease during their lifetimes. 
4.2 TB is mainly a respiratory disease caused by the bacterium called 
Mycobacterium tuberculosis (MTB). MTB is the etiologic agent of tuberculosis 
in humans, and humans are the only reservoir for the bacterium. 
4.3 TB usually causes disease of the lungs (pulmonary), but can affect any 
other part of the body (extra-pulmonary). Not all forms of tuberculosis are 
infectious. Those patients with TB in organs other than the lungs and larynx 
are rarely infectious to others. Extra-pulmonary TB, however, is occasionally 
contagious: it can be transmitted to others by inhalation of aerosols produced 
when pus/tissue from sites of infection are aspirated or irrigated and therefore 
universal precautions and the recommendations of this guideline should be 
followed at these times. 
Predisposing factors for TB include: 
• Prolonged close contact with infectious TB disease (>8 hours cumulative) 
• Those who have lived in, travel to or visited from a place where TB is 
prevalent 
• Those who live in an ethnic minority communities originating from places 
where TB is prevalent 
• Those with an immune system weakened by immunosuppressive 
medications, HIV infection or other acquire immunosupression, cancer, 
tranplantation or other medical co-morbidities like diabetes 
• Those with chronic poor health and nutrition due to social and lifestyle 
problems such as homeless, drug abuse or alcoholism 







5.0 LATENT TB 
5.1 TB can also present as latent TB in which people can be infected with 
Mycobacterium tuberculosis, but they do not have active presenting 




Table 1. Latent and Active TB 
Latent TB Active TB (in lungs or else where) 
MTB present/was present MTB present 
Tuberculin skin test positive Tuberculin skin test positive (can 
be negative) 
Quantiferon or T-spot positive 
( IFN gamma release assay 
(IGRA) positive)  
Quantiferon/T-spot positive (can 
be negative in 30% of active 
cases) 
Chest x-ray normal Abnormal chest x-ray if TB of 
lungs 
No acid-fast bacilli on sputum 
smear and culture negative 
In pulmonary TB Acid-fast bacilli 
on sputum smear and  or culture 
positive 
Or 
No acid-fast bacilli on sputum 
smear but culture positive 
In pulmonary TB or in extra pulm 
TB- other tissue samples might be 
smear or culture positive or 
histology suggesting TB 
No clinical symptoms of TB Clinical symptoms present 
including cough, fever, weight 
loss, night sweats, lymph node 
swelling, non healting ulvers or 
sinus tracts or joint sweellings, 
back pain in the case of disciitis 
Not infectious Often infectious prior to treatment 
if pulmonary or laryngeal 
 
 
6.0 TRANSMISSION OF TUBERCULOSIS 
6.1 The bacterium is usually transmitted by inhalation of aerosols produced 
by an infectious TB patient after prolonged contact, especially in those who 
are more susceptible to the disease i.e. the immuno-compromised or other 
risk groups. Prolonged contact is defined as a cumulative 8 hours or more. 
6.2 Once inhaled  the  bacteria reaches the lungs, and multplies over time. 





6.3 The majority of  persons exposed to TB bacteria can eliminate or kill 
the inhaled bacteria The minorityof those exposed will go on to develop 
infection clinical disease may then occur. 
6.4 In some instances, where a long period of time elapses between 
infection and development of disease, the dormant bacilli are thought to 
remain in either the lung or other sites, these can ‘reactivate’ in favourable 
circumstances for the organism (immunosuppression, elderly age, diabetes, 
cancer, HIV infection).  
6.5 Tuberculosis is generally spread by infectious droplets coughed or 
sneezed by a person with respiratory ‘pulmonary’ TB. Non-respiratory ‘non-
pulmonary’ TB is less infectious but procedures which generate infectious 
droplets pose a risk of transmitting TB (see above). Tuberculosis can be 
confined to a single site (respiratory is most common site) or can affect a 
combination of respiratory and non-respiratory sites, or single/multiple non-
respiratory sites. 
 
7.0 PRESENTATION OF TUBERCULOSIS 
 
Pulmonary TB (PTB) 
 
7.1 PTB is the most significant cause of cross infection as infectious 
persons can release TB bacilli to the environment and to contacts readily, 








7.3 Miliary (disseminated) TB occurs when TB bacilli is spread through the 
blood stream to other parts of the body and organs. May not be infectious, but 
isolation precautions must be followed. 
 
Atypical mycobacterial infection or Non-Tuberculosis Mycobacteria (NTMs) 
 
7.4 Non-tuberculous mycobacteria (NTMs) or ‘atypical mycobacteria’ rarely 
cause cross infection in normal individuals unless they are present in large 
numbers and the receiving patient (close contact) is severely 
immunocompromised.  Attention however to this is necessary in Cystic 
Fibrosis (CF) wards and clinics where NTMs like Mycobacterium abscessus 
can be transmitted by CF patients to other CF and predisposed patients. 
  
Multi Drug Resistant –TB (MDR-TB) 
 
7.5 MDR-TB is usually resistant to at least two anti-TB drugs Isoniazid and 
Rifampicin. MDR-TB requires a more complex drug regimen, prolonged 
patient isolation  and prolonged therapy (up to 24 months). Patients with 





and discharged only after they have 3 negative smears at weekly intervals 
and ideally have a negative culture 
(https://www.nice.org.uk/guidance/ng33/chapter/recommendations#multidrugr
esistant-tb-2). Discuss the decision to discharge a person with suspected or 
known multidrug‑resistant TB with the infection control team, the local 
microbiologist, the local TB service and the local PHE health protection team. 
(see the NICE Guidance and the MDRTB discharge form in the appendix 8)  
 
 
Particular risk factors for MDR-TB include: 
 
• History of prior anti-TB treatment or prior failure of treatment 
• Contact with a known case of MDR-TB 
• Birth or residence for > 3 months in a country with high incidence of 
susceptible TB and MDR-TB. (The World Health Organisation updates MDR-
TB list – 2016 WHO TB report) (LINK). 
• HIV co-infection 
 
7.6 The identification of the MDR-TB requires a rapid diagnosis, usually by 
a direct PCR (polymerase chain reaction) or GeneXpert test on a sputum 
sample to exclude Rifampicin resistance in addition to the immediate isolation 
in a negative pressure room. 
 
7.7 If MDR-TB is suspected, a Consultant in Microbiology/ Infectious 
Diseases and / or SpRs should be consulted for rapid diagnostic tests.  This 
includes nucleic acid amplification test (GeneXpert – Cepheid) to determine 
rifampicin resistance. The presence of rifampicin resistance may be used as a 
surrogate marker for MDR-TB. 
 
7.8 Patients with sputum microscopy-positive MDR-TB are potentially more 
infectious than fully sensitive susceptible TB and offer a worse prognosis.  




Extensively Drug Resistant TB (XDR-TB) 
 
7.10 XDR-TB is defined as TB which is resistant to anti-TB medication 
Isoniazid and Rifampicin, plus resistant to any fluoroquinolone and at least 
one of the three injectable second-line drugs. As XDR-TB is resistant to first-
line and second-line therapy, patients are left with less effective treatment 
options and a worse outcome.  
 
7.11 Both MDR-TB and XDR-TB could result from non-compliance with TB 
treatment, or following reactivation of the disease after an earlier TB episode 
treated unsuccessfully.  
1.12 Persons with HIV infection or other conditions which compromise the 





are more likely to develop TB disease once infected and have a higher risk of 
death from disease. 
8.0 INFECTION rISK FACTORS 
 
8.1 It is important to distinguish between respiratory and non-respiratory 
TB in determining the infectiousness and determining the required infection 
prevention and control precautions.  
 
8.2 Untreated patients who have a positive sputum microscopy from 
spontaneously expectorated sputum are highly infectious and require 
isolation using respiratory precautions. 
 
8.3 The majority of non-respiratory TB cases are not infectious, and can be 
nursed on a general ward, once PTB is excluded as a potential differential 
diagnosis. 
 
8.4 Those sputum smear negative patients with bronchial washings which 
are smear positive should be managed as infectious immediately after the 
bronchoscopy (as can become smear positive – sputum samples for acid fast 
bacilli should be sent) once the smear comes back negative the patients can 
be managed as non-infectious unless: 
1. The sputum is also positive or becomes so after bronchoscpy 
2. Are an inpatient after bronchoscopy; if the broncho-alveolar lavage is positive, the 
patient should be isolated with respiratory precautions. 
3. They are known or suspected of having MDR-TB or 
4. They are on a ward with immunocompromised patients (i.e. HIV, rheumatology, renal, 
haematoncology or oncology patients) 
Table 2. Infectiousness of people known to have or suspected of having TB disease 
Factors associated with non-
infectiousness 
Factors associated with infectiousness 
No cough Presence of a cough 
No cavity in the lung Cavity in the lung 
No acid-fast bacilli on sputum smear Acid-fast bacilli on sputum smear 
Extra-pulmonary (non-pulmonary) TB 
disease 
TB disease of the lungs, airway, or larynx 
Compliant with adequate treatment for 2 
weeks or longer if drug sensitive, if 
MDRTB  3 negative smears at weekly 
intervals and a negative culture. 
Not recieiving adequate treatment or non 
compliant or drug resistance to primary 
treatment options (MDR or XDR TB) 
Not undergoing cough-inducing 
procedures 
Undergoing cough-inducing procedures 
(e.g., bronochoscopy, sputum induction, 
and administeatrion of aerosolized 
medications, chest physiotherapy) 





9.0 Signs and sypmtoms of TUBERCULOSIS 
9.1 A diagnosis of TB should be suspected in any patient who presents 
with 3 or more of the following symptoms:  
• A persistent cough for >3 weeks 
• Haemoptysis  
• Fever 
• Night sweats  




10.0 DIAGNOSIS AND SPECIMEN COLLECTION 
 
10.1 DIAGNOSING PULMONARY TUBERCULOSIS 
1. Chest X-ray – if suggestive of pulmonary Tuberculosis, further tests required 
2. Sputum samples: at least one early morning sputum specimen, on three 
consecutive days should be collected and sent for acid fast bacilli (AFB) 
microscopy and culture. 
3. Pleural biopsy and aspiration to be collected if pleural effusion is present and 
also sent for AFB 
4. Biopsy specimens of the lung or bronchial washings take sample and send for 
AFB before commencing treatment, if possible, or within 7 days of starting 
treatment. 
 
10.2 NON-PULMONARY TUBERCULOSIS  
1. All patients with non-pulmonary TB should have a chest x-ray to exclude or 
confirm co-existing pulmonary TB. 
2. An early morning urine specimen on three consecutive days to test when 
miliary or urinary tract TB or TB in a person living with HIV is suspected.  
3. Pus or tissue specimen to be collected rather than swab (swabs will not be 
processed) 
4. Liver and bone marrow biopsy specimens are rarely indicated but may be 
sent for AFB when miliary TB is suspected particularly in patients with chronic 
pyrexia of unknown origin. Blood cultures for TB may also be sent when 
disseminated TB disease present. 
5. Peritoneal biopsy specimens are to be collected during laparotomy when TB 
peritonitis is suspected. 
6. A lumbar puncture to obtain cerebrospinal fluid must be collected when TB 
meningitis is suspected. An MRI of the brain is favoured over CT brain.  
 
10.3 If patients with X-ray changes cannot expectorate sputum for 





to obtain the sample and confirm a diagnosis.  If the broncho-alveolar lavage 
is positive, the patient should be isolated with respiratory precautions 
10.4 Specimens should be obtained in a safe manner, by expectoration in a 
single/side or negative pressure room and sent to the laboratory for smear 
examination. The TB team and IP&C teams should be informed to make them 
aware and discuss patient management.  
10.5 Specimens must be sealed securely; ensuring the outside of the 
container is not contaminated. Specimens should be obtained and placed in a 
specimen bag within the room. The request on electronic patient system must 
specify what examination is requested for the laboratory and the suspected 
diagnosis.  As with any respiratory samples these must NOT go in the 
pneumatic tube system. 
10.6 Patients with non-respiratory TB do not need isolation, but disposable 
gloves and apron must be worn when handling potentially contaminated 
materials, e.g. urine, pus or wound dressings. Abscess or wound irrigation 
can generate aerosols and such procedures should be carried out in a 
separate facility under strict infection control measures, visor, apron, gloves 
and face mask. 
 
11.0 OTHER TESTING - TUBERCULOSIS PATIENTS  
11.1 HIV testing as well as hepatitis B and C testing should be performed in 
all patients when a diagnosis of TB is made, and this should only be 
undertaken after informed consent has been obtained from the patient. 
Vitamin D should also be requested. Liver function tests and an eye 
examination  should be requested preferably at the start of TB treatment. 
 
12.0 TREATMENT 
12.1 Once the diagnosis of TB is made, the clinician responsible for care 
should refer to the person to the adult TB Team will supervise the treatment of 
all cases of adult TB. Children aged under 16 should be referred to the 
paediatric TB team. 
12.3 TB is curable with a combination of specific anti TB medication. The 
duration of treatment for drug sensitive TB disease is at least 6 months and 
for MDR-TB it can be up to 24 months. This prolonged period of infectivity and 
prolonged duration of treatment of MDR-TB are reasons for requiring strict 
infection prevention and control measures (i.e. negative pressure rooms) to 
minimize person to person transmission and outbreaks. 
 
13.0 ISOLATION PRECAUTIONS 
 
13.1 Patients with infectious TB disease are isolated to prevent cross-
infection, via the respiratory tract or direct contact, to other patients and health 





13.2 Patients who are suspected or confirmed as having pulmonary 
tuberculosis should be admitted to a side room, until their sputum status is 
known and risk assessment is made regarding infectiousness of the patient. 
The door should remain closed and a respiratory isolation notice must be 
displayed on the door. 
13.3 Children with tuberculosis, whether infectious or not, and their visitors 
should be segregated from the rest of the ward until visitors have been 
screened to exclude them as a source of infection. 
13.4 Do not admit patients with suspected infectious or confirmed 
pulmonary TB to a ward containing people and patients who are 
immunocompromised, such as transplant recipients, people living with HIV 
and those on anti-tumour necrosis factor alpha or other biologicals, unless 
they can be cared for in a negative pressure room in the same ward. 
Tuberculosis patients should not be mixed because these groups of 
immunocompromised patients can get severe disease if infected. 
13.5 If the sideroom is in or adjoining / adjacent / to a ward or area in which 
significantly immunocompromisd, especially HIV infected patients are nursed, 
the isolation room must have negative air pressure with more than 10 air 
changes per hour with continous monitoring. Please also refer to HTM. 
13.6 If an appropriate side-room is not available on the ward then this must 
be escalated to a senior nurse or the Clinical Site Manager.  
 
14.0 MDR-TB 
14.1 Patients suspected or confirmed as having MDR-TB should be 
transferred to a negative pressure room on 13F ward at the Royal London 
Hospital and notify Public Health England local public protection team.  
 
14.2 If none are available locally, transfer them to a hospital that has these 
facilities and a clinician experienced in managing complex drug-resistant 
cases.   
 
14.3 Carry out care in a negative pressure room for people with: 
 
1. Suspected MDR-TB, until resistance has been ruled out 
2. Confirmed MDR-TB, 3 negative smears at weekly intervals and a negative 
culture (absolute minimum requirement).  
3. Seek the local Public Health protection teams advice prior to discharge 
(Public Health England) for agreement with the above as a case by case 
basis. The MDRTB discharge form (Appendix 8) can be used to document the 







15.0 DURATION OF ISOLATION  
15.1 Patients with  smear positive disease not known or suspected to have 
MDR-TB, are usually non-infectious to others after two weeks of continous 
appropriate treatment. If there is extensive pulmonary disease with cavities, 
diabetes and immunosuppression this may not be the case. 
15.2 Consider de-escalating isolation after 2 weeks of treatment, taking into 
account the risk and benefit: 
• The person is taking and tolerating the prescribed treatment 
• There is a agreement to continued adherence to treatment 
• Diabetic patients and immunocompromised patients may require more than 2 
weeks before they are no longer infectious 
• There are not immunocompromised patient, such as tranplant recipients, 
people with HIV and those on anti-tumour necrois factor on the open ward. 
• Patients with smear grades which are higher than 2 may require more time to 
become sputum smear negative 
• There is not an extensive pulmonary involvment, including cavitation 
• There is no laryngeal TB 
15.3 The final decision to move a patient out of isolation should be made 
following discussion with the Respiratory or Clinical Infection (ID) Consultant, 
TB team and the Infection Prevention and Control Team. 
15.4 The decision to discharge the patient should be a multidisciplinary 
team approach, which includes provision for directly observed therapy, if 
required, and regular follow-up to supervise treatment compliance.   
16.0 RESPIRATORY MASKS 
Fit testing (at least once) should be performed by all staff working in bronchoscopy 
suites and nurses and medical staff working in 13F ward with TB and MDR-TB 
patients. This should be arranged by the charge nurse in co-ordination with Infection 
control. 
16.1 Staff and visitors attending the patient should wear FFP 3 masks before 
entering the room to a susceptible or resistant TB patient.   
16.2 The masks should be discarded outside the room into clinical waste and 
hands decontaminated, all masks are single use.   
16.3 Staff having contact with a suspected / confirmed MDR-TB and 
suctioning or carrying out bronchoscopy should wear FFP 3 masks which 
meet the European standard EN149:2001 published by the Health and Safety 
Executive (2005).  
16.4 Patients with or suspected to have MDR-TB should remain in isolation 
for the duration of their admission or until reviewed and advised otherwise by 
a specialist TB Consultant. 
 
16.5 Gloves and aprons should be worn when handling sputum or infected 
body fluids. Visors should also be worn if performing suctioning, intubation, 





16.6 The smear-positive TB patient should be advised on good cough 
hygiene (cover their cough, through away infectious waste) and wear a 
surgical mask (not an  FFP3) when the patient leaves their room (cough 
etiquette) e.g. for X-ray (as they may come into contact with other susceptible 
patients) for the first 2 weeks of treatment. 
 
16.7 Other considerations: 
 
• Staff suffering from any underlying immune dysfunction either innate or 
acquired or due to chemotherapy or undergoing immunosuppressive 
treatment and pregnant staff should be excluded where possible from 
managing TB patients. 
• Aerosol generating procedures (suctioning, bronchoscopy) must be performed 
only when using a FFP3 mask  
 
17.0     NEGATIVE PRESSURE ROOM  
17.1 Isolate all patients known or suspected to have infectious TB. A 
negative pressure room is one where the air from the room is removed by 
dedicated ducting through a filter and into the outside air, at a distance from 
all other air intakes. The pressure should be 5 Pascals below the ambient air 
pressure of surrounding areas and have at least 10 air changes per hour. 
Please also refer to HTM for more details. 
Bronchoscopy suites carrying out bronchoscopy for patients suspected or 
confirmed with having MDR-TB should be carried out in negative pressure 
endoscopy suites and be last on list so that a deep clean will be ensured. 
 
17.2 Bronchoscopy for known or suspected MDR/XDR-TB patients should 






18.0 VISITING OTHER DEPARTMENTS and SITES and TRUSTS 
18.1 If an infectious patient is to attend other departments/theatres/suites, 
the appropriate Manager/Head Nurse/ Senior Nurse must be notified so that 
arrangements can be made for the patient to be seen last on the list to allow 
time for appropriate cleaning to be carried out after the patient. 
Transport and Ambulances should also be notified so that they can also 
arrange appropriate protective wear for staff as well as book and arrange 
cleaning. 
 
19.0    WASTE 
19.1 Sputum should be expectorated into a disposable sputum container/ 
receptacle ideally with a tight fitting lid and then either handed to staff for 
transport to pathology or discarded into a yellow clinical waste bag.  
19.2 Used tissues and other waste must be disposed into the clinical waste 
stream within the room. 
 
20.0 LINEN 
20.1 Treat all soiled or infected laundry as clinically infected and dispose in 
a red alginate bag then into a clear bag. 
 
21.0     FOODS AND DRINKS 
21.1 It is not neccessary to use disposable crockery and cutlery as routine 
washing in a dishwasher will eliminate Mycobacterium tuberculosis.  
 
22.0    CLEANING 
22.2 The domestic cleaning the room is not at increased risk but should 
wear PPE as advised. The room should be cleaned with Hypocholite solution 
1000 ppm ensuring that all surfaces are cleaned daily.   
Tuberculosis may be transmitted via inadequately disinfected endoscopes. 
The correct decontamination processes of these instruments are identified in 







23.0 SCREENING WHEN PATIENT ON OPEN WARD HAS INFECTIOUS 
TB DISEASE  
23.1 If patients are exposed to a patient/member of staff  who has smear 
positive pulmonary TB >8 hours (or less for those particularly at risk, e.g. 
neonates, severly immunosuppressed patients) then they need to be 
assessed by their medical team regarding whether or not they are at 
increased risk of developing TB and treated accordingly.   They  will then 
be offered screening by the TB team in conjunction with the patients’ medical 
teams  and the Infection Prevention and Control Team.  
23.3 Staff contacts will be followed up by the Occupational Health 
Department with advice and support from both TB Team and Microbiology/ID 
Consultant.  
23.4 Exposure on a ward is a Serious Incident (link to Adverse Incident 
Policy).  A Datix and SI proforma must be completed and an incident meeting 
should take palce within 10 working days of the incident being declared. See 
Appendix 3: Algorithm For Dealing With TB Related Infection Control 
Incidents Within Barts Health Trust. 
 
 
23.5 A formal risk assessment needs to be carried out by the the Infection 
Prevention & Control Team in conjunction with the TB service of both other 
patients, members of staff and visitors. This should highlight any persons in 
these groups that are at risk, what the level of risk is, and whether they simply 
need to be advised about their exposure or screened by the TB service.  
A follow up meeting should take place 6-8 weks later to ensure that all the 
appropriate persons have been screen and to discuss the outcome of 
screening. This should include discussion on whether screening needs to be 
extended. A short formal report should be produced outling the incident and 
the numbers of staff, patients and visitors offered screening. 
 
STAFF 
Employees new to the NHS who will be working with patients or clinical 
specimens should not start work until they have completed a TB screen or 
health check, or documentary evidence is provided of such screening having 
taken place within the preceding 12 months. Employees new to the NHS who 
will not have contact with patients or clinical specimens should not start work 
if they have signs or symptoms of TB. Health checks for employees new to 
the NHS who will have contact with patients or clinical materials should 
include: 
• assessment of personal or family history of TB 
• asking about symptoms and signs, possibly by questionnaire 
• documentary evidence of TB skin (or interferon‑gamma release assay) 
testing within the past 5 years and/or BCG scar check by an occupational 
health professional, not relying on the applicant's personal assessment. 
Employees who will be working with patients or clinical specimens and who 





1.2.1) should have an individual risk assessment for HIV infection before BCG 









All new staff  are screened on commencement at work for TB.  The online 
pre-placment health questionnaire asks them to indicate any history of TB, 
history of vaccination and  to complete a symptoms check list.  Any indication 
of past history of TB or current symptoms will result in further enquiry. In 
addition all new NHS staff who will be working with patients or clinical 
specimens will be invited to attend Occupational Health (OH) for blood 
screening with an Interferon gamma release assay test – (T-spot – Oxford 
immunotec) and clearance is not issued until the results are received in OH 
and any clinically indicated follow up or treatment has been completed or 
established and advise to inform OH that they are fit for work has been 
received by the TB Nurses. 
23.5 For staff whose role involves them working directly with patients or with 
specimens and who do not have a visible BCG scar, documentary evidence of 
having received a BCG vaccination or who are able to give a clear history of 
being vacciated, the BCG vaccine will be offered ( when available).  These 
staff will be initially tested for T.Spot and HIV blood test is also taken with 
consent of the staff member prior to immunisation with the BCG. 
23.6  Any staff member whoes role involves direct patient contact or contact 
with specimens who declines the BCG vaccine, if offered as part of work 
protection immunisations would be required to complete a disclaimer, and 
their manager informed that they are not agreed to have the vaccine so that 
appropriate risk assessments can be completed in relation to the infection 
risks in the specific work environment. 
23.5 It is not common for hospital staff to acquire tuberculosis from patients 
but is most definitely possible, and it is also well documented that patients can 
and staff can acuire TB infection from staff with unrcognised active TB 
disease, hence awareness and vigilance is required at all times. 
23.6 Staff in contact with infectious TB patients and inappropriate protection 
– a cumulative close contact of 8 hours or more or contact for a week or more 
with a known TB case, or who may have undertaken mouth-to-mouth 
resusitation without appropriate protection or prolonged care of a high 
dependency patient. In these circumtances, staff should be considered as 
close contacts and standard procedures be followed which includes 
counselling the member/s of staff and referring to Occupational Health, who 
will in turn arrange initial screening at 8-10 weeks post the exposure to the 
patient/ colleague with diagnosed TB.  The initial screening is by T-Spot and a 
symptoms check list.  Those with symptoms suggestive of TB and/or a 
positive T-Spot result are referred to the TB Nurses clinic.  The OH 
department will also refer the staff member with a positive T-Spot for a chest 
x-ray in all cases.  Those with a chest x-ray result consistent with active TB 






23.7 Staff with less than 8 cumulative hours with a case of smear positive 
TB should be reassured that the risk of acquiring TB disease is minimal 
however they should be reminded of the possible symptoms of TB e.g. night 
sweats, fevers, cough for more than 2 weeks, weight loss, haemoptysis) and 
the importance of reporting such symptoms promptly to the Occupational 
Health Department. If a member of staff had less than 8 hours of contact but 
is immunosuppressed or living with HIV the screening for latent TB should be 
offered. 
23.8 Staff who have regular contact with tuberculosis patients and 
laboratory workers who handle TB specimens are at higher risk and should 
have regular education about the signs and symptoms of active TB and 
screen as necessary. Should any protective measures in the laboratory fail, 
members of staff should be counselled and referred to occupational health. 
23.9 BCG does not confer satisfactory protection and therefore tuberculosis 
most definitely can still occur in vaccinated healthcare workers. 
23.1.1 Staff working in high risk areas (respiratory and TB wards, A and E, 
medical admission unit, bronchoscopy suites, radiology, laboratory) should 
have periodic mask fit testing and appropriate advice on protective measures 
when looking after TB patients. 
New and existing staff, particularly those who have recently travelled to high 
TB incidence areas of the world, should undertake new employment 
screening for TB in Occupational Health, or screening as a returning traveller, 
which starts with a questionaire and may lead to IGRA testing and referral to 
the TB clinic if there is evidence of active or latent TB, so as to protect their 
patients (especially if these are neonates, children or the 
immunocompromised), colleagues, community and family.  
23.1.2 Staff with TB symptoms should seek immediate advice from 
Occupational Health or from their own GP so that they do not expose patients 
or colleagues to infection. 
 
PATIENTS 
23.1.3 A formal risk assessment needs to be carried out by the the Infection 
Prevention & Control Team in conjunction with the TB service. The risk 
assessment will include: 
1. The degree of the infectivity of the index case 
2. The duration and proximity of contact 





23.1.4 Contact tracing and testing will be undertaken in patients at significant 
risk. Identified patients will be managed as houshold contacts if exposed for 
long enough to be equivalent, or are particulary susceptible to infection. 
23.1.5 Patients are considered at risk if they spend more than 8 hours in the 
same open bay as a patient with sputum smear-positive TB and a cough. For 
these patients, such contacts should be documented in the notes, the patient 
should be informed, as should their GP and named Consultant.  
 
24.0 STAFF WITH TUBERCULOSIS 
24.1 Refer to Tuberculosis in Staff policy (LINK). When a healthcare worker 
is diagnosed with tuberculosis, whether occupationally acquired or not, liason 
is important between the treating physician, the Occupational Health 
Department, and the Infection Prevention and Control Team. If the worker has 
been at work while infectious, it is neccesary to identify patients and 
colleagues who have had significant contact and manage them with support 
from the patients’ Consultants, Occupational Health and the TB Team. 
Exposure on a ward is a Serious Incident (link to Adverse Incident Policy).  A 
Datix and SI proforma must be completed and an incident meeting should 
take place within 10 working days of the incident being declared (see above, 
as per screening an infectious patient).   
25.0 SPECIFIC MANAGEMENT- PAEDIATRIC CASES 
25.1 All paediatric cases of suspected or confirmed TB must be isolated in a 
side room. Any visitors of a child with TB in hospital should be screened as 
part of contact tracing and kept separate from other patients until they have 
been excluded as source of infection.  
 
25.2 Children with confirmed or suspected MDR TB will require isolation in a 
negative pressure side-room.  
26.0 PROTECTING VULNERABLE INPATIENTS 
26.1 Immunocompromised in-patients are at an increased risk of 
developing active TB; care must be taken to avoid exposure to persons with 
TB disease.   
 
• HIV positive 
• Patients who have had solid organ transplantation 
• Patients with haematological malignancy 
• Patients with chronic renal failure/ receiving haemodialysis 
• Patients who are receiving anti-TNF alfa treatment 
 





27.1 Intensive Care Units - Patients with MDR-TB should be nursed in a 
negative pressure facility.  If not available then the patient should be 
transferred to a facility that has negative pressure rooms.   
27.2 Risk is greatest during intubation and extubation; once the patient is on 
a closed suction system then risk to others is greatly reduced and should then 
be considered minimal. However, it is recommended that staff should wear 
FFP 3 masks for suseptible TB and MDR-TB.  Masks must be worn   at all 
times when administering patient care.   During procedures such as intubation 
and extubation in addition to the FFPs  mask full PPE (impermeable/water 
proof gown, visor and hair cap) should be worn  in a suitable facility (side 
room, side room with ante room or negative pressure room) and should be 
used regardless of drug resistance status. On ITU patients should be isolated 
in a side room, negative pressure room, please see section 27.3 for operating 
theatre. With regards to operating theatres patients should preferably be last 
on list so that a terminal clean and minimum 4 hours of non use can occur.  
The TB Infection Control precautions in an ICU are similar to anywhere else in 
the hospital - all respiratory precautions. Fit tested respirators (FFP3) are 
essential. If the patient is known to have TB and on effective 
therapy, the risk is minimal for transmission. However, the ICU is a place 
where TB can be missed, and those untreated patients pose a major risk. 
Periodic IGRA testing of staff should be considered. 
The main issue here is the ventilator, the endotracheal tube or tracheostomy 
tube and the need for regular suctioning, which generates cough and aerosol. 
Unless gas flows are stopped for longer than one hour between cases, M. 
tuberculosis has been shown to be able to pass through the anaesthetic 
machine. The presence of a soda lime canister does not guarantee 
eradication, as desiccated soda lime is not bactericidal. Therefore, it is 
recommended that a bacterial/HEPA filter is placed both by the patient’s 
airway (endotracheal tube) and on the expiratory limb of the circuit (ventilator). 
These should be able to filter more than 99.97% of particles greater than 
0.3μm. While not specially advocated by ASA, it would be good practice to 
sterilise the circuits after such a case. If heat disinfection or ethylene oxide for 
reprocessing disposable filters should be changed.  
The usual 10 air changes per hour are recommended, preferably the patient is 
cared for in a side room, but with a closed circuit this is not absolutely 
required. A deep clean is all that is required after the room is vacated, there is 
no role for fumigation. Routine surface cleaning targeting important droplet 
spread bacteria and viruses is, of course, recommended, as is hand washing 
(for other pathogens, not TB). Administrative, environmental, and respiratory 
protection interventions - especially early diagnosis and effective treatment 
are necessary for instituting good preventive measures and preventing 
nosocomial spread of TB. 
 
 
27.3 Theatres – If possible, non-urgent surgical procedures should be 
postponed until the patient is recorded to be converted/non-infectious (sputum 
smear and culture negative), if the patient necessitates an urgent operation 





(gown, visor, gloves, FFP3 and hair cap). The operating room air flow can be 
set to neutral or negative pressure for an operation involving an MDR or XDR 
TB patient. The theatre will then require a deep clean. If surgery does not 
involve to respiratory tree or an area of TB infection and the patient is 
intubated, positive pressure can be used as once the patient is intubated and 
airways are sealed using the circuit and the filter and closed suctioning – 
there is sufficient protection. TB patients should be on closed suctioning and 
disposable ventilator circuits. Operating theatres also have significant air 
dilution which is approximately 25 air changes per hour- which is nearly an 
airchange every 2 minutes- which reduces any risk even further. The theatre 
will then require a terminal clean. UV lamps can also be considered for 
sterilization of the theatre post op. 
27.4 If an emergency then the surgical procedure should be scheduled at 
the end of the day to maximize the time available for removal of airborne 
contamination prior to the next case. The patient should be brought straight to 
theatre, rather than wait in a central waiting area where exposure to other 
patients could potentially occur. The anaesthetist should ensure adequate 
anaesthesia and muscle relaxation to ensure that the patient does not cough 
on intubation. FFP3 masks should be worn by all staff during the procedure 
this is especially true for high-risk procedures, such as intubation and 
bronchoscopy. And staff fit tested for the mask. Movement inside the theatre 
should be minimised to essential staff with a minimum number of door 
openings and the names of all those present recorded. 
27.5     Ideally, the patients should be recovered in a private room, rather than 
in the central recovery area. Practically, this may mean that he or she will 
need to recover in theatre before going back to the ward directly. The surgical 
mask (changed at hourly intervals if necessary) should be placed back on the 
patient as soon as active airway management is no longer required. If FFP 3 
masks are used on a patient, consider increases in airway flow resistance by 
approximately 120% and that they should not be worn by the patient if he or 
she is hypoxic or in respiratory distress. Similarly, if hypoxia or respiratory 
distress occurs while wearing the mask, it should be removed.  
28.0 Visitors  
The nurse in charge of the ward has the overall responsibility to advise vistors 
of the risk of TB, however all members of staff should be share this 
responsibility and give a consistent message to members of the public.  
28.1 It is important to distinguish between household close contacts and 
other visitors. Household contacts are defined as those who share a bedroom, 
kitchen, bathroom and/or living room and frequent visitors to the home of the 
patient. Household close contacts should be allowed access to the patient, as 
household contacts are actively followed up by the TB team. Other visitors 
should generally be discouraged to visit pulmonary TB cases while under 
respiratory precautions. 
 
28.2 Visitors other than household contacts should be discouraged from 






28.3 Household contacts and any other visitor should be asked to follow the 
isolation precautions on the door signage which includes wearing an FFP 3 
mask, visitors and household contacts should be taught and given assistance 
in wearing their mask correctly. 
29.0 TRANSPORT OF PATIENTS 
 
29.1 Inpatients with smear positive pulmonary tuberculosis should be asked 
(with explanation) to wear a surgical mask (changed at hourly intervals if 
necessary) whenever they leave their room to other hospital departments until 
they are deemed non -infectious and are de-isolated. FFP3 masks with filters 
should NEVER be given to patients (the masks are designed to protect not to 
capture, the valve eliminates unfiltered air including the infectious TB bacilli). 
 
29.2 Transport delays to other departments should be minimized by liaising 
with porters and other departmental staff. Patients undergoing x-rays should 
not wait in radiology department corridors and must be prioritized to minimize 
the contact with other patients. Patients should not wait in discharge lounges 
for transport to home or other accommodation. 
 
29.3     Inter hospital transfers - Ambulance staff need sufficient information 
for organizing appropriate vehicle in addition to their own protection. As with 
visits to other departments, patients with smear-positive pulmonary TB should 
wear a surgical mask (changed at hourly intervals if necessary) during 
ambulance transport – if the patient has not completed 2 weeks of appropriate 
anti tuberculous treatment. If the patient is known or suspected to be infected 
with MDR-TB, then advice on transport should be sought on an individual 
basis from the IPCT, Respiratory Physician, or an ID physician. Standard 
procedures and close liaison with ambulance trust is necessary for contact 
tracing for ambulance staff who have been inadvertently in contact with a 
patient with confirmed infectious or potentially infectious pulmonary 





30.0 TRAINING AND AWARENESS 
 
30.1 All Infection Prevention & Control training sessions for clinical staff 
contain a section on TB. Infection Prevention and Control training is part of 
the Trust mandatory training programme. Managers are responsible for 
identifying staff training requirements, booking and following up 




31.1 Tuberculosis is a statutory notifiable disease; the TB team at the Trust 
will notify the appropriate external contacts.   
31.2 In all cases where TB is considered in the differential diagnosis the 





consult if an in-patient or referred to the TB service if an out-patient. The TB 
nursing team will co-ordinate case management including contact tracing. 
31.3 The doctor making the diagnosis is legally responsible for ensuring the 
TB team is notified. Contact tracing is organised by the TB nurse specialist. 
Notification triggers contact tracing procedures and also provides surveillance 
data to detect outbreaks and monitor epidemiological trends in incidence and 




Executive summary protocol for the admission and management of 
patients with confirmed or potential smear positive respiratory tract 
tuberculosis  
 
Admission of new patients.  
1. Patients presenting to A&E where respiratory tract tuberculosis is a 
differential diagnosis should be isolated in a side room if possible. Patients 
attending outpatient clinic who require admission with suspected smear 
positive respiratory tract tuberculosis should be isolated until a suitable room 
is available (see below).  
2. Unless there is a clear clinical or public health need, such as 
homelessness, people with suspected or confirmed respiratory tract TB 
should not routinely be admitted to hospital for diagnostic tests or for 
care.  
3. Sputum specimens should be obtained from patients with suspected 
respiratory tract tuberculosis in the A&E Dept before admission and labelled 
as “URGENT” with an appropriate contact bleep number. Samples should be 
taken immediately to pathology at all sites by a doctor or nurse in attendance. 
Out of hours, the on-call microbiology technician should be bleeped when the 
specimen has arrived. A result will usually be available within hours of the 
specimen arriving in the laboratory. In the case of young children, a gastric 
aspirate should be sent to the laboratory. Samples must not be sent using the 
pneumatic tube system.  
4. If sputum smear is positive for acid fast bacilli and there is a risk of MDR TB 
(request microbiology to perform a GeneXpert molecular test for detection of 
Mycobacterium tuberculosis and rifampicin resistance mutations. This is a 
same day test during normal working hours and weekdays. 
5. Multiple-drug resistant (MDR) TB refers to TB caused by an isolate of M. 
tuberculosis that is resistant to both isoniazid and rifampicin and possibly 
additional agents. MDR TB is difficult to manage and is being seen with 
increased frequency in London. All patients with known or suspected 
multiple-drug resistant TB (MDR TB) – must be admitted directly to a 
negative pressure room (13F ward at the Royal London). On Paediatric 
Wards the child will need to be admitted to a negative pressure side room in a 
paediatric ward.  
Risk factors for drug-resistance include: a history of previous TB treatment; 





contact with a known drug-resistant case; birth or residence in a country in 
which the World Health Organization reports that a high proportion (5% or 
more) of new TB cases are multidrug‑resistant.  
 
Patients with pulmonary MDR-TB must be admitted to a negative pressure 
room. Out of hours, the Site Nurse Practitioner(SNP) or other appropriate 
person must discuss the management of the case with the on-call doctor for 
Infectious Diseases/ Microbiology and/or Respiratory Medicine.  
 
6. If sputum is smear-positive and MDRTB is not suspected then admit as 
follows.  
Admit to a single/side room  
For Paediatric cases admit to a single/side room on a paediatric Ward  
Patients who are sputum smear-positive must never be admitted to a ward 
where immunocompromised patients are also located except if they are in a 
negative pressure single room.  
Neutral pressure siderooms can be used provided:  
The sideroom is not intentionally ventilated to positive pressure  
The sideroom has an en-suite  
The door to the side room is kept closed with a green respiratory precautions 
sign on the door and FFP3 masks available at the entrance. 
The patient does not have a productive cough  
The patient is not considered to be an MDR TB case  
 
In the event of it being necessary to enact this guidance it will be necessary 
once the patient and side room has been identified, for a member of the IPC 
team to visit the ward to ensure that ward staff have the appropriate facilities 
and give any training that is necessary to ensure that the patient can be safely 
cared for; out of hours it will be the responsibility of the SNP to fulfil this 
requirement.  
 
. Paediatric cases should be admitted to a side room in a paediatric ward.  
• Children under 10 years with pulmonary TB are unlikely to be infectious, 
however the child should be isolated in a single room until the Paediatric 
Infectious Disease/Respiratory doctor has reviewed and advised on isolation 
requirements.  
• Children under 5 years isolation with respiratory precautions however the 
use of masks is not required but consider risk from parent/ carer until they 
are seen by the TB team.  
 
10. Patients admitted to a side room or negative pressure isolation with known 
or suspected drug-sensitive smear positive pulmonary TB should be moved 





There is laboratory confirmation of negative status (i.e. a minimum of 3 
smear-negative sputa) or a revised clinical diagnosis that excludes smear 
positive TB. If TB is suspected clinically but the results of sputum tests are 
unavailable, the patient must continue to be assumed to be smear-positive.  
11. If the initial sputum-smear is negative but pulmonary TB is still suspected, 
follow guidance for smear-positive patients outlined above. However, if no 
single rooms are available, cases must be discussed with the on-call Clinical 
Infection/Chest SpR before placement. Patients with suspected pulmonary TB 
must never be admitted to an open ward.  
12. It is recommended that patients be admitted under the care of a 
Consultant from either the Infectious Disease or Respiratory Medicine teams 
or transferred to one of these teams as soon as possible after admission.  
 
13. Patients already admitted within the Trust and subsequently diagnosed 
with, or suspected of having, smear positive pulmonary TB must be 
transferred to either a neutral pressure or negative pressure isolation room, in 
accordance with the above protocol.  
 
General  
1. Standard precautions should be carried out when handling body fluids and 
contaminated equipment. All single patient use clinical equipment should be 
disposed of as clinical waste and contaminated linen disposed of as infected 
linen. Re-usable clinical equipment must be decontaminated in accordance 
with the Trust decontamination policy. With MDR and XDR TB patients a 
stethoscope should be assigned to the patient and left in the room/ante room. 
2. Staff performing invasive procedures, respiratory suctioning, bronchoscopy 
of TB patients must wear gloves; disposable long-sleeved gowns and FFP3 
particulate filter respirator masks. In the event of the patient having drainage 
of collections potentially containing Mycobacterium tuberculosis bacteria (e.g. 
pleural effusion) specific attention must be paid to personal protection 
including eye protection. Staff who suspect or know they are 
immunosuppressed should not attend the patient without clearance from the 
Occupational Health Department.  
3. Patients must wear a surgical mask if they are being transported to other 
areas of the hospital. Patients should be encouraged to self-isolate and use 
cough etiquette as is feasible.  
 
Visitors  
1. It is the responsibility of the nurse in charge of a ward to advise visitors of 
the risk of TB.  
2. In general people who have had previous close contact (family members, 
including their children) with the patient can visit as long as they are fit and 
well and accept to use the protective measures and abide by visiting 
regulations. Other visitors should be discouraged whilst the patient is 





3. Individuals (including staff members) who are immuno-suppressed must 
not visit. For further advice please contact a member of the Infection Control 
Team.  
4. All visitors who are not previous close contacts must be advised to wear a 
FFP3 particulate filter respiratory mask.  
5. Parents/ carers of children with suspected or active pulmonary TB should 
be kept separate from other patients until they have been excluded as a 




1. Treatment is multidisciplinary and must involve a Consultant with 
specialised training in TB (Respiratory or Infectious Diseases Physician) and 
the TB specialist nurses. In Paediatric cases this is led by one of the 
Paediatric Infection Diseases Consultants .  
2. It is essential that patients comply with the multiple drug regimen 
prescribed, to ensure effective treatment and to minimise the risk of the 
development of anti-microbial resistance.  
3. After a period of two weeks of therapy, patients with drug-sensitive TB 
should demonstrate signs of clinical improvement and will normally be no 
longer be infectious. Patients unlikely to be infected with Rifampicin resistant 
M. tuberculosis, or those with a negative molecular test for Rifampicin 
resistance mutations, may then leave isolation, but only on the advice of a 
Chest or Infectious Diseases Physician. This will not be the case for patients 
who have MDR-TB, who will require extended therapy and isolation.  
4. It is essential that the TB nurses are informed of a patient prior to them 
being discharged so that follow up and contact details can be obtained.  
 
Notification  
1. Tuberculosis is a notifiable disease, and all cases must be notified to the 
Consultant in Communicable Disease Control (CCDC) for North East London 





33.0 Duties and Responsibilities  
All staff working in the 
Trust  
This policy applies to all employees of the Trust in all 
locations including the Non-Executive Directors, 
temporary employees, locums and contracted staff.  
Managers  
It is the responsibility of Directors and Managers to 
ensure compliance with this standard. 
Infection Prevention 
and Control Team 
Responsible for updating the policy in line with new 
guidance issued.  Ensure that staff have infection 
prevention and control training that includes the 
guidance set out in this policy. Ensure that non-





34.0 Monitoring /audit 
 
34.1 Any instances of non-compliance with this policy will be reported as an 
incident on the Trust datix reporting system and investigated accordingly, 
where contact tracing is required this will be reported as a Serious Incident 
(SI) as per Trust policy.  
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Appendix 2: Impact assessments 
 Equalities impact checklist - must be completed for all new policies 
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In the event of patients identified with suspected smear positive 
pulmonary TB they may be isolated in a neutral pressure sideroom 
provided:  
The sideroom is not intentionally ventilated to positive pressure  
The sideroom has an en-suite  
The sideroom is maintained with the door closed  
The patient does not have a productive cough  
The patient is not considered to be an MDRTB case  
Staff caring for the patient MUST wear FFP3 disposable masks, and follow 
respiratory precautions as per the IPC policy  
In the event of it being necessary to enact this guidance it will be necessary 
once the patient and sideroom has been identified, during normal working 
hours for a member of the IPC team to visit the ward to ensure that ward staff 
have the appropriate facilities and give any training that is necessary to 
ensure that the patient can be safely cared for; out of hours it will be the 
responsibility of the SNP to fulfil this requirement.  
 
 
Appendix 3: Advice on the correct use of masks/respirators  
How to put on an FFP3 mask/respirator: 
• Select an FFP3 mask/respirator (NB staff have to be fit-tested for 3 
respirators). 
• Place over nose, mouth and chin. 
• Fit flexible nose piece over Nose Bridge. 
• Secure on head with elastic. 
• Adjust to fit. 
• For non-valve masks perform a quick fit-check:  
o inhale – mask should collapse 
o exhale – check for leakage around the face  
Removing an FFP3 mask/respirator  
• Break ties/elastic at side to remove. 
• Pull off face without touching outside of mask  
• Discard mask in a clinical waste bin. 
• Wash hands.  
Dos and don’ts  
• Do not hang the mask around your neck or rest in your pocket  
• Do not handle the outside of a worn mask  
• Do not re-use the mask. FFP3 masks/respirators can be worn for eight hours 
continuously but are single use only. 
• Do not give valved masks/respirators to patients/parents 





• CXR clear and where available, the sputum/gastric washings are reported to 
be smear negative and the patient does not have MDR TB.  
• Please confer with the Infection Control and Infectious Diseases Teams on a 
case by case basis if the above information is not available or the results are 
not reported to be clear”. 
Members of staff who are immunosuppressed/post-transplant should avoid 
contact with patient with suspected or confirmed TB.  
Contact Occupational Health for further information. 
PPE (above standard precautions) is not required for non-pulmonary TB when 












































Appendix 4  
Algorithm For Dealing With TB Related Infection Control Incidents 




Algorithm For Dealing With TB Related Infection Control Incidents 










Duties of ward/ site lead nurse and clinician: 
• Identify patients and staff at risk: 
o Greater than 8 hours of cumulative 
exposure 
o Immunosuppression 
o Liaise with IPCT/OH for further details 
• Deceased patients (any cause) to avoid letters 
being sent to their home 
Immediate actions:  
• If patient in an open bay currently – nurse in charge (NIC) to call site manager and move to isolation side 
room urgently 
• NIC to alert Infection Control and Prevention Team (IPCT) in hours 
• NIC to alert TB service in hours 
• NIC to complete incident form (Datix) within 24 hours with patient’s consultant as incident manager 
Duties of TB service: 
• Alert OH  
• Alert Public Health England 
(PHE) 
• Treat patient/ staff member and 
notify 
• Household contact screening 
Sputum AFB smear + patient identified who is not/ was not under respiratory isolation in hospital 
Incident Meeting  
• Should be representation from TB/ microbiology clinician, TB nurse,  ICPT, OH, Patient Safety, governance , lead nurse for 
ward/ site, named consultant of patient, lead matron for hospital, comms and PHE 
• Chaired by site DIPC or designated lead. Minutes by site DIPC PA/site governance 
• Agenda: 
§ Review case 
§ Risk assessment and plan for contact screening of staff, patients and vistors 
§ Agree timeline for sending letters to staff and patients, and screening  
§ Assess if beach of protocol, if incident is an SI, and if so, identify investigators (likely to be clinician or nurse from 
ward, supported by the TB team and IPCT) 
§ Identify lessons learned so far and action points 
§ Incident to be discussed in relevant M+M meeting (minutes to governance and investigator) 
§ Agree follow up meeting to discuss outcomes and close incident (6/52 for internal and 8/52 for external investigation) 
• OH to visit ward/ site with lead nurse to explain when and how staff can contact OH (contact staff by email/letter) 
• Governance  to feedback to  site SI meeting 
• Minutes of meeting to be sent to all attendees and SI meeting 
 
 
Follow up Meeting (6-8/52): 
§ Governance/ site DIPC  will arrange meeting and ensure SI report available to review 
§ Review outcome of contact screening 
§ Review  action points from incident meeting 
§ Review outcome of any investigation including action points and dissemination of report 
§ Decision if incident can be closed 
§ Minutes to site SI meeting 
Duties of IPCT: 
• Support and advise ward/ site 
lead nurse and clinician 
• Inform site DIPC to arrange 
incident meeting within 10 days 







APPENDIX 5: London Health Protection Team MDR Discharge Plan 
 
HOSPITAL DISCHARGE PLAN: MDR Tuberculosis patient 
 
 
Hospital No: …………………  LTBR No: …………………NHS No: 
………………..… 
Title: ...……     First Name: …………….....  Last Name: 
…………..……………… 
Sex:    M        F     D.O.B. ….../……/……       Age: 
………………yrs          
Ward: …………………………………………….         Date Admitted: 
….../……/…..…. 
 
Language: ………………............        Translator Used: 
……………………………… 
UK Entry: ……/……/……  Country of Birth: ……………… 
Country of Citizenship: ………………..  
Immigration status:  Asylum seeker     Refugee      Student      
Visitor       New entrant   
Prisoner / Custody:  Yes     No     
 
 
Those to be involved in the discharge of this patient include 
 
MEMBER NAMED CONTACT 
Chest Physician   
TB Nurses  
Infection Control Team  
Outreach team   
Microbiology  






Other (please specify) 
 
Before discharge the following sections must be completed. 
 
SECTION Criteria Completed (sign and 
date) 
1.  Clinical 
condition  









Secure arrangements in 
place for administration of 
ALL TB treatment. 
 
4. Risk to others Patient is not infectious 
and/or poses no risk to others 




SECTION 1. Clinical condition 
 
Q1. Clinical history  
a.) Pulmonary or non pulmonary TB? Pulmonary    
 Non-pulmonary   
b.) Date treatment started   / /  
c.) Date MDR appropriate treatment started   / /  
d.) Number of weeks on MDR appropriate treatment _________________ 
 
Q2. Microbiological information 
 
SMEAR RESULTS CULTURE RESULTS 
DATE RESULT DATE RESULT 
    
    
    
    
    





    
    
 
Q3. Patient clinically fit to leave hospital Yes  No 
 
Q3A. Does the patient cough?  Yes  No 
             
Q4. Is the patient currently infectious?  Yes  No 
             






FINAL SIGN OFF 
Patient is fit to be discharged             Yes  





SECTION 2.   Accommodation 
 
 
Q5. Issues re: immigration status?   Yes    No  
  (go to Q 6) 





a.) Could these problems impact on eligibility for housing services?   
   Yes     No    
(go to Q 6) 
If YES     Ensure there is early discussion with Outreach Team and/or Find and 
Treat 
 
Q6. Eligible for social services support?   Yes    No   
 (go to Q 7) 






..    
Postcode……………..…….……. Telephone………………………………….. 
 
Q7. Normal residence / accommodation: 
Home setting        (go to Q 8) 
Flat-share          (go to Q 9 overleaf) 
Communal setting (student hostel)      (go to Q 9 overleaf) 
Communal setting (residential hostel)     (go to Q 9 overleaf) 
Communal setting (other)       (go to Q 9 overleaf) 






Q8. Further details on HOME accommodation 
a.) Are any members in the household immunocompromised?        Yes   No  
  
If YES discuss with local HPT 
……….……………………………………………………………………………….…
…… 
b.) Will the patient have their own room?  Yes   No  
  





Q9. Further details on HOSTEL accommodation 
a.) Are any members in the hostel immunocompromised?             Yes   
No    




b.) Will the patient have their own room?  Yes   No  
  




c.) Will the patient have access to a fridge?  Yes   No     Not 
applicable   










Relation  Age Screened (Y/N) and 
methods (CXR, 
TST, IGRA)  
Result: (active TB, LTBI, 
discharged)  
    
    
    
    
    
    
    
    
    
    
 
FINAL SIGN OFF 
Suitable accommodation arrangements in place              Yes  
Address: …………………………………………………………………………..    
Postcode: ……………………     Telephone: ………………………………….. 





SECTION 3.   Community management  
 
Q10. Nurses are required to do home visits*?  Yes   
 No    
* For OPAT (Outpatient Parenteral Antimicrobial Therapy) or DOT (directly 
Observed Therapy)  
If YES, by whom? .......................................................... 
Date arranged? .................................................. 
 
Q11. Infection risk to nurses on home visits?   Yes   
 No   
 
Directly observed treatment (DOT) arrangements  
DOT must be arranged if the patient diagnosed with MDR TB. 
Q12.  Named DOT supervisor…………………………………….. 
Contact details:     Tel.……………………..Mobile………………………….. 
Address………………………………………………………………………………
……………………………………….………Postcode……………..………. 
Q13. Role of DOT Supervisor:   
TB nurse         Community nurse        Social worker         Family 
member   
Other         Details……………………………………………….….. 




Clinical assessment arrangements 
Q15. Follow up appointment arranged?  Yes   No   
If NO discuss with TB nurses 
 Date of first follow up appointment ………………………….. 
 
Q16. Patient eligible for hospital transport?  Yes   No    
If NO provide info. on travel 







FINAL SIGN OFF 
 
Secure arrangements are in place for administration of TB treatment in 
community          Yes  
Agreed by Consultant     TB Nurse     HPT  
 
 
SECTION 4.   Risk to others 
 
Q18. Is the patient infectious now (section 1)?    Yes     
No     
If YES  
a.) Date 6 wk culture result will be available? -
…………………………………. 
 
Q19. Are accommodation arrangements agreed (section 2)?  Yes    
No     
 
Q20. Is there any risk of infection to household/hostel contacts (section 
2)?  
     Yes     No     
 
Q21. Are robust arrangements for community treatment and follow up in 
place (section 3)?      Yes    No     
 
Q22. Is there any risk of infection to support staff (section 3)? Yes     
No     
 
Q23. Is the patient due to fly home?     Yes     






Q24. Is the patient due to be deported / incarcerated?   Yes     
No     
 
Q25. Has all necessary contact tracing (household and close contacts 
and extended screening if required) been undertaken?   Yes     
No     
 
Outcome and agreed Plan - Complete after discussion with HPT: 
 
 1. Patient is ready to be discharged.  
 2. Patient can be discharged when culture results are ready & discussed 
with HPT. 
 3. More information is needed. 




FINAL SIGN OFF 
 
Patient is not infectious and/or poses no risk to others 
          Yes  
Agreed by Consultant     TB Nurse     HPT  
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